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Abstract 
Cardiovascular disease including myocardial dysfunction and vascular 
disease is a major cause of morbidity and mortality among patients with type 1 
diabetes mellitus. Early detection of myocardial dysfunction and identification 
of its determinants may be helpful in preventing diabetic heart muscle disease.  
In this thesis, I studied myocardial and vascular function in 53 subjects 
– 19 with type 1 diabetes mellitus (aged 21 ± 4 years, HbA1c 8.8 ± 1.6 %) and 
34 controls (aged 25 ± 3). I measured myocardial functional reserve using 
myocardial velocity imaging during dobutamine in 18 patients and 21 controls.  
The main findings of this thesis were:  
1. Longitudinal shortening of the left ventricle was reduced in type 1 
diabetes mellitus. (medial mitral annular excursion 1.2±0.2 vs. 1.4±0.2 
cm, p =0.01).  
2. During dobutamine, long-axis peak systolic velocity was lower in type 
1 diabetes by 20% at 10 and 13% at 20 μg/kg/minute (both p =0.05; 
ANOVA, p=0.003) but systolic velocities at peak dobutamine were 
similar and thus myocardial functional response was.  
3. Longitudinal displacement was reduced in subjects with type 1 diabetes 
mellitus both at rest and during dobutamine stress. (by 15%, p =0.001). 
4. Early diastolic relaxation was lower in type 1 diabetes, measured 
globally as the mitral E/A ratio (1.5±0.4 cm/s vs. 1.8±0.4 cm/s, p=0.02) 
or regionally as the early diastolic velocity of the medial mitral annulus 
(e’ -13.0±2.7 cm/s vs. -14.8±2.0 cm/s, p=0.02).  
  
 
 
 iv 
5. Features of adiposity and adverse lipid profiles, more than glycaemia, 
are major determinants also for myocardial and vascular dysfunction in 
young subjects with type 1 diabetes mellitus.  
In conclusion, there is evidence of myocardial dysfunction in young 
subjects with type 1 diabetes mellitus, and early changes may be related to 
metabolic rather than structural changes. Control of other risk factors such as 
dyslipidaemia, and maintenance of normal body weight, may be important 
measures in preventing progression of subclinical myocardial dysfunction into 
overt clinical disease. 
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1 
CHAPTER 1- BACKGROUND  
1.1 Vascular disease and type 1 diabetes mellitus  
1.1.1 Epidemiology 
 
Subjects with type 1 diabetes mellitus (T1DM) are at increased risk of cardiovascular 
diseases. [1] T1DM is associated with a four (in men) to eight (in women) -fold increase in 
coronary artery disease. [2, 3] Even though the incidence of cardiovascular disease in T1DM  
is lower than that in type 2 diabetes mellitus, younger people are affected.[1] The relative risk 
of mortality for both coronary artery disease and stroke in T1DM is significantly elevated in 
the United Kingdom. [4, 5] The Wisconsin Epidemiologic Study of Diabetic Retinopathy 
(WESDR) demonstrated the cumulative incidence for myocardial infarction to be 14.8% and 
18.1% for angina in T1DM respectively. [6] Actually, age-adjusted relative risk for CVD in 
T1DM may even be higher than that in type 2 diabetes mellitus. [7] 
1.1.2 Pathogenesis of vascular disease in Diabetes Mellitus 
 
The exact mechanism for accelerated atherosclerosis in diabetes mellitus remains 
unclear. It is thought to be multifactorial. Endothelial dysfunction may be caused by 
hyperglycaemia and other metabolic derangements in T1DM. Atherosclerosis is essentially 
an inflammatory disease and subjects with diabetes mellitus are in a state of proinflammatory 
and prothrombotic conditions. [7, 8] 
  
 
 
 
 
 
2 
1.1.2.1 Endothelial dysfunction 
 
Endothelial dysfunction is thought to be an important initial change in the 
pathogenesis of atherosclerosis. Endothelial dysfunction in diabetes mellitus may result from 
oxidative stress which could be caused by hyperglycaemia via a variety of mechanisms such 
as the sorbitol pathway, activation of protein kinase C (PKC), the hexosamine pathway and 
non-enzymatic glycation of proteins. [9] 
Normal endothelium is a single layer of cells lining the inner layer of blood vessels. It 
is an active and complex organ which regulates vascular tone, permeability and vascular 
tissue homeostasis. [10]  Studies have shown endothelial dysfunction in both type 1 and type 
2 diabetes mellitus. [11] [12] Hurks et al reported endothelial dysfunction detected by 
impaired flow mediated dilatation (FMD) in young patients with type 1 diabetes mellitus 
before any evidence of early atherosclerosis. Lower FMD in type 1 diabetes mellitus was also 
reported by other researchers. [13] [14]  
1.1.2.2 Hyperglycaemia 
 
Hyperglycaemia may cause vascular injury via a range of mechanisms such as: 
increase in intracellular glucose leading to more production of sorbitol via polyol pathway, an 
increase in production of glucosamine-6-phosphate via hexosamine pathway and the 
activation of PKC (protein kinase C) via de novo synthesis of DAG (diacylglycerol). [9] 
  
 
 
 
 
 
3 
1.1.2.3 Sorbitol pathway  
 
Under normal circumstances, most glucose is metabolized by glycolysis. However, 
in a hyperglycaemic state, a higher percentage of glucose goes through other metabolic 
pathways such as the sorbitol pathway due to increased substrate availability for the aldose 
reductase (AR) enzyme which has low affinity for glucose under physiological conditions. 
[15] 
Glucose can be metabolized to sorbitol and fructose in most cells, resulting in 
increased oxidation of NADPH to NADP+ and increased reduction of NAD+ to NADH.  
This pathway results in imbalance of redox potentials and favours the formation of advanced 
glycation endproducts (AGEs) and enhances oxidative stress. [16]  This altered redox state 
resembles hypoxia and it is called “pseudohypoxia”.  Moreover, NADPH is essential for 
glutathione reductase activity and reduced availability of NADPH results in reduced 
glutathione reductase activity, increasing oxidant injury. [17] 
1.1.2.4 Advanced glycation endproducts (AGEs) 
 
Advanced glycation endproducts (AGEs)  are proteins formed by non-enzymatic 
reaction between the carbonyl group of glucose and the N-terminus of free amino acids of 
proteins.[18] Non-enzymatic glycosylation of basic fibroblast growth factor in vitro reduces 
the mitotic activity of endothelial cells. [19]  AGE has been shown to increase permeability 
of human endothelium in vitro. [20]  AGEs are chemotactic for mononuclear cells and AGEs 
on the subendothelium induces monocytes migration across the endothelium.[21] Receptors 
for AGE (RAGE) seem to exert their effects on target organs by expression of cytokines and 
growth factors and expression of proinflammatory, and pro-coagulatory molecules by 
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endothelial cells such as thrombomodulin, tissue factor and the cell adhesion molecule 
VCAM-1(vascular cell adhesion molecule-1). [15] 
1.1.2.5 Protein Kinase C (PKC) activation 
 
The PKCs are a family of serine/threonine kinases that act on the cell membrane in 
the regulation of signal transduction in a variety of cells and are usually activated by 
diacylglycerol (DAG). [22]  PKC iso-enzyme  in the endothelium is activated by elevated 
DAG level in the presence of hyperglycaemia. [23] PKC reduces endothelial nitric oxide 
synthetase (eNOS) expression by inhibiting protein kinase B  in vivo and in vitro. [24] PKC 
may mediate atherosclerosis by increased production of reactive oxygen species (ROS), 
reduced NO production and increased endothelin ET1 production. [25] In healthy humans, 
PKC  inhibition prevents impaired endothelium dependent vasodilatation caused by 
hyperglycaemia. [26] However, PKC  inhibition failed to do so in diabetes mellitus. [27] 
1.1.2.6 Oxidative Stress 
 
Hyperglycaemia increases the production of reactive oxygen species (ROS) which in 
turn increases cellular oxidative stress.  Neutrophils from poorly controlled diabetes mellitus 
produce excess superoxide via phospholipase A2. [28] Auto oxidation of glucose and 
formation of advanced glycation end products (AGEs) produce ROS in diabetes mellitus. 
[29] Hyperglycaemia increases the synthesis of reactive oxygen species which inactivate 
nitric oxide (NO). Hyperglycaemia may initiate superoxide synthesis via electron transport in 
mitochondria. [30]  
There are many metabolic abnormalities observed in diabetes mellitus which were 
thought to be the basis for the pathophysiology of vascular disease in diabetes mellitus. 
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Understanding pathophysiology may be helpful in preventing vascular disease in diabetes 
mellitus.   
1.2 Diabetic Heart Muscle Disease and Diabetes Mellitus 
1.2.1 Epidemiology 
 
Atherosclerotic cardiovascular disease is common in diabetes mellitus.  However, it is 
postulated that diabetic cardiomyopathy or diabetic heart muscle disease, which is 
independent of coronary artery disease, also exists. The Framingham Heart Study proved that 
diabetes mellitus is a risk factor for heart failure [31] and this was subsequently confirmed in 
many other studies such as the Strong Heart Study.  [32] It is recognized that there is an over-
representation of patients with diabetes mellitus in heart failure trials, accounting for about 
25% of subjects. [33] Many other epidemiological studies such as the  Cardiovascular Health 
Study [34]  and the  Euro Heart Failure Survey [35] suggested that the presence of diabetes 
mellitus is an independent risk factor for development of heart failure. Patients with diabetes 
mellitus are not only at higher risk of heart failure but also have poorer outcomes. [36] 
Rubler et al first described the term “diabetic cardiomyopathy” after performing post-
mortem histology in 4 patients who had heart failure in the absence of ischaemic, 
hypertensive and valvular heart disease. [37] There is cumulative histological and clinical 
evidence of heart muscle disease in diabetes mellitus, particularly in type 2 diabetes mellitus.  
1.2.2 Pathogenesis  
 
The exact mechanism for the cause of myocardial dysfunction in diabetes mellitus is 
not known. It may be multifactorial in origin. A variety of possible mechanisms has been 
described; 
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1.2.2.1 Substrate metabolism 
 
Diabetes mellitus is characterized by reduced glucose and lactate metabolism. 
Decreased glucose supply and utilization was found in diabetic cardiomyocytes and diabetic 
patients. [38] [39]  Myocardial glucose transport may be impaired due to reduced myocardial 
concentrations of glucose transporters, GLUT1 and GLUT4. [40] In an animal model of type 
2 diabetes, db/db mice, cardiac function was observed to be reduced whereas in transgenic 
human GLUT4 db/db mice, abnormal cardiac function was corrected. [41] Pyruvate 
dehydrogenase, a key enzyme for aerobic glycolysis, may also be inhibited by increased free 
fatty acid oxidation and its end-products, acetyl co-A. [42] 
1.2.2.2 Free fatty acids utilization 
 
In the presence of defective glucose metabolism, cardiac myocytes use  oxidation of 
free fatty acids (FFA) as the main source of energy. [43] Availability of FFA in diabetes may 
be increased by enhanced adipose tissue lipolysis and by hydrolysis of augmented myocardial 
triglyceride stores. Utilization of FFA by cardiac myocytes may have detrimental effects on 
cardiac myocytes because of the higher oxygen consumption for  oxidation and the 
production of toxic intermediates of free fatty acids, which may promote apoptosis of cardiac 
myocytes. [43]  In monogenic db/db mice, a model of type 2 diabetes mellitus with extreme 
obesity and hyperglycaemia, plasma membrane FFA transports were found to be increased on 
cardiomyocytes, facilitating increase FFA utilization. [44] 
 1.2.2.3 Calcium homeostasis 
 
Impaired calcium homeostasis may play an important role in the pathogenesis of 
diabetic cardiac muscle disease. Calcium is essential for myocardial excitation and 
contraction coupling. When the cardiac cell membrane is depolarized by the action potential, 
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calcium enters the cell through voltage dependent L-type Ca channels in the sarcolemma. 
This triggers the release of further calcium into the cytoplasm from sarcoplasmic reticulum 
through ryanodine calcium release receptors (RyR). Increased intracellular calcium facilitates 
the binding of calcium to myofilament, initiating cardiac contraction. For relaxation to occur, 
calcium needs to be removed from the cytosol. The majority of the calcium is pumped back 
into the sarcoplasmic reticulum by sarcoplamic/endoplasmic reticulum Ca2+ ATPase 
(SERCA) and the rest is rejected out of the cell by the sarcolemmal ( Na+/ Ca2+) exchange 
(NCX), plasma membrane Ca2+- ATPase (PMCA) or mitochondrial calcium uniport. [45] In 
rodent models of both type 1 and type 2 diabetes mellitus, there are evidences to suggest 
altered expression, activity and function of all transporters involved in excitation contraction 
coupling namely SERCA [46], NCX [47], RyR [48] and PMCA [49]. Overexpression of 
SERCA in the diabetic heart improved both calcium handling [50] and cardiac function. [46] 
1.2.2.4 Reactive oxygen species and oxidative stress 
 
Oxidative stress is an imbalance between the production of reactive oxygen species 
(ROS) and antioxidant defences. Oxidative stress may induce changes in signalling pathways 
or even cellular damage at high level. ROS have been implicated all stages of heart failure, 
from hypertrophy to fibrosis, contractile dysfunction and failure. [51] High rates of fatty acid 
oxidation increases ROS production by augmenting mitochondrial action potential. Under 
physiological conditions, ROS are removed by antioxidants. [52] In the event of excessive 
ROS production as observed in streptomycin induced diabetic rats and db/db mice, it causes 
damage to cardiac myocytes  and augmented apoptosis. [53] [54]  Moreover, overexpression 
or administration of the antioxidant, metallothionein, in rodent models of diabetes have been 
shown to improve morphological and function changes of diabetes heart muscle disease. [55] 
[56] 
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1.2.2.5 Poly (ADP-Ribose) Polymerase (PARP) 
 
PARP is a nuclear enzyme which is involved  in DNA repair. [57] Oxidative stress 
secondary to hyperglycaemia damages DNA strands. [58] Extracellular glucose excess not 
only induces oxidative stress but also activates PARP. [59] PARP catalyses the cleavage of 
NAD+ to nicotinamide and ADP-ribose. It uses ADP-ribose to synthesize a branched 
polymer, poly ADP- ribose. This process is an energy dependent process and depletes the 
cellular ATP. [60] 
PARP may also damage myocardium by activating nuclear factor κB (NFκB) and 
inducing expression of endothelin 1 (ET1) , a potent vasoconstrictor, and its receptors. [61, 
62] Hyperhexosaemia induced cardiac muscle hypertrophy is prevented by PARP inhibition 
in an animal study. [63] Inhibition of PARP has  been shown to reverse endothelial and 
cardiac dysfunction in diabetic animals.[64, 65] However, no polymerase inhibitor is 
currently available to be used safely in human studies or clinical trials. 
1.2.2.6 Advanced glycation end-products (AGEs)  
 
Advanced glycation end-products are formed by non-enzymatic irreversible reaction 
between aldose sugar and lipids or protein. Receptors for AGEs (RAGE) are found on the 
endothelial surface and AGE-RAGE interaction seems to induce oxidative stress and an 
inflammatory reaction. [66] AGEs may affect myocardial function by cross-linking with 
collagen in the myocardium, causing increased ventricular stiffness. [67] AGEs may also 
cause impaired relaxation of the myocardium through myocyte calcium handling by AGE-
RAGE interaction. [68] Cross linking breaker of AGEs, ALT-117,  has been shown to 
improve diabetes related myocardial and vascular stiffness in animal studies. [69] [70] 
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 1.2.2.7 Structural changes in myocardium  
 
Rubler et al were the first to describe structural changes observed in diabetic 
cardiomyopathy. [37]  They found ventricular hypertrophy, fibrotic changes in myocardium 
and thickening of intramural arterioles, and they postulated that diabetic cardiomyopathy may 
be secondary to diabetic macroangiopathy as a result of abnormal myocardium metabolism in 
diabetes. 
In animal studies, increase in myocardial mitochondria, apoptosis, intramyocardial 
lipid accumulation and fibrosis are common findings. Myocardial fibrosis has been described 
in many histological studies [71] [72] and echocardiography studies of backscatter [73] [74] 
in humans.  
1.2.3 Diastolic myocardial dysfunction in diabetes mellitus  
 
Diabetic heart muscle disease is widely regarded to be a diastolic disease.[75] [76] 
[77] One of the earliest studies which described diabetic cardiomyopathy as a diastolic 
dysfunction was carried out by Raev who studied 157 asymptomatic young subjects (mean 
26.6 years) with type 1 diabetes mellitus and 54 controls, with M-mode echocardiography. 
He suggested that left ventricular diastolic function was impaired before systolic function. 
[78] Earlier studies used mitral inflow early (E) and late (A) velocities and their ratio (E/A) as 
a marker of diastolic dysfunction. Zarich et al showed that the  E/A ratio was significantly 
lower in 21 type 1 diabetes mellitus than in 21 controls. [79] This finding was confirmed in 
other studies.  [80] [81]  
Moreover, some measures such as the Valsalva manoeuvre and measurement of 
pulmonary venous flow on echocardiography seem to have increased the sensitivity of 
conventional Doppler in diagnosing subclinical disease in diabetes mellitus. In a study of 46 
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type 2 diabetes mellitus patients  without diabetic complications and cardiovascular diseases, 
left ventricular diastolic function was assessed by measuring the E/A ratio during the 
Valsalva manoeuvre and by recording  pulmonary venous flow. Left ventricular diastolic 
dysfunction was found in 60% of the subjects of whom 28% had a pseudonormal pattern of 
mitral flow  on Doppler assessment. [82] 
It is generally accepted that diastolic dysfunction is the earliest change in diabetic 
heart muscle disease as parameters like IVRT, E/A, E/E’ were frequently found to be 
abnormal in diabetes mellitus in the absence of systolic dysfunction. [83] [77] Perhaps 
conventional echocardiography may not be sensitive enough to detect early subtle systolic 
dysfunction. Moreover, these parameters are load dependent and can be affected by 
ventricular loading conditions.  
Despite the conventional assumption that diabetic cardiomyopathy is diastolic 
dysfunction, with advances in technology in the area of myocardial imaging, it may be 
possible to assess systolic function more sensitively than before and therefore to explore 
subclinical myocardial dysfunction in diabetes mellitus more in its early stages.   
1.2.4 Systolic myocardial dysfunction in diabetes mellitus  
 
Indeed, left ventricular longitudinal systolic dysfunction was detected in later studies 
using tissue Doppler imaging. Andersen et al demonstrated abnormal longitudinal systolic 
velocity in a study of 32 type 2 diabetes mellitus with normal ejection fraction. [84] Mean 
peak systolic velocity and mean peak systolic strain rate were significantly lower in diabetic 
group. Abnormal systolic velocities in diabetes mellitus were confirmed in further studies by 
Vinereanu et al [85] and Fang et al [86]. Ernande et al questioned the conventional 
acceptance of isolated diastolic dysfunction as an early change in diabetes cardiomyopathy as 
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they demonstrated both systolic and diastolic dysfunction on echocardiography and speckle 
tracking in 114 patients with type 2 diabetes mellitus.[87]  
However, not all the studies  were positive for subclinical dysfunction in diabetes 
mellitus. Konduracka et al studied 185 type 1 diabetes mellitus and 105 non-diabetic controls 
by using conventional Doppler and tissue Doppler imaging; 89% of the studied subjects had 
diabetic retinopathy and 45% had cardiovascular autonomic neuropathy. They did not find 
any significance difference in either systolic or diastolic dysfunction between controls and 
diabetics. [88] In fact, they even looked at 17 deceased patients who had had diabetes 
mellitus for more than 20 years. Even though autopsy showed microscopic evidence of small 
vessel disease in the myocardium, echocardiographic changes were reported to be normal for 
those patients as well.  
1.2.5 Radial myocardial dysfunction in diabetes mellitus 
 
Radial systolic function has not been widely investigated. The results are conflicting. 
Two studies [85, 89] by Vinereanu et and Fang et al  respectively  showed reduced 
longitudinal systolic function but increased radial function in diabetes mellitus. “Radial 
compensation” to reduction in longitudinal function was postulated. It implies that 
longitudinal fibres in subendocardium are more affected and ischaemic pathology, possibly 
microvascular disease, as a causative factor is suspected. It was regarded that midwall fibres 
which are responsible for radial systolic function are more or less spared in the early disease 
process. However, in a more recent study by Ernande et al, reduction in both radial and 
longitudinal strain on speckle tracking was reported in type 2 diabetes mellitus.[90] Similar 
findings were observed by Nakai et al in a group of type 2 diabetes mellitus. [91] In contrast, 
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Ng et al reported normal radial strain with reduced longitudinal function in type 2 diabetes 
mellitus on speckle tracking. [92] 
There are limited numbers of studies which assessed radial function and the reports 
are conflicting. The role of radial myocardial function in subclinical myocardial dysfunction 
in diabetes mellitus, particularly in type 1 diabetes mellitus, remains an area to explore 
further.  
1.2.6 Myocardial velocity imaging in detecting subclinical myocardial dysfunction 
 
Echocardiography is the most commonly used non-invasive tool for the investigation 
of cardiac structure and function at present. Myocardial velocity imaging, also known as 
tissue Doppler imaging, is a new technique which gives quantitative assessment of  regional 
myocardial function. It is well validated, reproducible and readily assessable. [93] Traditional 
Doppler Echocardiography is based on the Doppler effect, i.e. a change in the frequency of 
ultrasound signal reflected from moving objects. Doppler echocardiography is used to assess 
blood flow whose reflected signal has low amplitude and high frequency. On the other hand, 
cardiac structure has high amplitude and low frequency signal. Tissue motion creates Doppler 
shift and the machine can be equipped with filters which can exclude the low amplitude high 
frequency signal. In myocardial velocity imaging, to record low velocity tissue motion, gain 
amplification is reduced and high pass filters are bypassed so that the tissue signal directly 
enter the autocorrelator. Both systolic and diastolic function can be assessed and quantified. 
[94] It has been used to detect subclinical myocardial dysfunction in many conditions 
including diabetes mellitus (see Table 1.1).  
1.2.7 Dobutamine stress echocardiography in subclinical myocardial dysfunction 
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Attempts have been made to find a way to diagnose earlier myocardial dysfunction. 
Stress echocardiography seems to be promising in detecting myocardial functional reserve. 
Vinereanu et al demonstrated that longitudinal peak systolic velocity was low at rest and at 
peak stress with dobutamine in a study of 35 asymptomatic patients with type 2 diabetes 
mellitus. [85] However, this finding of impaired myocardial functional reserve in diabetes 
mellitus was not in agreement with the findings of Fang et al. [86] They reported reduced 
peak systolic longitudinal velocity at rest in type 2 diabetics but normal response to 
dobutamine. A study by Von Bibra et al supported findings by Vinereanu et al. They studied 
43 diabetic patients with dobutamine stress echocardiography, and longitudinal systolic 
velocity was lower at peak stress in diabetics when compared with controls (Vs. 10.7+/-2.7 
vs. 13.6+/-3.4). [95] Further studies are needed to evaluate myocardial functional reserve, 
which may reveal further insight into the pathophysiological processes of diabetes 
cardiomyopathy, particularly in type 1 diabetes mellitus. A summary of echocardiographic 
studies for myocardial function in diabetes mellitus are listed in table 1.1. 
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Table 1.1: Summary table of selected studies of assessment of myocardial function in diabetes mellitus  
 
Author  Type No 
(DM+CTRL) 
Age Duration 
(yr) 
Methods Findings Comments 
Suys   
(2004)[80] 
1 80+52 6.2-21.6 
4.1-20.2 
F (6.83.7) 
M (5.73.2) 
Conventional echo and 
tissue Doppler (e/e’) 
Larger left ventricular 
posterior wall, higher E’, 
E/E’, IVRT and A in female 
No changes in 
male. Wide age 
range.  
Raev 
(1994)[78] 
1 157 +53  Mean 26.6  M-mode 
echocardiography 
Systolic function by 
fractional shortening, 
mean velocity of 
circumference fibre 
shortening and stroke 
index. Diastolic function 
by slope of anterior 
mitral leaflet in early 
diastole, IVRT and left 
atrium emptying index. 
Diastolic dysfunction more 
common than systolic 
dysfunction. It was concluded 
that diabetes affects diastolic 
function before systolic 
function. 
Early study to 
prove diastolic 
function is more 
affected in 
diabetes. 
Romanens 
(1999)[96] 
1 20+20 DM -358 
Ctrl- 
3210 
178 Conventional echo and 
pulsed Doppler at Mitral 
valve 
No difference found.  
Von Bibra 
(2005) [95] 
2 43+33 DM 
60.67 
Ctrl- 
59.77.5 
 
NA Tissue Doppler at rest 
and stress (dypyridamole 
and/or dobutamine) 
Dobutamine stress resulted in 
lower Vs. and Ve in diabetics 
 
Patients with IHD 
were included. 
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Fang 
(2004)[97] 
1+2 53+53 DM 
599 
Ctrl- 
5810 
1311 Tissue Doppler imaging. 
Significant IHD excluded 
by stress echo. 
Longitudinal Sm, Em, strain 
and strain rate were 
significantly lower in diabetic 
patients whereas radial Sm, 
strain and strain rate were 
higher in diabetic patients. 
Radial 
compensation was 
postulated. 
 
Di Cori 
(2007)[98] 
1 40+40 DM 
284.2 
Ctrl- 
304.1 
8.93.7 Conventional echo and 
tissue Doppler. 
Integrated backscatter. 
Peak systolic strain lower in 
diabetic subjects.  
HbA1c 7.41.2 
Poirier 
(2001)[82] 
2 46 38-67 0.25 to 32  Conventional echo and 
transmitral Doppler flow 
velocity. Pseudonormal 
patterned identified by 
measuring pulmonary 
venous flow during 
Valsalva manoeuvre. 
Left ventricular diastolic 
dysfunction was found in 
60%, of whom 28% had 
pseudonormalizaton. 
Highlighted the 
importance of 
excluding 
pseudonormalizat
on. 
Significant age 
difference in 
LVDD group. 
Fang  
(2003)[86] 
1+2 41+41 
(5 patients 
with type1) 
 
DM- 568 
Ctrl- 
599 
 
1110 Tissue Doppler with 
dobutamine stress was 
used. (up to 
40g/kg/min). 
PSV lower in diabetic 
subjects at rest. However, no 
significant difference in 
systolic function in response 
to dobutamine. Em was lower 
at rest and during stress in 
DM. 
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Muranaka 
(2009) [99] 
NA Ctrl-16 
DM-17 
DM+HT-22 
 
DM-
6310 
DM+HT- 
617 
Ctrl-
6210 
DM-109.8 
DM+HT- 
10.38.4 
Myocardial velocity 
imaging is used to 
measure strain rate in left 
ventricle and left atrium. 
Lower LVs, LVe, Las and 
LAe in DM group. 
DM+HT group has lower 
LVe and LAe than DM 
group. 
 
Andersen 
(2003)[84] 
2 32+32 537 0.5-20 Myocardial velocity 
imaging was used to 
measure longitudinal 
systolic function and SR. 
Tissue tracking score 
index was used. 
Mean PSV and peak SR were 
lower in DM group. 
Smokers in DM 
group> controls. 
IHD excluded by 
history. Early 
study to 
demonstrate 
systolic function 
could also be 
impaired in 
DCMP.  
Shivalkar 
(2006) 
[100] 
1 100+75 DM-
46.69.7 
Ctrl-
4211 
2-36 FMD, IMT and tissue 
Doppler of 12 left 
ventricular segments 
were measured. 
FMD was reduced and IMT 
was increased in diabetic 
group. FMD correlated with 
number of myocardial 
segments with reduced 
function. 
Subgroup analysis 
in under 50 did 
not show any 
difference in 
vascular function 
between the two 
groups. 
Vinereanu 
(2003) [85] 
2 35+35 DM- 
5710 
Ctrl- 
5612 
NA Conventional echo was 
performed. 
Dobutamine stress echo 
with tissue Doppler was 
PSV was reduced in DM both 
at rest and at peak stress. 
Myocardial functional reserve 
was also reduced. Radial 
Subclinical 
dysfunction was 
also related to 
serum lipids and 
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used to measure 
longitudinal and radial 
myocardial velocity. 
function was higher in 
diabetics. 
HbA1c. 
Radial 
compensation was 
suggested.  
Celentano 
(1995) 
[101] 
2 N=25 
IGT=15 
DM=24 
DM-574 
IGT-616 
Ctrl- 
585 
NA Conventional echo was 
done. 
Subjects were divided 
into three groups 
depending on glucose 
tolerance.  
Left ventricular end systolic 
diameter indexed for BSA 
was higher in IGT and DM 
groups whereas peak E/A was 
lower. 
Changes were 
observed even in 
impaired glucose 
tolerance group. 
Karamitsos 
(2006) 
[102] 
1 66+66 3510 209 Conventional echo and 
tissue Doppler were 
performed to measure 
mitral and tricuspid flow 
and mitral and tricuspid 
annular velocities. 
Tricuspid flow E/A ratio and 
tricuspid annular diastolic 
velocities were reduced in 
DM group. 
Evidence of RV 
involvement as 
well as LV. 
Baldi 
(2006) [83] 
2 13+15 DM-
45.36.2 
Ctrl- 
47.65.2 
NA Conventional and Tissue 
Doppler 
Maximal oxygen 
consumption was 
assessed within 2 wks of 
echo. 
No difference in S’, E,A and 
E/A. However, E’, E/E’ and 
E’/A’ were lower in type 2 
DM subjects.  
High BMI in both 
groups.  
Konduracka 
(2007) [88] 
1 185+105 DM- 
34.87.9 
Ctrl- 
34.57.8 
22.88.7  Conventional echo and 
tissue Doppler were 
performed. 
Histological studies were 
done on 17 hearts of 
Apart from systolic S 
pulmonary flow/diastolic D 
pulmonary flow ratio and 
E/E’, all other echo 
parameters were not different 
Essentially a 
negative study. 
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T1DM patients. NT-
proBNP level was also 
measured. 
between two groups. 
Microscopy of 17 hearts 
revealed early atherosclerotic 
changes in large epicardial 
coronary arteries, and mild 
fibrosis. 
Karamitsos 
(2008) 
[103] 
1 44+21 DM+CAN
- 
18 
DM-CAN- 
24 
Ctrl-21 
247 
 
216 
Conventional echo and 
tissue Doppler. Cardiac 
autonomic neuropathy 
identified by ECG using 
R-R interval variation 
and Valsalva manoeuvre.  
Diastolic dysfunction more 
pronounced in CAN patients 
as evident by lower Em and 
Em/Am ratio and higher 
mitral inflow A. 
 
Palmieri  
(2006) 
[104] 
1 20+24 DM 34±10 
Ctrl 33±9 
2-30  
Median 14 
Colour tissue Doppler 
study  
Low dose dobutamine 
given up to 7.5µg/kg/min 
Only systolic lateral mitral 
annulus was lower in DM at 
rest. 
 
Only type1 
diabetic subjects 
received 
dobutamine, not 
controls. * 
Palmieri 
(2007) 
[105] 
1 25+32+24 
DM1+NT+ 
HT 
3310 
408 
469 
148 Echo and tissue Doppler. 
Exercise test and SV and 
CO were measured 
during exercise using 
bio-impendence 
cardiographer. 
Peak exercise SVi and COi 
were lower in DM group than 
HT&NT group. 
Subnormal LV 
function reserve in 
DM which may 
not be apparent at 
rest was 
suggested. 
Carugo 
(2001) 
1 56+20 DM 35±2 
Ctrl 
32±1.8 
 14±11 Conventional Echo Increase LV wall thickness, 
increase LVMI, increase wall 
thickness/EDV ratio and 
reduced E/A.  
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1.2.8 Determinants of myocardial function in diabetes mellitus- current 
evidence 
1.2.8.1 Hyperglycaemia 
  
Elevated glycosylated haemoglobin was linked with impaired 
myocardial function. Peak systolic strain was associated with HbA1c in a 
study involving 219 type 2 diabetes mellitus patients without known 
cardiovascular disease. [106] In the Wisconsin Epidemiologic Study of 
Diabetic Retinopathy (WESDR) HbA1c was significantly associated with 
cardiovascular mortality. [6] In the EURODIAB study, after 8 years of follow-
up, HbA1c was linked to coronary artery disease. [107]  
In the DCCT trial, 1441 T1DM subjects aged 13-39 years were 
allocated randomly to two groups, intensive glycaemic control and 
conventional glycaemic control. Both groups were followed up for mean 
duration of 6.3 years. The intensive controlled group achieved a mean HbA1c 
of 7.2% whereas the conventional group achieved 9.0%. At the end of DCCT 
trial period, intensive treatment reduced major cardiovascular events and 
peripheral vascular events by 41%, but not to the level of statistical 
significance. [108] Nevertheless, after a mean 17 years of follow-up in the 
DCCT/EDIC study, 144 cardiovascular events occurred in 83 patients, 46 
among 31 patients originally allocated to intensive therapy and 98 among 52 
patients assigned to conventional treatment. The respective event rates were 
0.38 and 0.80 per 100 patient-years. (P=0.007). A life-table analysis of the 
cumulative incidence of a first cardiovascular event showed that intensive 
treatment was associated with a 42% reduction in risk in comparison with 
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conventional treatment. (95% confidence interval, 9 to 63%; P=0.002) The risk 
of first occurrence of non-fatal  myocardial infarction or stroke or death from 
cardiovascular disease was also reduced in the intensive treatment group 
despite the fact that HbA1c of the two groups converged over the course of 
EDIC study.  [109] .  
In type 2 diabetes mellitus, the UKPDS [110] failed to prove that 
intensive glycaemic control reduced cardiovascular mortality apart from 
treatment with metformin in overweight type 2 diabetes mellitus patients. 
[111] Moreover, the results of the ACCORD trial showed that the strategy of 
lowering HbA1c level closer to normal was not effective in type 2 diabetes 
mellitus. [112]  
There is evidence to suggest that intensive glycaemic control reduce 
cardiovascular events and mortality in type 1 diabetes mellitus. However, there 
is no strong evidence to suggest so in type 2 diabetes mellitus. The reason for 
this apparently less effective effect of glycaemic control on cardiovascular 
mortality in type 2 diabetes mellitus remains unclear. However, type 2 diabetes 
mellitus patients tend to have other associated risk factors such as 
dyslipidaemia and hypertension.  
1.2.8.2 Brain Natriuretic peptide 
No significant relation between BNP and subclinical myocardial 
dysfunction in diabetes mellitus was found. [113] 
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1.2.8.3 Vascular Stiffness 
Diabetes mellitus increases vascular stiffness. Aortic stiffness measured 
by M-mode echocardiography was associated with left ventricular diastolic 
function measured by tissue Doppler echocardiography in a study of  57 
asymptomatic type 2 diabetes mellitus and 25 healthy controls. [114] Systolic 
and diastolic diameters of the aorta were measured with M-mode 
echocardiography in a parasternal long-axis view and aortic root distensibility 
was calculated. Aortic distensibility was significantly reduced in type 2 
diabetics and was negatively associated with mitral A wave velocity, IVRT 
and Am velocities. It was also positively associated with mitral E wave 
velocity, E/A ratio, E’ velocities and E’/A’ ratio. An association was found 
between elevated left ventricle filling pressure as measured by (E/E’) and 
central pulse pressure measured by radial tonometry in type 2 diabetes 
mellitus. [115]  
Moreover, pulse wave velocity (PWV), a marker of vascular stiffness, 
measured by whole body impedance cardiography and calf impedance 
plethysmography, was impaired even in a group of type 2 diabetes mellitus 
patients  with short duration of diabetes mellitus (mean duration 1.8 years) and 
also in patients with type 2 diabetes mellitus, PWV was associated with low 
average myocardial systolic velocity and mitral annular early diastolic 
velocity. [116] 
Even though it is not possible to find causal relationships in a cross-
sectional study, it is possible that similar disease processes affect both the heart 
and the vessels, in parallel. Long term prospective studies are needed to 
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determine if there are causal relationships between vascular stiffness and 
myocardial dysfunction. More studies are also needed to evaluate the 
relationship between vascular stiffness and subclinical myocardial dysfunction, 
particularly in type 1 diabetes mellitus.  
 1.2.8.4 Endothelial dysfunction 
100 type 1 diabetic patients underwent assessment of flow mediated 
dilatation (FMD), carotid intima-media thickness (cIMT), and myocardial 
function by tissue Doppler imaging. [100] Subjects with type 1 diabetes 
mellitus had significantly lower FMD and higher cIMT. FMD was also 
correlated with the number of segments of myocardium showing abnormal 
function, for both systolic and diastolic dysfunction.   
1.2.8.5 Conclusion 
 
 Identifying associations or determinants of subclinical myocardial 
function may be helpful in risk stratification. It is not yet clear which factors 
determine myocardial function in type 1 diabetes mellitus. Studies showing 
associations of myocardial function are summarised in table 1.2.  
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Table 1.2: Summary table of studies showing myocardial function in diabetes mellitus and its associations  
Author Type No. Age 
(years) 
Duration 
of DM  
(years)  
Methods Findings Comment 
Shishehbor 
(2003) [81] 
1 25+26 4511 
4610 
2610 Pulsed Doppler of 
mitral inflow and 
tissue Doppler of 
basal segment were 
measured together 
with HbA1c. 
IVRT prolonged in DM. 
Lower E/A ratio. HbA1c 
was correlated with 
E/Em. 
HR significantly 
higher in DM. 
Patients with 
microalbuminuria 
was included in the 
study. 
Berg 
(1999) [117] 
1 52 
 
4013 1713 Conventional echo 
and pulsed Doppler. 
Measurement of 
Advanced glycation 
end products. (AGEs) 
and carboxymethyl 
lysine (CML). 
AGEs were positively 
correlated with IVRTs 
and LVD whereas CML 
were positively 
correlated with IVRT, 
LVFS and LVEF.  
No control group in 
the study. A wide 
range of patients 
including patients 
with microvascular 
complications. 
Smokers also 
included. 
Didangelos 
(2003) [118] 
1 24 
(+DAN) 
33(-DAN) 
29.810.7 
 
40.417.3 
16.06.5 
 
21.28.9 
Radionuclide 
ventriculography was 
done to assess left 
ventricular function. 
Diabetic autonomic 
neuropathy was 
diagnosed by criteria 
from ADA and 
DAN patients had 
impaired LV filling 
pattern such as a reduced 
peak filling rate. 
Significant age 
difference between 
two groups. (DAN 
group older). 
Microalbuminuria, 
a recognized 
complication of 
microvascular 
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American Academy of 
neurology.  
disease and a 
cardiovascular risk, 
is present in all 
patients with DAN 
and was statistically 
different to the 
other group. 
Fang 
(2005) [106] 
2 120 5412 
(LVD) 
 
5810 
(no LVD) 
98 
 
118 
LV dysfunction 
identified by using 
colour tissue Doppler. 
IHD excluded by 
either exercise or 
DSE. Patients were 
grouped into two 
depending on the 
presence of LVD. 
LV systolic dysfunction 
by strain was 
independently associated 
with HbA1c level and 
lack of ACEI treatment 
where diastolic 
dysfunction by Em was 
predicted by age, 
hypertension, insulin and 
metformin treatment.  
 
Taskiran 
(2004) [119] 
1 10+10+10 
+/- AN 
492 
452 
471.0 
223.0 
214.0 
LV diastolic function 
was assessed by pulse 
Doppler  whereas 
systolic function by 
MRI. 
Significant decrease in 
E/A ratio in AN+ 
compared to controls. DT 
shorted in AN+ 
compared to AN- and 
controls. Greater LVMI 
in AN+ compared with 
controls. 
 
Liomaala 
(2005) [116] 
2 49+15 52.35.6 
48.37.4 
1.8 Cardiac function 
assessed by pulsed 
Lower age-adjusted Sm 
and Em in DM, pwv 
Significant 
differences in age, 
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Doppler and tissue 
Doppler. Vascular 
wall elasticity by 
whole-body 
impedance 
cardiography. 
higher in DM group. Pwv 
was correlated with age 
and HbA1c, Age, BMI 
and pwv correlated with 
Em. 
BMI and blood 
pressure between 
the groups. 
Seyfeli 
(2008) [114] 
2 57+25 496 (DM) 
467 (ctrl) 
8262 
(months) 
Tissue Doppler was 
used to assess 
myocardial function 
and aortic 
distensibility by 
measuring aortic 
diameter during 
systole and diastole. 
Aortic distensibility and 
strain were significantly 
lower in DM and Aortic 
distensibility was 
correlated to septal basal 
Em/Am ratio. 
Age and sex not 
matched. Patients 
on antihypertensive 
were included. 
Karamitsos 
(2008) [103] 
1 18+24+21 
CAN+, 
CAN-, ctrl 
408 
387 
3710 
247 
216 
Tissue Doppler 
imaging was used. 
CAN was diagnosed 
by using ADA and 
American Academy of 
Neurology statement.  
Em, and Em/Am were 
significantly lower in 
CAN in comparison with 
CAN – and controls 
whereas Am was higher 
in CAN group. 
Patients with 
microalbuminuria 
were included in 
the study. 
Karamitsos 
(2008) [120] 
1 66   Patients were grouped 
according to Em/Am 
ratio. Em/Am>1 
regarded as LV 
diastolic dysfunction. 
Aortic stiffness 
calculated by 
Aortic stiffness was 
increased in LVD group. 
Was correlated with 
Em/Am, IVRT and DT. 
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measuring aortic 
diameter from echo. 
Guo 
(2009) [121] 
2 50+50 48.58.6 
47.68.8 
 Conventional echo, 
tissue Doppler and 
Acoustic densitometry 
were used. 
Em and Em/Am lower in 
DM. Am and E/Em were 
higher in DM. IVS-IBS% 
and LVPW-IBS% were 
higher in DM.HbA1c 
was negatively correlated 
with E/A, Em, Em/Am 
and positively correlated 
with E/Em,  
 
Astrup 
(2008) [122] 
1 136(DM1) 
 
529 
(normoalbu
minuria) 
489  
(diabetic 
nephropath
y) 
317 
349 
Cine MR LVMI significantly 
higher in diabetic 
nephropathy group, so 
was NT-proBNP. 
Age not matched. 
Nephropathic group 
had significantly 
higher usage of 
antihypertensive, 
statins and aspirin. 
Yazici 
(2008) [123] 
2 72+50 49.19.8 
46.19.8 
5.14.2 Conventional echo, 
colour flow Doppler 
M-mode and tissue 
Doppler. 
Systolic function was 
normal. However, 
diastolic function was 
impaired in DM. Lower 
Em, and Em/Am, Higher 
mitral inflow A. VE was 
lower and E/Ve higher in 
DM during colour M 
mode flow propagation. 
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HbA1 related to diastolic 
dysfunction such as E/A, 
Em/Am. LV function 
was correlated with age 
and diabetes duration. 
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1.2.9 Treatment of subclinical myocardial dysfunction in diabetes 
mellitus  
There are no major interventional studies designed to treat subclinical 
myocardial dysfunction in diabetes mellitus. In one prospective interventional 
study, 36 subjects with suboptimal glycaemic control (HbA1c > 7%) were 
followed up for 1 year and HbA1c and echocardiographic parameters were 
monitored at 6 months and 12 months. [124] There was significant 
improvement in HbA1c (from 10.1 ± 1.6 % to 8.1 ± 1.4 %, P< 0.001). 
Negative correlations were found between HbA1c level and percentage 
changes of the peak lengthening rate of LV diameter (+dD/dt), HbA1c level 
and percentage changes of the peak thinning rate of the LV posterior 
wall,(dW/dt).   
Similarly, in a study by Andersen et al, 20 type 1 diabetes mellitus 
patients were followed up after starting on insulin pump therapy for a mean 
period of 45 days. [125] HbA1c improved significantly as well as mean left 
ventricular strain rate. (-1.58± 0.3 at baseline vs. -1.80 ± 0.4, p<0.05). 
However, peak systolic velocity was not significantly improved. Von Bibra et 
al also reported improvement in diastolic velocity with insulin treatment in 25 
patients with type 2 diabetes mellitus over 3 week duration. [126] In a cross-
over study by Von Bibra et al, 12 patients with type 2 diabetes mellitus were 
treated with rosiglitazone and glimepiride. Early diastolic tissue velocity E’ 
improved significantly after 16 weeks with  rosiglitazone.[127]   
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The effect of exercise on myocardial function in diabetes mellitus was 
tested by Loimaala et al. [128] 48 men with type 2 diabetes mellitus were 
randomized into two groups, exercise group and the conventional treatment 
alone group and followed up for 1 year. Patients in exercise group received 
supervised training 4 times a week. After one year, even though HbA1c 
declined significantly in the exercise group, no significant changes in 
myocardial function such as early mitral annular Ea, systolic velocity, systolic 
strain and strain rate were observed. Similarly, Hare et al studied the effect of 
intensive exercise on myocardial function by randomizing patients with type 2 
diabetes mellitus into an  intensive exercise programme or usual treatment. 
Patients were followed up for 3 years and at the end of the study; no difference 
in myocardial function between the two groups was noted. [129]  In a similar 
study involving 223 type 2 diabetes mellitus patients, no difference in 
myocardial function was noted in the intensive exercise group after 1 year. 
[130] It was hypothesized that exercise activity might not be rigorous enough.  
Incomplete follow- up was another issue with the exercise intervention study.  
 The effect of controlling postprandial glucose on diastolic function was 
studied in 61 patients with type 2 diabetes mellitus by Von Bibra et al; patients 
were randomized into three groups of mixed insulin two times a day, basal 
bolus regime or bolus insulin treatment alone. Postprandial glucose was higher 
in the conventional treatment group and it was associated with lower E’. [131]  
Treatment with ramipril was also reported to improve E’ in 16 patients 
with type 2 diabetes mellitus when compared with those who did not have 
treatment with ramipril after 9 month follow up. [132]  
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In a retrospective echocardiographic study of 430 patients ,who had 
coronary artery disease but who were not known to have heart failure, the use 
of statins was associated with favourable myocardial function such as higher 
E’, lower mitral inflow E velocity and lower E/e’ ratio. The study involved 121 
patients with diabetes mellitus.  
There have been many small studies with a short duration of treatment 
showing improvement in subclinical myocardial function with various 
treatment but not exercise. Those studies are summarised in table 1.3. Whether 
these results can be translated into long term prevention of heart failure is 
debatable. Treatment with rosiglitazone by Von Bibra [127] is a good example, 
as rosiglitazone now has now been clearly shown to increase the risk of  heart 
failure  in patients with type 2 diabetes mellitus.[133] [134] Therefore, larger 
trials with longer follow-up are needed to determine the effects of 
interventional treatment such as improved glycaemic control on the  
progression of subclinical disease into clinical heart failure in diabetes 
mellitus.
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Table 1.3: Summary table showing treatment of subclinical myocardial dysfunction in diabetes mellitus  
Author  Type  No. Age 
(years) 
Duration of 
DM (years) 
Methods Findings Comments 
Grandi 
(2006) [124] 
1 36 3610 10.85.6 36 patients with T1DM 
followed up for 12 months. 
Assessed at 6 months and 12 
months after insulin therapy 
was modified for better 
glycaemic control. Cardiac 
function evaluated at each visit 
by echocardiography. Peak 
lengthening and shortening 
rates of LV diameter and peak 
thinning rate of LV posterior 
wall were also measured. 
Peak lengthening rate, 
peak wall thinning rate 
and E/A ratio improved 
after 6 months. 
Improvement correlates 
with HbA1c level. No 
further improvement at 
12 months. 
9 patients dropped 
out between 6 month 
and 12 month. 
Andersen 
(2007) [125] 
1 19 22-65 8-43. 19 patients with poorly 
controlled DM1 were followed 
up after initiation of insulin 
pump. Followed up by 
measuring SR after 35-50 
days. 
Mean LV SR improved 
so did HbA1c. Changes 
in SR correlates with 
changes in HbA1c. 
Wide age range for 
relatively small 
number of patients.  
Variable follow up 
period. 
Loimaala 
(2007) [128] 
2  24+24 52.8 ±6.0 
52.8 ±5.2 
<3 48 newly onset DM2 were 
randomized into two groups, 
conventional treatment 
without exercise and with 
supervised exercise 4 
times/week. Followed up for 
No significant 
improvement in mitral 
flow velocities, septal 
strain and strain rate. 
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12 months with echo and 
tissue Doppler. 
Von Bibra  
(2004) [126] 
2 25 60 ± 9 8 ± 7 Either insulin was treated or 
oral hypoglycaemic therapy 
intensified. Followed up for 
0.7 month. 
Fasting capillary glucose 
level fell and diastolic 
velocity improved in 
insulin treatment group. 
Very short duration. 
Only capillary 
glucose monitored 
and self-reported.  
Hare  
(2011) [129] 
2 186 
(92+94) 
55 ± 10 6.3 ± 6.5 223 patients were randomized 
into 2 groups, intensive 
exercise and usual treatment. 
186 patients remained at the 
end of 3 years and analysed. 
No difference between 
the intensive exercise 
group and usual 
treatment group.  
3 year follow up  
Hordern 
2009 [130] 
 
2 176 56.1±11.7 Not 
available 
176 patients randomized into 
intensive exercise and usual 
care.  
No difference in 
myocardial function after 
1 year.  
 
Von Bibra 
(2008) [127] 
2 12 59 ± 12 3 Cross over study with 12 
patients treated with 
glimepiride or rosiglitazone. 
E’ improves with 
rosiglitazone.  
 
Siegmund 
(2007) [132] 
2 12  52 ± 8 9 ± 6 Type 2 diabetes mellitus 
patients on insulin were 
treated with ramipril and 
compared with 8 matched 
controls. 
E’ improve after 9 month 
follow up.  
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1.2.10 Conclusion 
There are some epidemiological, clinical and histological data to 
support a view that heart muscle disease exists in diabetes mellitus. However, 
it remains elusive regarding its natural history, aetiology and determinants of 
myocardial function. Radial function and myocardial functional reserve are 
fairly untested in type 1 diabetes mellitus. Moreover, the precise link between 
myocardial dysfunction and vascular disease, vascular stiffness in particular, 
remains elusive.   
1.3 Non-invasive assessment of vascular structure and function in 
diabetes mellitus  
1.3.1 Carotid intima media thickness (cIMT) 
The arterial wall is made up of three layers: namely intima, media and 
adventitia. The intima is composed of a single continuous layer of endothelial 
cells. It is supported by a layer of smooth muscle cells. The medial layer 
consists of elastic and collagen fibres mixed with smooth muscle cells and is 
responsible for the elastic properties of a medium size artery. The adventitia is 
mainly made of fibroblasts and collagen. 
Details of delineation the structure of the arterial wall can be visualized 
by using high resolution B mode ultrasound. Carotid intima media thickness 
(cIMT) can be non-invasively measured by high resolution B mode ultrasound, 
as demonstrated firstly by Pignoli et al in 1986. [135]  Carotid IMT as 
measured by B mode ultrasound is regarded as a surrogate marker of 
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atherosclerosis. [136] Measurement of cIMT is highly reproducible [137] and 
it has been used as a surrogate endpoint in many interventional studies.  
Carotid intima media thickness (cIMT) is the measurement between the 
leading edge of the lumen-intima interface to media adventitia interface. [138] 
cIMT can be measured on common carotid artery and is usually measured 
starting from 1 cm proximal to the carotid bulb. [139] It is commonly 
measured on the far wall of the common carotid artery. Even though 
reproducibility is more or less the same for the near wall and the far wall, far 
wall intima media thickness is more reflective of true intima media thickness 
from autopsy studies. [140, 141]  
cIMT reflects the burden of atherosclerosis. Increased cIMT correlates 
with an increased absolute risk of cardiovascular disease. [142] [143] [142]  
Several prospective studies have shown that increased cIMT correlates with 
the risk of ischemic heart disease and cerebrovascular disease. [144, 145] 
Carotid intima media thickness was found to be higher in young 
patients with type 1 diabetes mellitus and seems to be associated with higher 
cumulative doses of insulin. [146]  
cIMT is also found to be associated with higher left ventricular mass. 
There is an argument that cIMT is a mere reflection of the shear forces of the 
vessel wall.  
cIMT adjusted for age  in children with type 1 diabetes mellitus was 
demonstrated to be thicker than controls by Krantz et al. [147] In the same 
study, it was also shown that subjects with diabetic complications such as 
microalbuminuria, hypertension or retinopathy had thicker cIMT. However, 
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the control group only had cIMT measurement and therefore it is not possible 
to know that whether the control group’s BMI and other parameters were 
matched with the study group. Similar findings were reported by Jarvislo et al 
who studied 40 type 1 diabetes mellitus children and 30 age matched controls 
and demonstrated that cIMT was higher in type 1 diabetes mellitus. Flow 
mediated dilatation (FMD), a marker of endothelial function, was lower in type 
1 diabetes mellitus. Those with lower FMD among type 1 diabetes mellitus 
have higher cIMT and LDL cholesterol levels.  Atabek et al [148] reported 
similar findings of increased cIMT in children with type 1 diabetes mellitus. 
Age, duration of diabetes, BMI, waist hip ratio, systolic blood pressure and 
triglycerides were significantly associated with cIMT on  Pearson correlation.  
Systolic blood pressures, duration of diabetes and waist hip ratio are 
independently associated with cIMT on multiple regression analysis.  
Patients with type 1 diabetes mellitus of longer duration were studied 
by Distiller et al. [149] The mean age of the patients was 48 years and the 
median duration of diabetes mellitus was 26 years. On multiple regression 
analysis, age, duration of diabetes, hypertension and BMI were positively 
associated with cIMT whereas HDL cholesterol was negatively associated.  On 
logistic analysis, age, hypertension, smoking status and retinopathy appeared 
to be associated with presence of plaque. HbA1c did not show any associations 
with cIMT in this study. 
Not all the studies for cIMT in type 1 diabetes mellitus were positive. 
Studies by Yavuz et al [150]  and Gunczler  et al [151] did not show 
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differences in cIMT between subjects with type 1 diabetes mellitus and 
controls.  
In a systematic review of 23 studies, which included 4019 type 2 
diabetes patients and 1110 with impaired glucose tolerance, Brohall et al [152]  
found that cIMT was greater in diabetes in 20 out of 21 studies. They 
concluded that type 2 diabetes mellitus was associated with a 0.13 mm 
increase in cIMT compared with control subjects. cIMT progresses faster in 
type 2 diabetes mellitus. It progresses with time [153] and may halt 
progressing [154] or even regress with treatment. [155] In  the DCCT/EDIC 
study, intensive treatment slowed down the rate of cIMT progression; the 
effect was sustained even 12 years after stopping intensive treatment, although 
the effect was attenuated  after 6 years. [156] 
Meta-analysis of many studies which used cIMT as an end-point failed 
to prove that those changes in cIMT, either progression or regression, relate to 
cardiovascular events. [157] [158] Whether the use of cIMT in diabetes 
mellitus could increase predictive value in risk stratification to an established 
scoring system such as Framingham Risk Score remains controversial, as 
results were conflicting. Currently no data are available if increased cIMT 
relates to subclinical myocardial dysfunction in type 1 diabetes mellitus. A 
summary of studies assessing cIMT in patients with diabetes mellitus is shown 
in table 1.4. 
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Table 1.4: Summary table of selected studies on carotid intima media thickness cIMT in diabetes mellitus  
Author Type of 
diabetes 
No. Age 
(years) 
Duration 
(years) 
Method Findings Comment 
Yamasaki 
(1994) 
[159] 
1+2  105-DM1 
529-DM2 
104- 
controls 
4-25 
31-86 
 
7-76 
0.5-17 
0.5-49 
Mean cIMT cIMT significantly 
increase in DM1 but 
not in DM2 in 
comparison with age 
matched control. 
Duration of DM and 
age are associated with 
cIMT. 
 
Krantz 
 
(2004) 
[147] 
1 142+87 162.6 
18.83.1 
6.6  0.5 in 
male 
7.9  0.5 in 
female 
Mean cIMT Age adjusted IMT 
higher in DM1. Among 
DM1, cIMT was higher 
in those with 
complications.  
Not age-matched. 
Controls older than 
DM1. No other 
parameters apart from 
cIMT were collected 
form control group.  
Jarvislo 
( 2004 ) 
[14] 
1 45+30 112 4.4  2.9 FMD and mean  
and maximum 
cIMT 
Both mean and 
maximum cIMT higher 
in DM1. FMD response 
was lower in  
 
Atabek 
(2006) 
[148] 
1 45+33 14.82.5 
14.12.1 
4.42.5 Mean cIMT Increase IMT in DM1 
and correlates with 
duration of DM 
 
Distiller 
(2006) 
[149] 
1 148 19-76 
Median-
48 
18-59 
Median- 26 
Mean cIMT was 
measured. 
Analysis done on 
Median IMT 0.66 mm. 
Age, duration of DM, 
BMI and hypertension 
No control group 
included. Wide range 
of patient with 
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several models, 
depending on 
presence of 
plaque, actual 
IMT thickness 
and risk based on 
IMT thickness.  
appear to be major risk 
for increase IMT in 
DM1. 
different 
complications.  
Gunczler 
(2002) 
[151] 
1 20+20 11.9±3.6 3.4±3.3 IMT on both 
carotid arteries 
measured. 
Cardiac function 
assessed by 
echocardiography. 
No difference in IMT 
or cardiac function 
noted. However, LDL 
was higher in DM1.  
 
  
 
 
 
 
 
39 
1.3.2 Characteristics of the vascular tree and their impact on stiffness 
The elastic properties of arteries vary along the vascular tree. The more 
proximal along the arterial tree the more elastic the vessel is and the more 
distal the stiffer the artery is. This heterogeneity has important physiological 
consequences. As a pressure wave propagates along the vascular tree it is 
augmented by reflected waves coming back from reflection sites such as 
bifurcation of arteries. This phenomenon is called “ amplification 
phenomenon” [160] Therefore, brachial arterial pressure may sometimes be  
higher than central arterial pressure. The use of brachial pulse pressure instead 
of central pulse pressure to calculate regional arterial stiffness may not be 
accurate.  
1.3.3 Arterial stiffness 
Arterial stiffness is a dynamic component of arterial performance and it 
is not uniform throughout the arterial tree. [161] Arterial stiffness can be 
assessed as local, regional and systemic stiffness. Local and regional stiffness 
can be assessed directly and non-invasively.  
1.3.4 Pulse wave velocity (PWV) 
Pulse wave velocity is the most simple and reproducible method to 
assess regional arterial stiffness. Carotid femoral PWV is considered as the 
gold standard measurement for arterial stiffness. It is usually measured using 
foot to foot velocity method using various waveforms at different sites. It can 
be obtained transcutaneously at the right carotid artery and right femoral artery 
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and the time delay measured at the feet of two wave forms. [160]  The major 
limitation factor for the measurement of carotid femoral PWV is the 
inaccuracy of the distance measured. The prognostic value of aortic PWV in 
the general population was assessed in a prospective study by Willum-Hansen 
et al. [162] One thousand six hundred and seventy eight (1678) subjects 
between 40 and 70 years old were followed up for a median of 9.4 years. Even 
after adjustment for age, sex, body weight, blood pressure and smoking status, 
aortic PWV was proved to have prognostic significance. With one standard 
deviation increase in PWV i.e. 3.4m/s, the risk of cardiovascular events 
increased by 16 to 20%.  
Increased pwv was also found to be associated with increased mortality 
in patients with diabetes mellitus. [163] Arterial stiffness measured by 
systemic arterial compliance, carotid femoral transit time and aortic 
augmentation index was increased in type 2 diabetes mellitus and subjects with 
impaired glucose tolerance. [164]  
1.3.5 Other indices of local arterial stiffness 
Direct measurement of arterial stiffness requires simultaneous 
measurements of changes in arterial diameter and pressure at the same site. 
Diameter changes can be accurately measured by using a wall tracking 
technique with high resolution ultrasound. However, the estimation of pressure 
changes could be difficult because of the amplification of pulse pressure and 
the inaccuracy of sphygmomanometer systems. [165]  Indices of local stiffness 
are listed in table 1.5.
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Table 1.5: Indices of local arterial stiffness (adapted from O’ Rourke et al) [166] 
 
Index Definition Formula  
Arterial distensibility  Relative diameter ( or area ) change for a pressure increment  ( ∆D/∆P × D) ( mmHg -1) 
Arterial compliance Absolute diameter ( or area ) change for a given pressure step at fixed 
vessel length 
∆D/∆P ( cm/mmHg) or 
 (cm2/mmHg) 
Elastic modulus The pressure step required for ( theoretical) 100% stretch from resting 
diameter at fixed vessel length 
( ∆P ×D/∆D) mmHg  
Young Modulus  The pressure step per square centimetre required for ( theoretical ) 100% 
stretch from resting length 
∆P  D / ( ∆ D× h) ( mmHg/cm)    
Stiffness index  Ratio of logarithm ( systolic/diastolic pressures) to relative change in 
diameter 
Ln ( Ps/ Pd) / ( Ds-Dd)/Dd 
( non- dimensional)  
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1.3.6 Central pulse wave analysis  
 
When the heart ejects, a forward running pressure wave is generated, 
which is reflected in the periphery and returns as a backward running wave 
towards the heart. The pressure measured at a point consists of the 
superposition of these forward and backward pressure waves. [167] When the 
artery stiffens with increasing age or disease, the waves travels faster. As a 
consequence, the reflected wave add onto the forward running wave in early 
systole , rather than in late systole or diastole as it happens in young subjects.  
This changes the morphology of central pressure wave form from so called C 
type in young subjects to A type in older subjects. This augmented pressure 
wave increases systolic pressure and thus increases the load on the heart 
(afterload and heart work). 
Quantification of central pressure wave forms might provide more 
useful measures than peripheral pressure. This wave reflection is commonly 
expressed as the  “ augmentation index”. Augmentation index is defined as the 
ratio of augmented pressure, attributed to the reflected wave to the amplitude 
of the pulse (pulse pressure).  
AIx = 100 × AP/PP 
 
Assessment of augmentation index requires measurement of pressure 
wave morphology. Augmentation as a relative measure, can be derived from 
non-calibrated pressure tracings. [167] However, the morphology of the 
pressure wave needs to be valid. The identification of the inflection point 
where the reflected wave adds on to the forward wave is critical in calculating 
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augmentation index. In C type waveform, inflected waves arrive late in systole, 
therefore inflection point occurs after the pressure has reached systolic 
pressure. In these cases, augmented pressure and augmentation index are 
negative. In A type wave form, the inflected point occurs before systolic 
pressure, Therefore, augmented pressure is positive and so is augmentation 
index. However, in waveforms between A and C, inflection point may occur 
every close to or buried by the systolic peak. Visual identification of inflection 
point is prone to error. The most well-known method was the one described by 
Takazwa et al based on 4
th
 order derivatives. The exact procedure for 
determining the inflection point in commercially available systems like 
Sphygmocor is not disclosed.  
The major disadvantage of augmentation index is that it is a composite 
measure depending not only on the magnitude of wave reflection but also on 
other parameters such as subject’s height, heart rate and aortic stiffness. 
Lacy et al [168] studied carotid femoral PWV and augmentation index 
in  66 subjects with diabetes mellitus ( 25 type 1 diabetes mellitus) and in 66 
controls. Despite finding a higher PWV and pulse pressure, an increase in 
augmentation index was not observed in the diabetic population. It was 
suggested that pulse wave analysis may not be as reliable as PWV in diabetic 
population to assess arterial stiffness. Moreover, Wilhelm et al compared 
augmentation index among patients with cardiovascular disease, patients with 
diabetes mellitus and healthy controls. [169] Even though augmentation index 
was higher in diabetic subjects, it did not prove to be statistically significant.  
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On the other hand, Haller et al [170] demonstrated that young children 
( 10 -18 years) with type 1 diabetes mellitus had increased augmentation index 
in comparison with age matched controls. Similarly, Wilkinson et al [171] 
proved that augmentation index was increased in type 1 diabetes mellitus. 35 
patients with type 1 diabetes mellitus of long duration (a minimum of 10 years 
) were studied together with age matched controls. Augmentation index was 
significantly higher in the diabetic group.  
1.3.7 Endothelial function 
 
Endothelial dysfunction is considered to be a key early event in the 
atherosclerotic process. Assessment of endothelial function may help clinicians 
identify and stratify subjects at risk of vascular disease. Endothelial function 
may be assessed by non-invasive methods such as flow mediated dilatation 
(FMD). Flow mediated dilatation (FMD) measures the change in diameter of 
the brachial artery in response to shear stress induced by increased flow after 
the release a pressure cuff applied around the forearm for several minutes. It 
measures the response of vascular smooth muscle to nitric oxide by released 
endothelial cells. (i.e. endothelial dependent endothelial relaxation). FMD has 
been demonstrated to predict cardiovascular events in subjects with peripheral 
vascular disease in a prospective study. [172] 
 
 
 
 
  
 
 
 
 
 
45 
1.3.8 Wave intensity 
 
The confluence of waves in the arterial circulation results in 
simultaneous changes in pressure and flow. Wave intensity (WI) is defined as 
the product of the time derivatives of the measured pressure (dP/dt) and 
velocity (dU/dt) spatially averaged across the vessel diameter. [173] 
 
WI = (dP/dt) × (dU/dt) 
 
WI provides information regarding the dynamic action of the heart and 
blood vessels as well as their interaction.  To measure WI, pressure can be 
obtained either invasively or non-invasively. Harada et al described a method 
where WI could be estimated non-invasively from a carotid artery by echo-
tracking method. [174] With non-invasive measurement, local pressure wave 
forms can be estimated from changes in the arterial diameter and velocity can 
be acquired by colour flow Doppler from the same site. It is feasible to derive 
pressure wave from diameter change because diameter change was shown to 
be linearly related to changes in pressure. [175] Therefore, diameter can be 
calibrated for pressure using this non-invasive method.  
The methods used in most clinical studies provide net WI. Studies in 
the aorta have shown three major components (Figure 1.1) [176] ; the first 
peak  is due to the net forward compression wave in early systole resulting 
from left ventricular contraction. It is followed by net negative wave intensity, 
the backward compression wave, in midsystole secondary to wave reflections 
from reflection sites. The third wave intensity peak is the forward expansion 
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wave which starts in the late systole and coincides with ventricular relaxation, 
slows down the blood flow and reduces pressure [177].  
 
Figure 1.1:  PWI output (Aloka 5500) – The relationship of pressure and 
velocity shown in the upper graph and the PWI output shown in the lower 
graph 
 
 
 
  Separated forwards and backwards travelling waves can be 
estimated. Local wave speed is calculated from the slope of the pressure-
velocity loop in early systole and within this measurement the separated waves 
can be calculated using an application of the water hammer equation. The 
Pressure 
Velocity  
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Expansion 
wave  
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individual wave separation could provide more insight in the interaction 
between the left ventricle and the arterial system i.e. ventriculo-arterial 
coupling. This method of wave separation has been described by Rakebrandt et 
al, using customised software. [178]  
The wave intensity method using carotid arterial wall tracking is non-
invasive and does not require any assumption from models of circulation. 
[160] However, in this method blood pressure is normally measured in brachial 
artery and blood pressure and changes in arterial diameter are not measured 
simultaneously. The clinical utility of the WI method has been used in some 
clinical and epidemiological studies for their potential clinical use. Laio et al 
studied the link between carotid artery stiffness and the development of 
hypertension. [179]  In the Bogalusa Heart study, increased pressure-strain 
modulus ε was associated with concentric left ventricular hypertrophy. [180] 
In the SMART study (Second Manifestation of ARTerial disease) carotid 
stiffness was associated with cardiovascular events in those patients who had 
had vascular disease before[181]. However, after adjustment for age, the 
relationship did not exist anymore.  
Increased β and ε were related to impaired longitudinal myocardial 
function.[182] Because of the information provided on wave separation, WI 
may be a useful method in assessing ventriculo-arterial coupling and may be a 
useful tool in predicting subclinical myocardial dysfunction.  
1.3.8 Ventriculo-arterial coupling  
 
Arterial stiffness should be considered together with cardiac function. 
Ventricular-arterial coupling, the interaction between the heart with the 
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systemic vasculature is a key determinant for cardiovascular performance. 
[183]  Both the left ventricle and arterial system could be considered as elastic 
chambers with known volume elastances. [165]  Under normal circumstances, 
the left ventricle and arterial system couple optimally resulting in maximal 
cardiac stroke work and cardiac metabolic efficiency. However, in heart 
failure, due to left ventricular systolic dysfunction, ventricular-arterial coupling 
is impaired and pump dysfunction leads to increased impedance and decreased 
compliance in arterial system. Moreover, there is some evidence that 
ventricular-arterial coupling may impair before significant pump failure. [184] 
In an animal model of type 2 diabetic mice, it was reported that although 
mechanical efficiency and myocardial contractility were impaired, cardiac 
output was maintained by increased preload and decreased afterload.  
1.4 Chapter  Conclusion 
 
From this review of the literature, relating to myocardial and vascular 
function particularly in type 1 diabetes mellitus, several questions remain. In 
particular it remains unclear whether  left ventricular dysfunction in early 
stages of myocardial dysfunction  in type 1 diabetes mellitus is mainly 
diastolic or not; if there is any evidence of reduced myocardial functional 
reserve in type 1 diabetes mellitus which may suggest small vessel disease; any 
role of “radial compensation” in the presence of longitudinal dysfunction. 
Moreover, there is some evidence to suggest early atherosclerosis and conduit 
artery stiffness in type 1 diabetes mellitus. Nevertheless, their association with 
myocardial function has not been fully explored.  
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CHAPTER 2- HYPOTHESES AND OBJECTIVES 
 2.1 Hypotheses  
 
This study addresses the following hypotheses:  
 
 Young subjects with type 1 diabetes mellitus have reduced 
myocardial function, both systolic and diastolic. 
 Young subjects with type 1 diabetes mellitus have reduced 
myocardial functional reserve compared to controls. 
 Young subjects with type 1 diabetes mellitus have increased 
conduit arterial stiffness and early changes of atherosclerosis 
such as increased cIMT. 
 Changes in myocardial function and vascular function are 
correlated in type 1 diabetes mellitus.  
 2.2 Study Objectives  
 
The specific research objectives are:  
 
 To quantify regional myocardial function in young subjects 
with type 1 diabetes mellitus, both at rest and during 
dobutamine stress.  
 To assess the myocardial functional reserve in young subjects 
with type 1 diabetes mellitus in response to dobutamine stress. 
 To perform a comprehensive survey of large artery function.  
 To compare subclinical myocardial and vascular function in 
young subjects with type 1 diabetes mellitus.  
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CHAPTER 3- METHODS 
3.1 Introduction 
 
A study was conducted at the Wales Heart Research Institute to 
determine myocardial and vascular function in young subjects with type 1 
diabetes mellitus.  
3.2 Subjects and recruitment  
 
Patients aged less than 30 years with type 1 diabetes mellitus were 
recruited from diabetes clinics at Cardiff and Vale University Health Board.  
Inclusion criteria and exclusion criteria for the study subjects are as 
follow: 
Inclusion Criteria 
(1) Subjects with type 1 diabetes mellitus aged 16-30 years 
                                          (or) 
(2) Healthy subjects aged 16-30years 
 
Exclusion Criteria 
(1) Known cardiovascular diseases: cerebrovascular event, peripheral 
vascular disease 
(2) Heart failure or documented cardiomyopathy of any cause 
(3) Pregnancy, risk of pregnancy, or current breastfeeding 
(4) Type 2 diabetes mellitus 
(5) Uncontrolled medical conditions such as thyrotoxicosis which may 
potentially affect cardiovascular and haemodynamic status. 
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(6) Renal failure ( Creatinine >150μmol/l or on dialysis) 
 
From 74 eligible patients with type 1 diabetes mellitus who were 
approached, 19 agreed to participate in the study.  40 healthy volunteers were 
recruited by advertisement in Cardiff and Vale University Health Board 
hospitals.  The recruitment is summarised in figure 1.  
All subjects gave written informed consent.  The study was approved 
by the South East Wales Research Ethics Committee and was compliant with 
the Declaration of Helsinki. 
A detailed history was taken regarding diabetes duration and 
treatment. Case notes were reviewed and previous annual review results were 
reviewed for history of retinopathy and microalbuminuria. Detailed exercise 
history including type, hours per day and frequency was obtained from all the 
participants. From the 40 healthy volunteers who participated, 21 had 
dobutamine stress echocardiography and vascular studies. Among the rest, 20 
had baseline echocardiographic studies, and 13 had vascular studies; 7 
volunteers failed to attend for follow up vascular studies. 
19 subjects with type 1 diabetes mellitus participated in the study. All 
but one of them had dobutamine stress echocardiography and vascular studies. 
One subject opted only to have baseline echocardiography and vascular 
studies. None of the subjects were current or ex-smokers and they were not 
taking any other medications apart from insulin.  
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3.3 Study Endpoints 
 
Primary endpoints of the study are: 
Myocardial functional reserve and longitudinal myocardial function 
Secondary endpoints of the study are: 
Augmentation index, pulse wave velocity, stiffness index β, Peterson’s elastic 
modulus ε, carotid intima media thickness (cIMT). 
3.4 Study Sample size calculation 
 
Sample size estimation was based on the previous study of type 2 
diabetes mellitus for myocardial functional reserve by Vinereanu et. al. [85] 
The paper reports a mean myocardial functional reserve of 5.4 cm/s, SD 2.0 
cm/s in type 2 diabetes mellitus compared to mean 7.7 cm/s, SD 1.7 cm/s in 
controls. Assuming an SD of 2.0 cm/s for these within-subjects changes, a 
study comparing 25 cases v. 25 controls would be sensitive to detect a 
difference of 1.6 cm/s or greater between cases and controls with power 80% 
using a test at the conventional two-sided 5% level. 
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Figure 3.1: Flow diagram of study participants and assessment 
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3.5 Carotid intima media thickness measurement 
 
On visit 1 of the study, subjects came in the early morning after fasting for 10 hours. 
Subjects were asked to abstain from smoking and caffeine for 24 hours before the visit. 
Diabetic subjects were also asked not to have morning insulin and breakfast until after the 
scan. After arrival, subjects rested for 20 minutes in a quiet and temperature controlled 
environment.  
Carotid intima media thickness (cIMT) and stiffness parameters (β and 
ε)measurement: Subjects underwent  a B mode ultrasound scan of the carotid arteries on both 
sides of the neck together with wave intensity analysis on both sides, using an Aloka 5500 
ultrasound machine and a 7.5 MHz linear array transducer, with the subject lying supine and 
with the neck slightly extended and turned towards the side away from the site of scanning. 
The common carotid artery was scanned anteriorly and longitudinally. The gain control was 
adjusted to obtain a clear delineation of intima, media and adventitia layers of the far wall of 
the common carotid artery. The images were recorded and stored on the hard drive of the 
Aloka machine, synchronizing with ECG.  
cIMT was measured on the far wall of the common carotid arteries on both sides of 
the neck at  1 cm below the carotid bulb. Images were also analysed off-line for cIMT using 
Vascular Image Analysis software. A region of interest (ROI) was placed below 1 cm of the 
carotid bulb manually. The ROI was placed on the best delineated region of the common 
carotid artery covering a minimum of 1 cm length. Intima and media were marked 
automatically by the software respectively with I and M line. Carotid intima media thickness 
was measured by the software and an average value was taken from both sides. 
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Figure 3.2: B Mode ultrasound image showing carotid intima-media interface.  
 
 
3.6 Wave Intensity Methods 
 
Figure 3.3: Ultrasound image showing automated wall tracking of the media-adventitia 
boundaries of the near and far walls of the carotid artery. 
 
After carotid intima media thickness measurement, wave intensity measurement was 
carried out with the patient lying. The wave intensity measurement was also performed in the 
fasting state. Pulse and blood pressure were measured on the right arm. None of the subjects 
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were on any antihypertensive or beta blockers or calcium channel blockers or known to have 
diabetes.  
Subjects were supine on an examination bed and the carotid arteries were scanned on 
both sides of the neck in the anterior triangle. The neck was slightly flexed and turned to the 
opposite side of scanning. The Aloka 5500 machine was used to scan carotid arteries in pulse 
wave intensity (PWI) mode. Blood pressure was entered manually together with the patient’s 
height, weight and age. 
The carotid arteries within 2 cm from carotid bulbs were scanned on both sides of the 
neck, using 7.5 MHz probe. The junction of the carotid media and adventitia was identified 
and adjustable gates were placed at the junction on both anterior and posterior walls of the 
common carotid artery. Changes in diameter were calculated automatically from beat to beat. 
The difference between the displacement waveforms of the anterior and posterior walls of the 
artery was displayed in real time. At the same site, and independently steerable ultrasound 
beam was positioned to obtain the mean velocity of flow at the same site. An average 
pressure, diameter and wave intensity were obtained over 20 beats and analysed off-line for 
stiffness parameter  and . The values were measured on both sides of the neck and 
averaged.  
Stiffness parameter beta () was calculated by the formula:  
 = 1n (Ps/Pd)/(Ds-Dd)/Dd 
Peterson’s elastic modulus strain  was calculated by using the formula:   
=  (Ps-Pd)/ (Ds-Dd)   Dd, 
where Ps and Pd are systolic and diastolic pressures respectively, and  Ds and Dd are 
maximal and minimal diameters of the arteries as measured by wall tracking method at 
carotid intima media junction on carotid arteries. 
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 Wave intensity (WI) is the product of instantaneous changes in velocity and diameter. 
WI can be calculated by the formula: 
WI = (dP/dt) × (dU/dt) 
 
where dP =  derivatives of pressure change and dU= derivatives of velocity in change. 
3.7 Pulse wave analysis methods  
 
Figure 3.4: Pulse wave analysis on right radial artery with a tonometer 
 
 
 
Pulse wave analysis was performed by using tonometry on the right radial artery with a 
Sphygmocor machine. Subjects’ details and blood pressure were manually entered into the 
software. A high-fidelity micromanometer was used by placing the tip of the manometer on 
the right radial artery, perpendicular to the artery ensuring the probe flattening the artery but 
not occluding it. The data were transferred to a portable computer. The computer screen 
displayed waveforms so that the operator could recognize if the correct wave forms were 
obtained or not. 20 consecutive waves were obtained. The software generated peripheral and 
the central wave forms. Augmentation index was calculated by the software from central 
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wave form. Augmentation index is the difference between the first and second peaks of the 
central arterial wave expressed as a percentage of the pulse pressure.  
 
Figure 3.5: Schematic representation arterial pulse wave  
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 PP        
 
                                             ∆t 
  
  
AI = AP/PP × 100 
 
AP = augmentation pressure, PP = pulse pressure, AI = augmentation index and ∆ t = 
reflection wave transit time 
 
Carotid-femoral pulse wave velocity was also obtained with  tonometry. The distance 
from the sternal notch to the measurement site on the right carotid artery was measured in 
millimetres, using a measuring tape. The distance was entered into the computer system. 
Similarly, the distance from the sternal notch to the femoral artery was also measured in 
millimetres and entered into the system.  3 lead ECG monitor was attached to the patient and 
the computer system.  
Arterial waveforms were obtained sequentially from the right common carotid artery 
and the right femoral artery. Wave transit time was calculated by the software, using the R 
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Inflection 
point  
Aortic valve 
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wave from the simultaneously recorded ECG as a reference frame. The software calculated 
the carotid femoral pulse wave velocity using the surface distances entered and the transit 
time.  
3.8 Blood Tests 
 
After the vascular studies, fasting blood samples were taken for full blood count, urea, 
creatinine and electrolytes, fasting glucose, lipid profiles, liver function test, high sensitivity 
CRP, and glycated haemoglobin (HbA1c). Serum samples were analysed at the Biochemistry 
Laboratory at the University Hospital of Wales, Cardiff. 
3.9 Conventional Echocardiography Methods 
 
On Day 7, subjects returned to have echocardiography. Diabetic subjects were asked 
to have a light meal and the usual dose of insulin. Controls were also asked to have a light 
meal. A detailed baseline study was performed with the subject lying in a left lateral position, 
using a commercially available echocardiography machine (Vivid 7, GE Medical Systems, 
Horten, Norway) with a 2.5-MHz phased-array transducer. 
Images were recorded in apical four-chamber, two-chamber, and five-chamber, and 
parasternal long-axis and short-axis, views.  All imaging was performed by either of two 
experienced cardiologists who were blinded to whether the subjects were diabetic patients or 
controls. All analysis of  baseline grey-scale echocardiographic images and myocardial 
velocity imaging were performed by myself, also without knowledge of the status of each 
subject.   
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From the parasternal long-axis view (PLAX), the left ventricular outflow tract 
diameter was measured and cross-sectional area was calculated. (Figure 3.6)  
 
Figure 3.6: Parasternal long axis view (PLAX) for LVOT cross-sectional area 
calculation. 
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Mitral inflow velocities were recorded by using conventional pulsed-wave Doppler 
echocardiography, positioning the sample volume at the level of the tips of mitral valve 
leaflets in an apical four-chamber view. (figure 3.7) 
 
Figure 3.7: Pulsed Doppler for mitral inflow velocities 
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M-mode echocardiography was performed in accordance with the recommendation of the 
American Society of Echocardiography, in a parasternal long-axis view, to assess left 
ventricular dimensions. Indices of the left ventricular wall were measured.  
 
Figure 3.8: M-mode of left ventricle  
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Lateral and medial mitral annular excursions and tricuspid annular excursions were 
measured from M-mode examinations. (figures 3.9, 3.10, and 3.11) 
 
Figure 3.9: M-mode examination showing lateral mitral annular excursion 
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Figure 3.10: M-mode examination showing medial mitral annular excursion 
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Figure 3.11: M-mode examination showing tricuspid annular excursion  
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A colour M-mode recording of mitral flow propagation was performed in the apical 
long-axis view by placing the cursor parallel to the left ventricular inflow. (figure 3.12) 
 
Figure 3.12: Mitral flow propagation on colour M-mode 
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Intraventricular relaxation time (IVRT) was measured from pulsed Doppler 
examination near the LVOT. (figure 3.13) 
 
Figure 3.13: IVRT measurement by placing cursor for pulsed Doppler near LVOT 
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From pulsed Doppler for LVOT flow, the velocity time integral (VTI) was calculated. 
Stroke volume (SV) was calculated by multiplying the cross-sectional area of the left 
ventricular outflow tract (calculated from the dimension measured on the long-axis image) 
and the VTI. (figure 3.14) 
Cardiac output was calculated by multiplying SV and heart rate (HR). 
SV = VTI × CSA of LVOT 
 
CO = SV × HR 
 
Figure 3.14: measurement of velocity time integral (VTI) at LVOT  
 
 
VTI 
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Pulsed Doppler profiles of lateral and medial mitral annular motion and tricuspid 
annular motion were measured by real-time myocardial velocity imaging. (figure 3.15, 3.16, 
and 3.17) 
 
Figure 3.15: Pulsed Doppler of lateral mitral annulus  
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Figure 3.16: Pulsed Doppler of medial mitral annulus 
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Figure 3.17: Pulsed Doppler of tricuspid annulus  
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3.10 Dobutamine Stress Echocardiography Methods 
 
After acquiring baseline echocardiography images, a standard dobutamine stress 
echocardiogram (DSE) combined with myocardial velocity image was performed according 
the protocol. A cannula was inserted into a vein in the left antecubital fossa and a blood 
pressure cuff was applied to the right arm with the patient in the left lateral position. 
Myocardial velocity imaging was performed at each stage and images were stored for off-line 
analysis. Images were acquired in three apical imaging planes - a 4 chamber view, a 2 
chamber view, and a long axis view – and in parasternal long axis and short axis views, so 
that myocardial velocity could be analysed off line for longitudinal myocardial function in 
basal septal (BS), basal lateral (BL), basal anterior (BA), basal anteroseptal (BAS), basal 
posterior (BP) and basal inferior (BI) segments, and for radial myocardial function in the 
basal posterior segment.  
Images were acquired at the end of passive expiration with the patient holding his or 
her breath, in order to minimize disturbances from respiratory movement. Three cardiac 
cycles were recorded for each view. The depth and width of each image was optimized so 
that the frame rate recorded was more than 120 frames per second. Dobutamine was infused 
via a peripheral vein and increased every 3 minutes from a starting dose of 5 µg/kg/minute to 
10, 20, 30, and 40 µg/kg/minute or until the subject reached the target heart rate of 80% (220 
– patient’s age in years). 12 lead ECG, pulse and blood pressure were monitored every 3 
minutes throughout the procedure. Dobutamine infusion was stopped if the subject could not 
tolerate the infusion or when the target heart rate was achieved. 
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Images were analysed by myself off-line, for baseline echocardiographic 
characteristics, and longitudinal and radial myocardial function. The measurements were 
stored in an Excel spreadsheet.  
 
3.11Analysis 
 
Baseline echocardiography:  Left ventricular dimensions were measured from a 
parasternal M-mode recording, and left ventricular mass index was calculated by Devereux’s 
formula. [185]  Left ventricular volumes and ejection fraction were calculated from apical 4- 
and 2-chamber views using Simpson’s biplane method.   
 
Dobutamine stress echocardiography:  Images were analysed off-line using Echopac 
software (Echopac TV1, GE).  Systolic velocity (figure 3.19) and displacement (figure 3.18) 
were measured in 6 basal myocardial segments (basal lateral, basal septal, basal anterior, 
basal anteroseptal, basal inferior and basal posterior) at rest and during the final minute of 
every stage of the dobutamine infusion, from 3 beats and averaged.  Velocities of radial 
function were analysed from the basal posterior segment in a parasternal long-axis image. 
Systolic strain (figure 3.20), peak systolic strain rate and peak early diastolic strain rate 
(figure 3.21) were measured in basal septal and lateral segments at rest, at dobutamine dose 
of 20µg/kg/minute and 30µg/kg/minute respectively. All measurements were made by one 
observer.  
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Figure: 3.18 Displacement in basal septal and basal lateral segments  
 
 
 
Figure: 3.19 Regional myocardial velocities (S, E, and A) in basal septal segments 
(Velocities were measured off-line)  
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Figure 3.20 Measurement of strain in basal septal segment   
 
 
 
Figure 3.21 Measurement of strain rates in basal septal segment  
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3.12 Reproducibility of myocardial function  
 
Intra-observer reproducibility was assessed by reanalysing the digitally stored studies 
after a minimum interval of 2 weeks, from a random selection of 10 diabetic subjects and 10 
control subjects. Repeated measurements were made of myocardial systolic velocities in four 
basal segments, namely basal lateral (BL), basal septal (BS), basal posterior (BP), and basal 
anterior (BA) segments, at rest and at 10 and 30 µg/kg/min of dobutamine. Repeated 
measurements of systolic displacement were made in three basal segments namely BL, BA 
and BP at the same stages of the protocol. Reproducibility of measurement was assessed by 
coefficient of variation and by Bland-Altman method.  
3.13Reproducibility of vascular method 
 
Five healthy volunteers were recruited for studies of the reproducibility of the 
vascular method, and carotid ultrasound was performed twice in these subjects by myself, for 
cIMT measurement and measurement of stiffness parameters β and ε. Measurements were 
repeated at least 2 weeks apart in the same subjects and reproducibility was assessed by 
coefficient of variation and by Bland-Altman method.  
3.14 Statistical Methods  
 
Data were analysed by using SPSS software 16 version (SPSS Inc, Chicago, IL, 
USA). Parametric data were compared by using independent t test and non-parametric data 
were compared by Chi- square test. Differences between groups were tested for statistical 
significance by using analysis of variance (ANOVA). Pearson correlations were used to test 
correlation between two parametric data. The results are presented as mean value ± standard 
deviation. P value of <0.05 in a two-tailed test was regarded as statistically significant. 
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Reproducibility of measurement was tested by both Bland-Altman test and coefficient of 
variation.  
Pearson’s correlation was used to assess bivariate correlations between myocardial or 
vascular function and baseline characteristics and biochemical results. Multivariate analysis 
on linear regression was used to assess for independent factors for myocardial and vascular 
function.  
All analyses for displacement and velocities during dobutamine stress were performed 
by Repeated Measures Analysis of Variance (Linear Mixed Model) with subject treated as a 
Random effect and Dose/Diabetic Group as fixed effects.  Dose level was the repeated 
element. 
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CHAPTER 4- RESULTS - Baseline Characteristics 
 
4.1 Baseline Characteristics (whole group) 
 
Baseline characteristics of the subject in the whole group (n=53) are shown in Table 
4.1 
Table 4.1 Baseline Characteristics of the whole group (n=53)  
 
 Type 1 Diabetes 
Mellitus 
(n=19) 
Controls 
(n=34) 
P value 
Age (years) 21.1 ± 3.6 
(17-28) 
24.6 ± 3.0 
(20-29) 
0.001 * 
Height (m) 1.71 ± 0.10 
(1.53-1.93) 
1.74 ± 0.09 
(1.61-1.94) 
0.23 
Weight (kg) 73.7 ± 12.8 
(50-106) 
73.6 ± 13.1 
(49-101) 
0.98 
BMI (kg/m
2
) 25.1 ± 3.1 
(19.5-31.3) 
23.9± 2.8 
(18.2-30.9) 
0.17 
Waist circumference 
(cm) 
84.4 ± 9.3 
(68-106) 
84.7 ± 10.9 
(60-104) 
0.91 
Waist Hip Ratio 0.80 ± 0.07 
(0.69-0.93) 
0.81 ± 0.07 
(0.61-0.94) 
0.54 
Pulse (rate/min) 72± 10 
(53-90) 
64 ± 11 
(47-101) 
0.02* 
SBP (mmHg) 114 ± 9 
(100-132) 
115± 12 
(94-147) 
0.70 
DBP (mmHg) 72 ± 6 
(62-85) 
71 ± 6 
(60-84) 
0.62 
Duration of diabetes 
mellitus (years)  
7.46 ± 6.24  
(0.33-20)  
NA NA 
 
*Ranges of the data are presented in brackets.  
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 34 controls and 19 type 1 diabetes mellitus patients participated in the whole study. 
All of them had baseline echocardiography. Patients in the T1DM group were about 3 years 
younger than the control group. (21.1 ± 3.6 vs. 24.6 ± 3.0, p = 0.001). However, BMIs of the 
two groups were matched. (25.1 ± 3.1 vs. 23.9 ± 2.8, p = 0.17)  
Subjects with diabetes mellitus were not on any other medications other than insulin 
and control subjects did not take any medicine. There was no history of peripheral 
neuropathy, and no recorded history of retinopathy or microalbuminuria in subjects with 
diabetes mellitus.  
Resting pulse rate was significantly higher in type 1 diabetes mellitus in comparison 
with controls. (72 ± 10 vs. 64 ± 11, p= 0.02)  
There was no significant difference between the groups in waist hip ratio, and systolic 
or diastolic blood pressure.  
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4.1.1 Female: Male Ratio (whole group) 
 
The following table 4.2 shows participants in terms of gender and diabetes status.  
Table 4.2: Male Female Ratio (whole group) N=53 
 
 Sex 
Male Female Total 
T1DM 7 12 19 
Controls 20 14 34 
Total 27 26 53 
 
 
On Chi Square test, there is no significant difference in sex ratio of the whole group. 
(i.e. all those patient who had baseline echocardiography and vascular scan)   (p= 0.125)  
4.2 Exercise history  
 
All subjects gave a detailed exercise history including duration, frequency per week, 
type and intensity of exercise. The exercise activity is presented in metabolic equivalents 
(METs) as described by Jette et al. [186] There was no difference in the exercise activity in 
terms of METs per week between the two groups. (22.13 ± 26.17 vs. 26.07 ± 22.12, p=0.61)  
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4.3 Discussion  
 
Age 
 
 Subjects aged between 16 years and 30 years were recruited in the study. Mean age 
was 21 years for type 1 diabetics and 23 years for control group. Type 1 diabetic subjects 
aged between 12 and 18 years were studied with tissue Doppler imaging by Salem et al. [187]  
They found evidence to suggest left ventricular diastolic dysfunction even at a younger age. 
The mean duration of diabetes in that study was 7.6 ± 3.1 years and type 1 diabetic subjects 
had higher A, lower E/A ratio, lower Em and Em/Am. NT-pro-BNP was also found to be 
elevated in diabetic subjects. 
The mean age for subjects in this study with type 1 diabetes mellitus was 21.1 ± 3.6 
years. In comparison with previous studies for myocardial dysfunction in type 1 diabetes 
mellitus, the subjects in this study were much younger.  The mean ages for subjects with type 
1 diabetes mellitus in Palmieri’s studies were 34 ± 10 years, in a study with low dose 
dobutamine infusion  [104], and 33 ± 10 years in  another study . [105] In a study by Gul et 
al, the mean age for type 1 diabetes mellitus was 27.7 ± 6.9 years. [188] 
Gender  
 
The protective effect of female gender on cardiovascular disease is lost in both type 1 
and type 2 diabetes mellitus, and the reasons for this are poorly understood. [189]  The rate of 
coronary artery disease was similar in both sexes in the Epidemiology of Diabetes 
Complications Pittsburgh follow up study. [190] In the Framingham study, the risk for heart 
failure was increased three folds for women with prior coronary artery disease.[31] Male: 
Female ratio in my study is not different either for the whole group or for the stress group.  
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Heart rate 
 
 Resting heart rate (RHR) is determined by circulating catecholamine levels, drug 
treatment such as beta-blockade, body temperature and autonomic function status. In 
physically fit athletes, vagal tone tends to be higher and it leads to slower heart rate. On the 
other hand, diabetic subjects are prone to autonomic neuropathy and when parasympathetic 
nervous system is involved, unopposed sympathetic drive could result in sinus tachycardia. 
The higher resting heart rate in type 1 diabetics in our study could be either due to early 
autonomic neuropathy or simply because control subjects were generally fitter than type 1 
diabetics in my study. Autonomic neuropathy was not tested in my study. However, none of 
the subjects had any other microvascular complications of diabetes mellitus namely diabetic 
retinopathy or microalbuminuria. In the absence of other microvascular complications, it is 
unlikely that increased heart rate in subjects with diabetes is due to autonomic neuropathy.  
 Elevated resting heart rate is recognized to be a risk factor for cardiovascular 
mortality in the general population. [191] 
 In a follow up study of 523 diabetic patients including 221 type 1 diabetics, corrected 
QT interval (cQT) but not RHR was associated with cardiovascular mortality in T1DM 
whereas RHR but not cQT was associated with cardiovascular mortality in type 2 diabetes 
mellitus. [192]  RHR was also associated with survival in a one-year follow-up study of 
diabetic patients with coronary artery disease. [193] During an average of  6.5 years of  
follow-up in the DCCT study, the percentage of subjects with abnormal autonomic nervous 
system function tests nearly doubled.   Elevated resting heart rate may be due to increased 
sympathetic tone or impairment of vagal tone. RHR cannot be regarded as a reliable sign of 
autonomic neuropathy in the absence of other physical signs. [194]  Autonomic neuropathy 
was shown to be associated with impaired coronary artery flow and myocardial dysfunction 
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in diabetes mellitus. [195] In the DCCT/EDIC study, RHR was lower in the intensive 
treatment group and the effect persisted during the follow up period. The mechanism was 
unknown. However, higher RHR was associated with higher glycated haemoglobin level. 
[196]  In a recent prospective study of 1,088 type 2 diabetes mellitus patients  resting heart 
rate was demonstrated to be an independent predictor of cardiovascular risk and all-cause 
mortality. [197]  
 However, as can be seen in the previous section, the amount of exercise activity as per 
metabolic equivalents (METs) does not seem to be statistically significantly different from 
that of control group, but the variability of exercise time was high.  
Blood pressure 
 
Normal blood pressure is defined by JNC7 as a systolic BP <120 mmHg and a 
diastolic BP <80 mmHg. [198] The mean values for diabetic subjects and controls in our 
study met these criteria, although 21% had higher systolic pressures on single measurements. 
There is no significant difference in both systolic and diastolic blood pressure between the 
two groups.  
Duration of diabetes  
 
Duration of diabetes mellitus is also a risk factor for cardiovascular disease. [199] 
[200] Generally, the longer the duration of diabetes mellitus, the higher is the risk of CVD. 
Nonetheless, there are subjects with T1DM who do not develop vascular complications 
despite long duration of diabetes mellitus. [201] Genetic factors via elevated HDL-cholesterol 
level have been suggested to be protective. There is a wide variation in duration of diabetes 
mellitus among patients with type 1 diabetes mellitus in this study.  
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CHAPTER 5- RESULTS – biochemical results  
 
5.1 Biochemical results 
 
On the morning of the vascular study, subjects came in fasting from 22:00 pm 
overnight. Blood samples were taken for fasting glucose, HbA1c, lipid profiles, AST and 
high sensitivity C- reactive protein (hs CRP).   
Fasting blood results for both type 1 diabetes mellitus and control group are shown in 
the table 5.1 below.  
 
Table 5.1 Biochemical results (whole group)  
 
 
 Type 1 Diabetes 
Mellitus 
(n=19) 
Controls 
(n=34)  
P value 
Fasting glucose 
(mmol/L) 
11.35 ±6.21 4.77 ±0.42 0.00* 
HbA1c (%)  8.82 ±1.64 5.21 ±0.25 0.00* 
Creatinine (µmol/L) 72.26 ±10.92 81.18 ±10.01 0.004* 
Total Cholesterol 
(mmol/L) 
4.17 ±0.66 4.22 ±0.82 0.83 
HDL (mmol/L) 1.18 ±0.24 1.33 ± 0.23 0.042* 
LDL (mmol/L) 2.47 ±0.79 2.52 ±0.73 0.83 
TG (mmol/L)  1.18 ±0.90 0.84 ± 0.38 0.07 
AST (IU/L) 16.06 ±5.53 20.16 ± 6.73 0.04* 
hsCRP (mg/dL)  1.82 ±2.41 2.16 ± 4.49 0.76 
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Mean fasting blood glucose was 11.35 mmol/l with a standard deviation of ± 6.21 in 
type 1 diabetes mellitus. Mean HbA1c for diabetic group was 8.82 % with a standard 
deviation of  ± 1.64, indicating suboptimal glycaemic control in the study population.  
However, apart from HDL cholesterol, no statistically different lipid levels were 
observed between the controls and type 1 diabetics. HDL was about 10% lower in subjects 
with type 1 diabetes mellitus. There was a trend towards triglyceride being higher in subjects 
with T1DM.  
  Serum creatinine level was higher in the control group. Serum creatinine levels were 
about 12% higher in the control group.  
No difference in hsCRP level between the two groups was observed. There was no 
evidence of increased inflammatory reaction in type 1 diabetes mellitus. 
5.2 Discussion on biochemical results  
 
The current HbA1c target range set for young adults with type 1 diabetes mellitus is 
7.5% according to NICE clinical guidelines CG 51. The cohort in the study had suboptimal 
control. Fasting blood glucose levels were high as well. No difference in the lipid levels was 
noted apart from serum HDL level which was higher in control group.  
In a longitudinal study of young children with type 1 diabetes mellitus, serum total 
cholesterol correlated with the duration of diabetes mellitus and increasing HbA1c whereas 
HDL cholesterol fell with increasing age. [202]  Dyslipidaemia was documented in subjects 
with type 1 diabetes mellitus and the rise in serum total cholesterol was associated with the 
increase in HbA1c. Nevertheless, lipid abnormalities seem to be more prevalent in young 
patients with type 2 diabetes mellitus than in those with type 1 diabetes mellitus. [203]  
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The relationship between coronary artery disease and serum HDL may be more 
complex as Costacou et al pointed out in their study. [204] Costacou et al studied populations 
from the Pittsburgh EDC study and observed that although there was an inverse relationship 
between serum HDL level and coronary artery disease in male subjects with type 1 diabetes 
mellitus, the relationship in female seemed more like a U-shape with higher incidences of 
coronary artery disease at both lower and higher HDL levels.  
Serum creatinine level was higher in the control group than in the type 1 diabetes 
mellitus group. Higher creatinine level may be contributed by exercise activity or muscle 
bulk in the control group. In a population study, serum creatinine level was positively 
associated with upper arm circumference and physical activity. [205] 
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CHAPTER 6- RESULTS - Baseline echocardiographic results 
6.1 Baseline Echocardiographic results 
  
Baseline echocardiographic results are shown in table 6.1 for the whole group 
(N=53), comparing 19 subjects with T1DM with 34 controls, and in table 6.2 for the stress 
group (N=39), comparing 18 subjects with T1DM and 21 controls.  
Table 6.1: Baseline echocardiographic data (whole group)  
 Type 1 Diabetes 
Mellitus 
(n=19) 
Controls 
(n=34) 
P value 
Pulmonary 
Artery 
Acceleration time 
(ms) 
151.41 ± 28.77 149.30 ± 12.12 0.76 
Left atrial area 
(cm
2
) 
13.84 ± 2.13 14.44 ± 2.93 0.47 
Flow Propagation 
Velocity (cm/s) 
6.55 ± 0.92 6.87 ± 0.99 0.28 
Deceleration time 
of mitral inflow  
(ms) 
202.74 ± 36.83 215.48 ± 39.27 0.25 
IVRT 
(ms) 
104.32 ± 16.47 110.00 ± 16.48 0.24 
LVOT VTI 
(cm/s) 
20.67 ± 4.46 22.54 ± 3.13 0.09 
SV (ml) 69.43 ± 31.12 96.61 ± 22.55 0.001* 
HR (rate/min) 75.18 ± 14.99 64.29 ± 10.31 0.004* 
CO (ml/min) 4.83 ± 2.37 6.12 ±1.35 0.015* 
LVEDV (ml) 83.58 ± 22.52 105.73 ± 22.20 0.001* 
LVESV (ml) 29.66  ± 11.02 35.86 ± 8.17 0.023* 
EF % 66.27 ± 4.83 66.20 ± 3.51 0.95 
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Table 6.2: Baseline grey scale and pulsed Doppler echocardiographic data  
(Stress group) 
 
 Type 1 Diabetes 
Mellitus 
(n=18) 
Controls 
(n=21)  
P value 
Pulmonary 
Artery 
Acceleration time 
(ms) 
148.34 ± 26.45 149.30 ± 12.12 0.88 
Left atrial area 
(cm
2
) 
13.80 ± 2.20 14.80 ± 2.57 0.23 
Flow Propagation 
Velocity (cm/s) 
6.61 ± 0.91 7.05  ± 1.14 0.22 
Deceleration time 
of mitral inflow 
(ms) 
201.54 ± 37.51 211.65 ± 35.92 0.25 
IVRT 
(ms) 
103.52 ± 16.61 110.32 ± 15.43 0.20 
VTI 
(cm/s) 
20.67 ± 4.46 22.54 ± 3.13 0.09 
SV 
(ml) 
69.36 ± 32.07 102.91 ± 22.54 0.001* 
HR (rate/min) 75.81 ± 15.24 63.47 ± 9.77 0.005* 
CO (ml/min) 4.85 ± 2.43 6.43 ± 1.27 0.014* 
LVEDV (ml) 82.81 ± 22.91 110.15 ± 24.89 0.001* 
LVESV (ml)  29.51 ± 11.31 37.91 ± 8.85 0.013* 
EF % 66.24 ± 4.96 65.81 ± 2.99 0.74 
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As can be seen in table 6.1, there were no differences  in pulmonary artery 
acceleration time, the left atrial area, the propagation velocity of mitral inflow, the isovolumic 
relaxation time and velocity time integral of left ventricular ejection, between the controls 
and the type 1 diabetes mellitus group.  
Nevertheless, stroke volume was significantly higher in controls than in type 1 
diabetes mellitus (96.61 ± 22.55 vs. 69.43 ± 31.12, p = 0.001), due to a small difference in the 
LVOT diameter. Heart rate was higher in type 1 diabetes mellitus with a statistical 
significance.  
(64.29 ± 10.31 vs. 75.18 ± 14. 99, p = 0.004) 
Cardiac output was higher in the control group than in type 1 diabetes mellitus. 
Control groups also have bigger LVEDV and LVESV. However, overall global myocardial 
systolic function as indicated by EF was not different between the two groups.  
6.2 Discussion on baseline echocardiographic results  
 
The PAT (pulmonary artery acceleration time) was defined as the time in milliseconds 
from the onset of right ventricular ejection to the time of the  peak systolic velocity of 
forward pulmonary flow. [206] In normal individuals, the pulmonary acceleration time (PAT) 
exceeds 110 ms and it progressively shortens with increasing in pulmonary hypertension 
(PH). 
There have been few studies of right ventricular function in diabetes mellitus. 
Karamitsos et al studied 66 patients with type 1 diabetes mellitus and reported right 
ventricular diastolic dysfunction as indicated by reduction in tricuspid annular diastolic tissue 
velocities with normal right ventricular systolic function. [102] The pulmonary artery 
acceleration time is not a sensitive marker to detect early changes in right ventricular 
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dysfunction. In my study, pulmonary acceleration time in both type 1 diabetes mellitus and 
control were within normal range and they were not different between the two groups. 
Left atrial remodelling may be an indicator of chronic burden of cardiovascular 
disease. [207] [208]  Larger left atrial volume in type 2 diabetes mellitus subjects was 
reported by Poulsen et al. [209] Left atrial enlargement was thought to be due to pressure 
overload and it was associated with increased NT-proBNP, increased LV mass index, 
reduced total arterial compliance, and valvulo-arterial impedance. The subjects with LA 
enlargement were older than those without (63.0 ±10 years vs. 56.4 ± 11.3, p <- 0.001). 
Similarly, left atrial volume index in type 2 diabetes mellitus was also demonstrated to be 
higher in comparison with a normal population and when compared with subjects with 
hypertension. [210]  
However, the left atrial volume in this study was not different between type 1 diabetes 
mellitus and controls. Left atrial volume increases if there is a chronic increase in left 
ventricular filling pressure. Unless diastolic function in markedly abnormal, then with a 
relatively short duration of diabetes mellitus, left atrial volume is unlikely to be changed in 
young subjects with type 1 diabetes mellitus.  
Control subjects have bigger left ventricular volumes as evident by higher LV EDV 
and LV ESV from biplane measurements using Simpson’s method. As a result of bigger 
EDV, stroke volume in control subjects is higher than that in subjects with type 1 diabetes 
mellitus. Nevertheless, cardiac output was higher in the control group secondary to bigger 
stroke volume. LV EDV is influenced by a number of factors such as venous return, 
intrathoracic pressure, the duration of diastole, which in turn is determined by heart rate, and 
ventricular stiffness. [211]  
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Assessment of diastolic dysfunction demonstrated that IVRT and the deceleration 
time (DT) of mitral inflow were not significantly longer in type 1 diabetes mellitus. This is in 
contrast to the findings by Suys et. al [80], who reported that  young male type 1 diabetic 
subjects  had longer IVRT in comparison to controls, and by Schannwell et al [76], who also 
demonstrated increased IVRT and DT in subjects with type 1 diabetes mellitus. Also, in my 
study, the flow propagation velocity of mitral inflow, which is an indicator of early diastolic 
suction of the left ventricle, was not reduced.  All of these are global (“blood pool”) indices 
of left ventricular diastolic function, and they become abnormal once a substantial percentage 
of the myocardium shows similar regional changes.  
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6.3: M- mode data 
 
M-mode findings are shown in the table 6.3.  
 
Table 6.3: M- mode echocardiographic data (N=53)  
 
 Type 1 Diabetes 
Mellitus 
(N=18) 
Controls 
(N=21)  
P value 
Lateral mitral 
annulus excursion 
(mm) 
1.49 (± 0.24) 1.56 (± 0.26) 0.36 
Medial mitral 
annular excursion 
(mm) 
1.24 ( ± 0.17) 1.40 (± 0.21) 0.008* 
Tricuspid annulus 
excursion 
(mm) 
1.98 (± 0.46) 2.19 (± 0.40) 0.10 
LVOT diameter 
(cm) 
2.11 (± 0.31) 2.33 ( ± 0.22) 0.005* 
LVOT CSA 
(cm
2
) 
3.57 (± 1.12) 4.29 (± 0.81) 0.01* 
IVSd (mm) 0.82 (± 0.16) 0.79 (± 0.13) 0.44 
LVIDd (mm) 4.63 (± 0.67) 5.04 (± 0.52) 0.017* 
LVPWd (mm) 1.05 (± 0.25) 0.88 (± 0.15) 0.004* 
IVSs (mm) 1.06 (± 0.23) 1.10 (± 0.24) 0.61 
LVIDs (mm) 3.13 (± 0.64) 3.50 (± 0.50) 0.02* 
LVPWs (mm) 1.50 (± 0.23) 1.36 (± 0.30) 0.08 
FS % 32.53 (± 7.52) 30.54 (± 6.19) 0.31 
LVM (g) 169.03 (± 50.26) 171.56 (± 54.16) 0.87 
LVMI (g/m
2
) 92.32 (± 22.62) 90.74 (± 21.35) 0.80 
 
LVOT= left ventricular outflow tract, IVS= interventricular septum, LVID=left ventricular 
internal diameter, LVPW= left ventricular posterior wall, FS= fractional shortening, LVM= 
left ventricular mass, LVMI= left ventricular mass index, d=diastole, s=systole 
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On M-mode echocardiographic analysis, medial mitral annular excursion was lower 
in type 1 diabetes mellitus in comparison with the control group whereas no difference was 
observed between the two groups for lateral mitral annular and tricuspid annular excursions. 
Left ventricular outflow tract diameter and left ventricular outflow tract cross-
sectional area were higher in controls than in type 1 diabetes mellitus by 9.4%, and by 17% 
with a  p value of  0.005, and 0.01 respectively. 
M-mode measurements of left ventricular diameters showed that the control group 
had bigger left ventricular internal diameters in both systole and diastole, whereas LVPW 
during diastole was thicker in type 1 diabetes mellitus. However, overall left ventricular mass 
and left ventricular mass index showed no statistical difference between the two groups.  
6.4 Discussion on M-mode results  
 
LVOT diameter and cross sectional area were bigger in controls than those in type 1 
diabetes mellitus. The reasons why this might be the case is not clear. LVOT diameter may 
be used to calculate LVOT cross-sectional area. LVOT diameter was shown to be correlated 
to body surface area independent of sex.[212]  
LVOT diameter is measured from the parasternal long axis view. Potential errors in 
measurement may occur from two sources. Slight angulation or lateral displacement of the 
transducer could result in slightly oblong or oval section of LVOT which could lead to 
underestimation of LVOT diameter. Inaccurate identification of tissue-blood interface may 
also result in over or underestimation of LVOT diameter. [213] 
 LVOT CSA (LVOT cross-sectional area) was calculated by using the formula: 
 
LVOT CSA = π × (d/2) 2 where d = LVOT diameter. 
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Since LVOT diameter is halved and squared in the formula, a slight error in the 
measurement of LVOT d could lead to bigger error in LVOT CSA measurement and hence 
cardiac output (CO).  
 LVID both during systole and diastole was bigger in controls than in type 1 diabetes 
mellitus. However, LVPW was thicker in type 1 diabetes mellitus. Overall, left ventricular 
mass is similar. Left ventricular hypertrophy is a risk factor for the development of heart 
failure.  Two previous studies reported that patients with type 1 diabetes had increased LV 
mass. [119] [122] Both used magnetic resonance imaging, which is the most accurate non-
invasive method to measure this, but the mean ages of patients in those studies were 47 ± 2 
years and 50 ± 9 years respectively.  In the study by Astrup et al, the patients also had 
diabetic nephropathy and some had hypertension. [122] Epidemiological studies have 
reported that left ventricular mass is increased in diabetes mellitus, but they too had possible 
confounding factors.  In the Strong Heart Study, diabetic subjects had higher BMI and 
systolic blood pressure, and patients with hypertension were not excluded.[32]  In the 
Framingham study, about 15 % of the participants were already diagnosed to have 
hypertension or were taking antihypertensive drugs.  [214] Hypertensive subjects were 
included in the Cardiovascular Health Study. [215]  In my study, left ventricular mass index 
was not different between type 1 diabetic patients and controls, and it was within the normal 
range.  Unlike the previous studies, our patients were young and normotensive, and they had 
no other cardiovascular co-morbidities.  My data suggest that LV mass index  may not be 
increased in young subjects with diabetes mellitus without other risk factors, and that the 
higher LVMI observed in other studies may be related to  hypertension with increasing age. 
 
 
  
 
 
 
 
 
95 
CHAPTER 7 – RESULTS – Reproducibility of myocardial 
function assessment 
 
7.1 Reproducibility of myocardial displacement and velocities  
 
Peak systolic velocities at 0, 10 and 30 µg/kg/minute of dobutamine in BL, BS, BA and 
BP myocardial segments and displacement at 0, 10, and 30 µg/kg/minute of dobutamine in 
BL, BA and BP myocardial segments were analysed from 10 randomly selected subjects. 
Their digitally stored studies were re-analysed after an interval of at least 2 weeks. Intra-
observer reproducibility calculated by Bland-Altman methods and coefficients of variation 
are shown in the tables (7.1 & 7.2) and figures (7.1, 7.2, 7.4, 7.5, and 7.6. & 7.7). 
Similarly, mitral inflow early diastolic velocity (E), and lateral and medial tissue velocity 
e’, were measured in 10 subjects and reanalysed after at least 2 weeks . (See Figure 7.3)   
Intra-observer variability (coefficients of variation) was reported to be ranging from 6-
11% and inter-observer variability from 5-9% in basal segments. [216] [217] Therefore, my 
reproducibility results are comparable with other studies.  
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Table 7.1:  Intra-observer reproducibility of PSV at basal segments           
(Bland-Altman Analysis)  
 
 
 
 
Bias SD of Bias 95% Limit of agreement 
From To 
BL 0μg/kg/min 0.12 0.31 -0.50 0.73 
10μg/kg/min 0.57 1.20 -1.78 2.92 
30μg/kg/min -0.24 1.37 -2.94 2.45 
BS 0μg/kg/min -0.39 0.30 -0.97 0.19 
10μg/kg/min -0.03 0.26 -0.53 0.47 
30μg/kg/min -0.49 0.49 -1.45 0.48 
BA 0μg/kg/min 0.09 0.28 -0.46 0.64 
10μg/kg/min -0.05 0.45 -0.93 0.84 
30μg/kg/min 0.12 0.59 -1.04 1.29 
BP 0μg/kg/min 0.02 0.54 -1.04 1.07 
10μg/kg/min -0.19 0.34 -0.86 0.47 
30μg/kg/min -0.34 0.82 -1.93 1.26 
 
 
Table 7.2: Intra-observer reproducibility of displacement at basal segments (Bland-
Altman Analysis)  
 
 Bias SD of Bias 95% Limit of 
agreement 
From To 
BL 0μ/kg/min 0.27 0.45 -0.60 1.15 
10μg/kg/min 0.17 0.51 -0.81 1.17 
30μg/kg/min -0.23 0.90 -2.00 1.54 
BA 0μg/kg/min -0.01 0.89 -1.75 1.73 
10μg/kg/min 0.02 0.69 -1.34 1.38 
30μg/kg/min 0.22 0.83 -1.40 1.84 
BP 0μg/kg/min -0.14 0.59 -1.31 1.02 
10μg/kg/min -0.14 0.92 -1.95 1.67 
30μg/kg/min -0.52 0.75 -1.98 0.94 
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Figure 7.1: Intra-observer variability for peak systolic velocity  
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Figure 7.2: Intra-observer variability for basal displacement analysis 
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Figure 7.3: Intra-observer variability for diastolic velocities  
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Figure 7.4: Bland-Altman analysis PSVat Basal Lateral (BL) segments 
Bland-Altman of PSV BL at rest:Difference vs average
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Bland-Altman of PSV BL 10g/kg/min :Difference vs average
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Bland-Altman of PSV BL 30g/kg/min:Difference vs average
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Figure 7.5: Bland-Altman analysis of PSV in Basal Septal (BS) segments  
Bland-Altman of PSV BS at rest:Difference vs average
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Bland-Altman of PSV BS 10g/kg/min:Difference vs average
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Bland-Altman of PSV BS 30g/kg/min:Difference vs average
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Figure 7.6: Bland-Altman Analysis of PSV in Basal Anterior (BA) segments  
Bland-Altman of PSV BA at rest:Difference vs average
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Bland-Altman of Data PSV BA 10g/kg/min:Difference vs average
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Bland-Altman of PSV BA 30g/kg/min:Difference vs average
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Figure: 7.7: Bland-Altman Analysis of PSV in Basal Posterior (BP) segments  
Bland-Altman of PSV BP 0 g/kg/min:Difference vs average
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 CHAPTER 8- RESULTS -Diastolic function 
 
8.1 Diastolic function results  
 
Diastolic function in those patients who had stress echocardiography (N=39)  is 
shown in table 8.1.  
 
Table 8.1: Diastolic function (type 1 diabetes mellitus vs. controls) 
 
 Type 1 Diabetes 
Mellitus 
(n=18) 
Controls 
(n=21) 
P value 
Mitral early diastolic 
velocity (E) (cm/s) 
82.6 ± 16.9 83.7 ±10.8 0.80 
Mitral late diastolic 
velocity (A) (cm/s) 
58.6 ± 18.4 48.3 ± 10.0 0.03* 
E/A ratio 1.5 ± 0.4 1.8 ± 0.4 0.02* 
Lateral mitral annular 
early diastolic velocity 
(cm/s) 
16.9 ± 3.4 18.7 ± 2.9 0.07 
Medial mitral annular 
early diastolic velocity 
(cm/s) 
13.0 ± 2.7 14.8 ± 2.0 0.02* 
E/e' ratio 5.2 ± 1.1 5.0 ± 0.8 0.52 
 
Early diastolic velocity (E) as measured by pulsed Doppler at the mitral valve showed 
no difference between controls and type 1 diabetes mellitus. However, the late diastolic 
velocity (A) of mitral inflow was observed to be higher in type 1 diabetes mellitus than in 
controls. The E/A ratio was lower in type 1 diabetes mellitus than in controls.  
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On assessment of mitral annular velocities by tissue Doppler, there was a trend for the 
lateral mitral annular tissue early diastolic velocity to be lower in type 1 diabetes mellitus. 
The medial mitral annular tissue early diastolic velocity was significantly lower in type 1 
diabetes mellitus than in the controls. There was no statistically significant difference in e/e' 
ratio between type 1 diabetes mellitus and controls.  
8.2 Discussion on diastolic function  
 
Diastolic heart failure or heart failure with normal ejection fraction (HFNEF) may 
occur  as a manifestation of diabetic heart muscle disease. Whether DHF or HFNEF exists as 
a single syndrome independent of systolic heart failure remains controversial. [218] The 
Heart Failure and Echocardiography Associations of the European Society of Cardiology 
published a consensus recommendation on the diagnosis of diastolic heart failure or HFNEF 
in 2007. The summary flow chart is shown in figure 8.1   
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Figure 8.1: Diagnostic flowchart for the diagnosis of HFNEF  
 
Figure: Diagnostic flowchart on ‘How to diagnose HFNEF’ in a patient suspected of HFNEF. LVEDVI, 
left ventricular end-diastolic volume index; mPCW, mean pulmonary capillary wedge pressure; LVEDP, left 
ventricular end-diastolic pressure; t, time constant of left ventricular relaxation; b, constant of left ventricular 
chamber stiffness; TD, tissue Doppler; E, early mitral valve flow velocity; E0, early TD lengthening velocity; 
NT-proBNP, N-terminal-pro brain natriuretic peptide; BNP, brain natriuretic peptide; E/A, ratio of early (E) to 
late (A) mitral valve flow velocity; DT, deceleration time; LVMI, left ventricular mass index; LAVI, left atrial 
volume index; Ard, duration of reverse pulmonary vein atrial systole flow; Ad, duration of mitral valve atrial 
wave flow. (reproduced  from Eur Heart J 2007;28: 2539-2550.) [218] 
Left ventricular diastole consists of four phases (1) isovolumetric relaxation, (2) early 
diastolic filling, (3) diastasis, and, (4) atrial contraction. Diastolic function of the left 
ventricle may be assessed using pulsed wave Doppler ultrasound most simply by measuring 
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the mitral inflow pattern: early diastolic velocity (E), late diastolic velocity (A), and E/A 
ratio. From the E wave, the deceleration time (DT) of early mitral inflow can be derived. 
Under normal circumstances, early filling wave E is larger than late filling wave A, which is 
contributed by atrial contraction. In the presence of left ventricular diastolic dysfunction, with 
impaired relaxation of the left ventricle, the E velocity tends to be reduced whereas the A 
velocity is increased, leading to reversal of E/A ratio. The utility of measurement of mitral 
velocities may be limited, however, because the E velocity is load- dependent, being affected 
by changes in preload. With impairment of diastolic function, the left ventricle relaxes 
slower, and it may also become stiffer. Both DT and the IVRT may be prolonged in diastolic 
heart failure.  
Three patterns of mitral inflow related to abnormal relaxation of the left ventricle 
have been described. The first is abnormal relaxation with reversal of the E/A ratio. The 
second has been called pseudo-normalization, where the E/A ratio looks similar to a normal 
ratio because a compensatory increase in left atrial pressure restores the transmitral gradient 
to the normal range. The third pattern is termed a restrictive pattern, with a greatly increased 
E velocity, a short DT and a high E/A ratio in advanced diastolic failure. [219]  
The early diastolic velocity of the mitral annulus, and the flow propagation velocity of 
mitral inflow as measured by colour M-mode ultrasound, are less load-dependent than the 
mitral E velocity and they are not affected by pseudo-normalization.  
Many early studies reported that patients with diabetes mellitus had left ventricular 
diastolic dysfunction, using several different markers including abnormal mitral inflow 
patterns.   
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Regan  et al conducted an invasive study involving 17 patients with type 2 diabetes 
mellitus but no coronary artery disease. They reported that subjects with diabetes mellitus had 
elevated left ventricular end -diastolic pressure volume ratio. [220] 
It has been suggested that diastolic dysfunction may be one of the early 
manifestations of diabetic cardiomyopathy. Raev studied 157 asymptomatic young (mean 
26.6 years) subjects with type 1 diabetes mellitus by M-mode echocardiography and 
suggested that left ventricular diastolic function was impaired before systolic function. [78]  
In my study, the peak diastolic velocity during atrial contraction, (A) was higher in 
type 1 diabetes mellitus. As a result, the  E/A ratio was lower in type 1 diabetes mellitus, 
indicating mild diastolic abnormality compared with the controls (although still within 
normal range). This is in accordance with many other studies. Zarich et al showed that E/A 
was significantly lower in type 1 diabetes mellitus than in controls in a study of 21 type 1 
diabetics and 21 controls.[79] Similar findings were found in other studies involving type 1 
diabetes mellitus. [221] [222] [223] In a few studies, the E/A ratio was reported to be normal. 
[96] [88] 
Limitations of using the mitral inflow pattern to assess diastolic function are its load-
dependency, and inability to differentiate between a normal pattern and pseudo-
normalization. These limitations may be overcome by measuring other parameters of 
diastolic function which are less load-dependent such as mitral flow propagation and the 
velocities of the mitral annulus.  
In my study, mitral inflow propagation was similar between type 1 diabetes mellitus 
and controls. Other measures of diastolic function such as IVRT and DT of E wave were also 
similar between the two groups. None of the subjects fulfilled criteria for the diagnosis for 
HFNEF. (figure 8.1) 
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Mean left ventricular filling pressure, as estimated by the E/e’ ratio, and chronically 
by left atrial dimensions, was normal in the diabetic subjects and similar to the controls. 
These global left ventricular changes are affected once substantial amount of regional 
myocardium show similar changes.  
Slower relaxation of the myocardium was noted at the medial mitral annulus, as the 
early diastolic tissue velocity was reduced in comparison with controls. The early diastolic 
velocity of long-axis lengthening of the left ventricle may be a more sensitive regional 
marker of relaxation. 
These results, suggesting that subtle reductions in regional early diastolic function 
may be the most sensitive markers of myocardial dysfunction in patients with diabetes, are in 
agreement with previous reports 
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CHAPTER 9- RESULTS – Stress echocardiography results  
 
9.1 Baseline Characteristics (Stress Group) 
 
Baseline characteristics of all subjects who had dobutamine stress echocardiography 
are shown in table 9.1.  
 
Table 9.1 Baseline Characteristics of the stress group (N=39)  
 
 Type 1 Diabetes 
Mellitus 
Controls P value 
Number 
 
18 ( F= 11) 21 ( F=8) 0.205 
Age (years) 
 
21.3 ± 3.6 
(17-28) 
23.0 ± 2.4 
(20-28) 
0.90 
Height (m) 1.71 ± 0.10 
(1.53-1.93) 
1.76 ± 0.09 
(1.61-1.89) 
0.14 
Weight (kg) 74.8 ± 12.4 
(50-106) 
73.8 ± 12.2 
(52-93) 
0.81 
BMI (kg/m
2
) 25.4 ± 2.9 
(19.5-31.3) 
23.5 ± 2.2 
(19.3-26.7) 
0.04* 
Waist circumference 
(cm) 
85.2 ± 8.9 
(68-106) 
84.6 ± 9.6 
(60-99) 
0.84 
Waist Hip ratio (cm) 0.80 ±0.07 
(0.69-0.93) 
0.80 ±0.07 
(0.61-0.94) 
0.95 
Pulse (beats/minute) 72 ±10 
(53-90) 
63 ±9 
(47-83) 
0.005* 
SBP (mmHg) 114 ± 9 
(100-132) 
116 ±10 
(101-147) 
0.52 
DBP (mmHg) 72 ± 6 
(62-85) 
71 ± 5 
(62-82) 
0.52 
 
*Ranges of the data are presented in brackets.  
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There was no difference in age between type 1 diabetes mellitus and controls. 
However, BMI was 7.28 % higher in type 1 diabetes mellitus than controls.  (25.4  2.9 vs. 
23.5  2.2, P=0.04).   
Pulse rate was about 12% faster in type 1 diabetes mellitus whereas blood pressure, 
both systolic and diastolic was similar between the two groups.  
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9.2 Biochemical Results 
 
Biochemical results in the stress group are shown in table 9.2. 
Table 9.2 Biochemical results (stress group) (N=39)  
 
 Type 1 Diabetes 
Mellitus 
(n=18) 
Controls 
(n=21)  
P value 
Fasting glucose 
(mmol/L) 
11.3 ± 6.4 4.6 ± 0.4 
0.00** 
HbA1c (%)  8.8 ± 1.7 5.2 ± 0.3 0.00** 
Creatinine (µmol/L) 
72.0 ± 11.2 82.3 ± 9.6 
0.004** 
Total Cholesterol 
(mmol/L) 
4.2 ± 0.7 3.8 ± 0.5 
0.08 
HDL (mmol/L) 
1.2 ± 0.2 1.3 ± 0.2 
0.06 
LDL (mmol/L) 2.4 ± 0.8 2.2 ± 0.5 0.23 
TG (mmol/L)  
1.2 ± 0.9 0.7 ± 0.3 
0.03* 
AST (IU/L) 
16.3 ± 5.7 18.3 ± 3.8 
0.22 
hsCRP (mg/dL)  
1.9 ± 2.5 1.2 ± 2.3 
0.36 
As expected , the diabetic subjects had higher fasting glucose and HbA1c level. 
Serum creatinine was higher in controls than in type 1 diabetes mellitus. There were trends 
for serum cholesterol to be higher in type 1 diabetes mellitus, and  for serum HDL to be 
higher in control. Fasting serum triglycerides were higher in subjects with type 1 diabetes 
mellitus.  
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9.3. Myocardial Displacement  
 
9.3.1 Myocardial Displacement at rest 
Myocardial displacement in mm as measured by tissue Doppler imaging or 
myocardial velocity imaging, at rest is shown in table 9.3. It was reduced significantly in all 6 
basal segments in subjects with type 1 diabetes mellitus, compared with controls.  
 
Table 9.3: Myocardial displacement (mm) of basal segments at rest  
 
 Type 1 Diabetes 
Mellitus (n=18) 
Controls 
(n=21) 
P value 
Basal lateral  10.72 ± 1.84 12.40 ± 2.35 0.02* 
Basal septal 11.10 ± 2.17 13.16 ± 1.83 0.003* 
Basal anterior 11.20 ± 2.15 12.67 ± 2.19 0.04* 
Basal inferior 12.43 ± 2.53 14.54 ± 1.85 0.005* 
Basal anteroseptal 9.20 ± 2.04 11.24 ± 1.81 0.002* 
Basal posterior 11.26 ± 1.56 12.84 ± 2.57 0.03* 
 
Figure 9.1: Myocardial displacement (mm) in basal segments at rest 
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9.3.2. Myocardial Displacement at dobutamine dose of 5 µg/kg/min 
 
Similar reduction of myocardial displacement in basal segment was noted in the early 
stage of dobutamine stress (table 9.4 and figure 9.4) 
Table 9.4: Myocardial displacement (mm) of basal segments at dobutamine dose of 
5µg/kg/min 
 
 Type 1 Diabetes 
Mellitus (n=18) 
Controls 
(n=21) 
P value 
Basal lateral 11.76 ± 1.96 13.75 ± 2.07 0.004* 
Basal septal 11.69 ± 2.37 13.89 ± 2.13 0.004* 
Basal anterior 11.89 ± 2.12 13.26 ± 2.10 0.05* 
Basal inferior 13.01 ± 2.36 15.16 ± 1.90 0.003* 
Basal anteroseptal 9.61 ± 1.93 12.05 ± 2.34 0.001* 
Basal posterior 11.29 ± 1.85 14.01 ± 2.26 0.000* 
 
 
 
Figure 9.2: Myocardial displacement (mm) of basal segments at 5µg/kg/min 
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9.3.3 Displacement at dobutamine dose of 10μg/kg/min 
 
Similar reductions in myocardial displacement were observed to be maintained at a 
higher dose of dobutamine infusion except in the basal anterior and basal lateral segment 
where trend was present but, the differences were not significant. (table 9.5 and figure 9.5)  
Table 9.5: Myocardial displacement (mm) of basal segments at 10μg/kg/min  
 
 Type 1 Diabetes 
Mellitus (n=18) 
Controls 
(n=21) 
P value 
Basal lateral 12.58 ± 3.07 14.25 ± 2.63 0.08 
Basal septal 12.50  ± 2.46 14.88 ± 2.56 0.006* 
Basal anterior 13.01  ± 2.21 14.39 ± 2.40 0.07 
Basal inferior 14.13 ± 2.96 16.61 ± 2.50 0.007* 
Basal anteroseptal 11.37  ± 2.63 13.53 ± 2.87 0.02* 
Basal posterior 12.39  ± 4.06 16.64 ± 2.95 0.001* 
 
Figure 9.3: Myocardial displacement (mm) of basal segments at 10μg/kg/min 
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9.3.4 Displacement at dobutamine dose of 20μg/kg/min 
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At dobutamine dose of 20µg/kg/min, myocardial displacements at basal segments were again 
reduced in type 1 diabetes mellitus except for the basal anteroseptal segment where 
displacement was lower in type 1 diabetes mellitus but it was not statistically significant. 
(table 9.6 and figure 9.6) 
Table 9.6 Myocardial displacement (mm) of basal segments at 20μg/kg/min  
 
 Type 1 Diabetes 
Mellitus (n=18) 
Control 
(n=21) 
P value 
Basal lateral 12.83 ± 2.93 15.61 ± 2.43 0.003* 
Basal septal 11.99 ± 1.91 14.38 ± 2.52 0.002* 
Basal anterior 13.28 ± 2.72 15.00 ± 2.29 0.041* 
Basal inferior 14.39 ± 2.95 16.30 ± 2.57 0.037* 
Basal anteroseptal 11.54 ± 2.90 12.99 ± 3.02 0.14 
Basal posterior 14.02 ± 3.27 18.29 ± 2.32 0.000* 
 
Figure 9.4: Myocardial displacement (mm) of basal segments at 20μg/kg/min 
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9.3.5 Displacement at dobutamine dose of 30μg/kg/min 
 
Myocardial displacement in most basal segments remained lower in type 1 diabetes 
mellitus except in two, namely basal anterior and basal anteroseptal segments. The number of 
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subjects reduced in both groups because of the subjects' inability to tolerate dobutamine. 
(table 9.7 and figure 9.7) 
Table 9.7: Myocardial displacement (mm) of basal segments at dobutamine dose of 
30µg/kg/min 
 
 Type 1 Diabetes 
Mellitus (n=16) 
Control 
(n=20) 
P value 
Basal lateral 13.90 ± 2.45 15.94 ± 2.63 0.026* 
Basal septal 12.08 ± 2.57 13.89 ± 1.90 0.020* 
Basal anterior 13.03 ± 2.03 14.44 ± 2.82 0.10 
Basal inferior 13.66 ± 2.38 15.34 ± 2.46 0.045* 
Basal anteroseptal 11.26 ± 2.15 11.93 ± 2.75 0.43 
Basal posterior 14.55 ± 1.45 17.44 ± 2.93 0.001* 
 
Figure 9.5: Myocardial displacement (mm) of basal segments at 30μg/kg/min 
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9.3.6 Displacement at dobutamine dose of 40μg/kg/min 
 
Many subjects and patients could not tolerate higher doses of dobutamine. (table 9.8 and 
figure 9.8) 
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Table 9.8: Myocardial displacement (mm) at basal segments at dobutamine dose of 
40µg/kg/min 
 
 Type 1 Diabetes 
Mellitus (n=10) 
Control 
(n=13) 
P value 
Basal lateral 14.41 ± 3.00 15.99 ± 2.98 0.23 
Basal septal 12.03 ± 1.54 13.35 ± 1.77 0.08 
Basal anterior 13.21 ± 3.48 14.33 ± 2.87 0.40 
Basal inferior 13.70 ± 1.95 14.43 ± 1.63 0.34 
Basal anteroseptal 11.50 ± 2.12 13.01 ± 2.78 0.17 
Basal posterior 15.77 ± 1.72 17.21 ± 2.66 0.15 
 
 
Figure 9.6: Myocardial displacement (mm) in basal segments at 40µg/kg/min 
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Figure 9.7: Mean basal displacment during dobutamine stress  
 
 
All analyses for displacement and velocities during dobutamine stress were performed 
by a repeated measures analysis of variance (Linear Mixed Model) with subject treated as a 
random effect and dose/diabetic group as fixed effects.  Dose level is the repeated element. 
Mean myocardial displacement at the basal segments of myocardium at rest was 
lower in type 1 diabetes mellitus than in controls. Displacement increased both in subjects 
with type 1 diabetes mellitus and in controls, with increasing doses of dobutamine and it 
peaked at 20µg/kg/min of dobutamine. Thereafter displacement started to plateau in patients 
with type 1 diabetes mellitus and to decline in controls. Nevertheless, throughout the course 
of dobutamine infusion, displacements in type 1 diabetes mellitus were lower than 
displacements in controls. There were significant differences for both the  dose (p<0.001) and 
between type 1 diabetes and control group (p < 0.001). 
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9.4 Longitudinal myocardial velocity 
 
Longitudinal myocardial velocities (peak systolic velocity) of all 6 basal segments at 
different stages of dobutamine are shown in tables 8.7-8.11 and figure 8.8-8.12) Overall, PSV 
was not different between the two groups in most segments during dobutamine infusion, apart 
from the stage of dobutamine 10µg/kg/min where PSV was lower in the subjects with type 1 
diabetes mellitus in the basal inferior, basal anteroseptal and basal posterior segments. (table 
9.11) 
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9.4.1 Longitudinal myocardial velocity (Systolic velocity, S) at rest 
 
Table 9.9: Peak Systolic Velocity (PSV) (cm/s) of Basal Segments at Rest  
 
 
 Type 1 Diabetes 
Mellitus (n=18) 
Control 
(n=21) 
P value 
Basal lateral 8.29 ± 1.55 9.18 ± 2.04 0.14 
Basal septal 5.71 ± 1.11 6.51 ± 1.15 0.04* 
Basal anterior 8.02 ± 1.57 8.68 ± 2.26 0.31 
Basal inferior 6.52 ± 1.01 6.77 ± 0.79 0.39 
Basal anteroseptal 5.44 ± 0.93 6.07 ± 1.24 0.09 
Basal posterior 7.85 ± 1.51 8.01 ± 1.79 0.76 
 
Apart from basal septal segment no other statistical significant was found for peak systolic 
velocity (S) at rest for basal segments.  
Figure 9.8: Peak Systolic Velocity (PSV) (cm/s) of Basal Segments at Rest  
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9.4.2 Longitudinal myocardial velocity (Systolic velocity, S) at dobutamine 
5μg/kg/min 
 
Table 9.10: Peak Systolic Velocity (PSV) (cm/s) of Basal Segments at dobutamine 
5μg/kg/min 
 
 
 Type 1 Diabetes 
Mellitus (n=18) 
Control 
(n=21) 
P value 
Basal lateral 8.90 ± 2.14 10.06 ± 1.92 0.08 
Basal septal 6.38 ± 1.24 6.78 ± 0.74 0.22 
Basal anterior 8.57 ± 2.06 9.41 ± 2.11 0.22 
Basal inferior 6.71 ± 1.16 7.33 ± 1.00 0.08 
Basal anteroseptal 5.70 ± 0.82 6.68 ± 1.31 0.009* 
Basal posterior 7.86 ± 1.94 8.88 ± 1.74 0.09 
 
 
 
Figure 9.9: Peak Systolic Velocity (PSV) (cm/s) of Basal Segments at dobutamine 
5μg/kg/min 
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9.4.3 Longitudinal myocardial velocity (Systolic velocity, S) at dobutamine 
10μg/kg/min 
 
 
Table 9.11: Peak Systolic Velocity (PSV) (cm/s) of Basal Segments at dobutamine 
10μg/kg/min 
 
 
 Type 1 Diabetes 
Mellitus (n=18) 
Control 
(n=21) 
P value 
Basal lateral 10.54 ± 3.05 12.03 ± 2.63 0.11 
Basal septal 7.22 ± 1.98 8.41 ± 2.02 0.07 
Basal anterior 10.15 ± 2.67 11.79 ± 2.80 0.07 
Basal inferior 7.85 ± 2.06 9.54 ± 2.39 0.02* 
Basal anteroseptal 10.15 ± 2.67 11.79 ± 2.80 0.04* 
Basal posterior 10.10 ± 3.49 12.37 ± 2.59 0.03* 
 
 
Figure 9.10: Peak Systolic Velocity (PSV) (cm/s) in Basal Segments at dobutamine 
10μg/kg/min 
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9.4.4 Longitudinal myocardial velocity (Systolic velocity, S) at dobutamine 
20μg/kg/min 
 
 
Table 9.12: Peak Systolic Velocity (PSV) (cm/s) of Basal Segments at dobutamine 
20μg/kg/min 
 
 
 Type 1 Diabetes 
Mellitus (n=18) 
Control 
(n=21) 
P value 
Basal lateral 13.48 ± 3.10 16.31 ± 2.67 0.005* 
Basal septal 10.20 ± 2.70 11.76 ± 2.63 0.08 
Basal anterior 13.82 ± 3.70 15.44 ± 2.59 0.13 
Basal inferior 11.00 ± 2.83 12.27 ± 2.59 0.15 
Basal anteroseptal 10.74 ± 2.90 12.20 ± 3.04 0.14 
Basal posterior 14.65 ± 3.05 17.08 ± 2.76 0.02* 
 
 
Figure 9.11: Peak Systolic Velocity (PSV) (cm/s) in Basal Segments at dobutamine 
20μg/kg/min 
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9.4.5 Longitudinal myocardial velocity (systolic velocity, S) at dobutamine 
30μg/kg/min 
 
Table 9.13: Peak Systolic Velocity (PSV) (cm/s) of Basal Segments at dobutamine 
30μg/kg/min 
 
 Type 1 Diabetes 
Mellitus (n=15) 
Control 
(n=20) 
P value 
Basal lateral 17.08 ± 2.96 18.76 ± 2.69 0.09 
Basal septal 13.16 ± 2.41 13.10 ± 2.37 0.95 
Basal anterior 16.08 ± 3.00 16.98 ± 3.12 0.40 
Basal inferior 13.22 ± 1.95 13.02 ± 2.19 0.78 
Basal anteroseptal 13.55 ± 1.99 13.31 ± 2.57 0.77 
Basal posterior 17.01 ± 3.5 19.40 ± 3.04 0.04* 
 
 
 
 
Figure 9.12: Peak Systolic Velocity (PSV) (cm/s) of Basal Segments at dobutamine 
30μg/kg/min 
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9.4.6 Longitudinal myocardial velocity (systolic velocity, S) at dobutamine 
40μg/kg/min 
 
Table 9.14: Peak Systolic Velocity (PSV) (cm/s) of Basal Segments at dobutamine 
40μg/kg/min 
 
 
 Type 1 Diabetes 
Mellitus (n=10) 
Control 
(n=14) 
P value 
Basal lateral 18.01 ± 3.86 20.22 ± 2.52 0.10 
Basal septal 14.04 ± 1.61 13.48 ± 2.35 0.52 
Basal anterior 17.23 ± 3.96 17.86 ± 2.46 0.64 
Basal inferior 14.34 ± 2.23 13.76 ± 1.94 0.50 
Basal anteroseptal 15.29 ± 1.94 14.65 ± 3.51 0.61 
Basal posterior 19.97 ± 4.29 20.69 ± 2.99 0.64 
 
 
 
Figure 9.13: Peak Systolic Velocity (PSV) (cm/s) of Basal Segments at dobutamine 
40μg/kg/min 
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Figure 9.14: Mean peak systolic velocity during dobutamine stress 
 
 
The peak systolic velocity of long-axis shortening, averaged from 6 basal myocardial 
segments, was similar at rest in the diabetic subjects to the controls but it increased more 
slowly during the infusion of dobutamine with significantly lower values at 10 and 20 
μg/kg/minute. The velocities at higher doses (30 μg/kg/minute) were similar. Similar to 
displacement, there was no interaction and there were significant differences for dose 
(p<0.001) and between type 1 diabetes mellitus and control groups (p=0.003). 
  
 
 
 
 
 
127 
9.5 Radial myocardial function 
 
Radial myocardial function as measured in the basal posterior segment in the posterior 
wall in a parasternal long-axis view is shown in table 9.15 and figure 9.17.  
 
Table 9.15: Radial myocardial function (systolic velocity) (cm/s) during dobutamine 
stress 
 
 Type 1 Diabetes 
Mellitus 
Control P value 
at rest 5.56 ± 0.99 5.02 ± 1.41 0.15 
5μg/kg/min 5.91 ± 1.54 6.51 ± 1.42 0.22 
10μg/kg/min 9.22 ± 2.89 9.92 ± 2.50 0.43 
20μg/kg/min 11.97 ± 3.53 13.37 ± 2.73 0.18 
30μg/kg/min 14.88 ± 3.40 14.58 ± 2.95 0.78 
40μg/kg/min 16.06 ± 2.65 14.69 ± 2.35 0.22 
 
Figure 9.15: Radial myocardial function during dobutamine stress 
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There were no differences in radial function between controls and diabetics at rest or 
during dobutamine (two way ANOVA, p = 0.21). 
9.6 Discussions on left ventricular systolic function and radial myocardial 
function 
 
Global left ventricular systolic function, as indicated by ejection fraction, was similar 
in the type 1 diabetic subjects to controls and both were within the normal range, but 
longitudinal systolic function as indicated by excursion of the medial mitral annulus was 
reduced by an average of 11%. This site, at the base of the ventricular septum, is the one 
which shows the earliest signs of ageing and of subclinical myocardial disease in many 
conditions, perhaps because the basal septal segment has the largest radius of curvature and 
therefore the greatest regional wall stress. 
Longitudinal displacements of the myocardium in the basal segments are persistently 
lower in type 1 diabetes mellitus both at rest and during dobutamine stress even though 
systolic velocities are similar between groups. This might indicate that displacement may be a 
more sensitive marker than peak systolic velocity in detecting early subtle changes in 
subclinical myocardial dysfunction in type 1 diabetes mellitus.  
A reduction of longitudinal function with preservation of global function usually 
implies that there has been a change in shape of the left ventricle so that it becomes more 
spherical. In earlier studies of type 2 diabetic subjects, reduced longitudinal function was 
associated with an increase in radial function [85] [89] perhaps because a more spherical end-
diastolic shape increases the end-diastolic length of the midwall myocardial fibres which then 
contract more as a result of the Frank Starling relationship. Nevertheless, in a study of type 2 
diabetes mellitus patients by Ernande et al, systolic radial function was reduced in type 2 
diabetes mellitus on echocardiography by speckle tracking method. [90] This may just be a 
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reflection of different stages in the  natural history of the disease in the subjects studied in 
those studies or it might be related to technical factors related to different imaging modalities.  
 In the type 1 diabetic subjects in my present study, however, there was no significant 
increase in radial function, measured either as fractional shortening (which was 6% higher in 
the diabetics, n.s.) or as the systolic velocity of inward motion of the basal posterior wall in a 
parasternal image. Given their relatively short duration of diabetes and younger age, the 
diabetic subjects in this study may be at an earlier stage in the subclinical progression of 
myocardial dysfunction.  
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9.7 Myocardial functional reserve 
 
Myocardial functional reserve, which is the absolute increment of PSV at maximal 
dobutamine dose from PSV at rest, is shown in table 9.16 and figure 9.18.  
Table 9.16: Myocardial functional reserve (cm/s) in basal segments 
  
 Type 1 Diabetes 
Mellitus 
Control P value 
Basal lateral 8.07 ± 3.06 10.26 ± 2.36 0.02* 
Basal septal 7.29 ± 2.45 6.78 ± 1.85 0.47 
Basal anterior 7.99 ± 3.27 8.83 ± 2.93 0.41 
Basal inferior 6.93 ± 2.84 6.66 ± 1.79 0.73 
Basal anteroseptal 8.52 ± 2.57 8.18 ± 2.86 0.71 
Basal posterior 10.04 ± 4.38 11.32 ± 4.58 0.40 
 
Figure 9.16: Myocardial function reserve (cm/s) in six basal segments  
0
2
4
6
8
10
12
14
BL BS BA BI BAS BP
T1DM Controls
 Myocardial functional reserve was not different between subjects with type 1 diabetes 
and controls, except in the basal lateral segment where it was 21% lower in the diabetics (p = 
0.018)  
  
 
 
 
 
 
131 
9.8 Discussions on myocardial functional reserve 
 
Palmieri et al studied 20 patients with type 1 diabetes mellitus by giving low dose 
dobutamine with a peak dose of 7.5µg/kg/minute and reported that peak systolic lateral mitral 
annular velocity was lower in type 1 diabetes mellitus at rest in comparison with controls. 
[104] The control groups in their study did not receive dobutamine and therefore, functional 
reserve were not compared between the groups in that study. In a different study by Palmieri 
et al, they reported that stroke volume index and cardiac index (measured by bioimpedance) 
were the same in patients with type 1 diabetes compared with normotensive and hypertensive 
controls at rest, but they were reduced at peak exercise. [105] 
In previous studies of patients with type 2 diabetes mellitus, the peak systolic velocity 
of long-axis shortening of the left ventricle (Vs) was reduced, both at rest and at peak stress 
with dobutamine [89] or only during peak stress. [86] A reduction in left ventricular 
functional reserve in type 2 diabetes mellitus was also reported by Von Bibra et al. [95]  In 
our study of subjects with type 1 diabetes, however, peak systolic velocity (Vs) did not show 
any difference between patients and controls at rest or at peak doses; it was significantly 
lower only at intermediate doses of dobutamine (10 μg/kg/minute and 20 μg/kg/minute).  
The hypothesis that myocardial response to dobutamine would be blunted in type 1 
diabetes mellitus, therefore, was not confirmed.  
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9.9 Early diastolic velocity during dobutamine stress  
 
Mean early diastolic velocity responses to dobutamine are shown in figure 9.19.  
 
Figure 9.17: Early diastolic velocity during dobutamine stress  
 
 
 
 
There is no significant interaction (p=0.996). Mean early diastolic velocity (tissue) 
response to dobutamine is not different between type 1 diabetes mellitus and control (p=0.60) 
However, as can be observed from the figure, early diastolic velocity response in type 
1 diabetes mellitus is somewhat flat whereas in control it increases incrementally from rest to 
dobutamine dose of 10µg/kg/minute.   
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9.10 Strain and strain rate  
 
Systolic strain, peak systolic strain and early diastolic strain rates are shown in table 
9.17.  
Table 9.17: Strain and strain rate in basal septal and basal lateral segments 
   Type 1 
Diabetes 
Mellitus 
(N=18) 
Controls 
 
(N=21) 
P-value 
Basal 
Septal 
segment 
Systolic 
strain (%)  
 
at rest -19.8 ± 6.1 
 
-24.5 ± 5.2 0.014* 
20µg/kg/min 
 
-26.3 ± 5.8 -24.8 ± 6.2 0.44 
30µg/kg/min 
 
-26.8 ± 7.9 26.7 ± 6.9 0.97 
Peak 
systolic 
strain rate  
(l/s) 
at rest 
 
-1.5 ± 1.0 -1.9 ± 1.1 0.31 
20µg/kg/min 
 
-2.3 ± 0.66 -2.5 ±0.71 0.38 
30µg/kg/min 
 
-2.8 ± 0.99 -3.0 ± 1.4 0.63 
Early 
diastolic 
strain rate  
(l/s) 
at rest 
 
2.2 ± 0.86 2.5 ± 0.9 0.37 
20µg/kg/min 
 
2.7 ± 1.05 2.9 ± 1.05 0.59 
30µg/kg/min 
 
3.5 ± 1.6 3.6 ± 1.3 0.76 
Basal 
Lateral 
segment 
Systolic 
strain (%) 
 
at rest 
 
-14.3 ± 6.9 -17.0 ± 6.7 0.23 
20µg/kg/min 
 
-15.8 ± 5.8 -17.4 ± 5.8 0.44 
30µg/kg/min 
 
-14.8 ± 5.9 -16.5 ± 5.9 0.40 
Peak 
systolic 
strain rate  
(l/s) 
at rest -1.4 ± 0.61 -1.4 ± 0.63 0.86 
20µg/kg/min 
 
-1.8 ± 1.1 -2.1 ± 0.71 0.25 
30µg/kg/min 
 
-1.9 ± 0.93 -2.3 ± 1.3 0.27 
Early 
diastolic 
strain rate 
(l/s)   
 
at rest 
 
1.8 ± 0.7 2.03 ± 0.9 0.42 
20µg/kg/min 
 
2.5 ± 1.6 2.4 ± 1.0 0.77 
30µg/kg/min 2.3 ± 1.3 2.9 ± 1.1 0.17 
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Apart from systolic strain at rest in the basal segment which was lower in type 1 
diabetes mellitus, measurements of strain, and strain rates were similar between the two 
groups.  
9.11 Discussion on strain and strain rate  
 
The majority of studies of myocardial function in diabetes mellitus used myocardial 
velocity rather than strain and strain rate. Two studies [98] [90] did investigate strain and 
strain rate in diabetes mellitus, at rest. Di Cori et al [98] reported lower peak systolic strain in 
type 1 diabetes mellitus. Ernande et al  [90] showed lower longitudinal strain on speckle 
tracking in basal and mid segments of the septal and lateral walls in type 2 diabetes mellitus. 
No study in type 1 diabetes mellitus using strain and strain rate during stress was found. Even 
though a difference in displacement during dobutamine infusion was observed in this study, 
no difference was found for systolic strain, peak systolic strain rate and early diastolic strain 
rate. 
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9.12 Heart rate, systolic and diastolic blood pressure responses during 
dobutamine stress 
 
Changes in heart rate, systolic blood pressure, and diastolic blood pressure in response 
to dobutamine infusion are shown in table 9.18-9.20. 
Table 9.18: Heart rate (beats/minute) response to dobutamine infusion  
 Type 1 diabetes 
mellitus (n=18) 
Control (n=21) P-value 
at rest 75 ± 11 62 ±10 0.001* 
5μg/kg/min 77 ± 13 63 ±10 0.000* 
10μg/kg/min 78 ± 12 70 ± 11 0.034* 
20μg/kg/min 98 ± 24 93 ± 16 0.42 
30μg/kg/min 120 ± 20 114 ± 19 0.37 
 
Table 9.19: Systolic blood pressure (mmHg) response to dobutamine infusion  
 Type 1 diabetes 
mellitus (n=18) 
Control (n=21) P-value 
at rest 114 ± 9 120 ± 14 0.12 
5μg/kg/min 114 ± 13 122 ±12 0.06 
10μg/kg/min 127 ± 26 133 ± 17 0.32 
20μg/kg/min 144  ± 29 158 ± 24 0.10 
30μg/kg/min 159 ± 27 162 ± 21 0.70 
 
Table 9.20: Diastolic blood pressure (mmHg) response to dobutamine infusion 
 Type 1 diabetes 
mellitus (n=18) 
Control (n=21) P-value 
at rest 70 ± 9 71 ± 9 0.57 
5μg/kg/min 70 ±11 69 ± 6 0.71 
10μg/kg/min 70 ±11 69 ± 6 0.54 
20μg/kg/min 72 ± 8 72 ± 7 0.61  
30μg/kg/min 73 ± 9 75 ± 9 0.50 
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Figure 9.18: changes in heart rate, SBP and DBP during dobutamine stress 
 
                                            ◊ = type 1 diabetes mellitus; ● = control 
As can be seen the figure 9.20, heart rate was higher in type 1 diabetes mellitus at rest. 
Heart rate in controls increased incrementally from a dobutamine dose of 5µg/kg/minute and 
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was similar to that of the subjects with type 1 diabetes mellitus at dobutamine doses  
≥10µg/kg/minute. The heart rate in type 1 diabetes mellitus was higher at rest and the 
response to dobutamine was somewhat blunted when compared to controls between 
dobutamine doses of 5µg/kg/minute and 10µg/kg/minute.  
No significance differences were observed in terms of SBP and DBP responses to 
dobutamine infusion in type 1 diabetes mellitus and controls.  
9.13 Discussion on heart rate and blood pressure response to dobutamine  
 
Dobutamine exerts its inotropic effect mainly via β1 receptor in the myocardium even 
though it has some actions via β2 and α1 receptors. [224] Vasodilatory effects of β2 are 
normally countered by vasoconstrictive effects of α1 and net changes in blood pressure are 
minimal. It is well recognized that heart rate and systolic blood pressure increases with 
dobutamine, but diastolic blood pressure normally does not increase significantly or may 
even decrease with dobutamine infusion. [225] [226] [227] 
Therefore, changes in blood pressure observed in my study are consistent with normal 
responses to dobutamine infusion in both type 1 diabetes mellitus and controls. Nevertheless, 
blunted heart rate responses in type 1 diabetes mellitus after dobutamine dose of 
10µg/kg/minute may be due to denervation of receptors in the myocardium in type 1 diabetes 
mellitus. In animal studies, there is some in-vitro evidence of β2 receptor attenuation in 
cardiomyocytes in the  hyperglycaemic state. [228] Moreover, treatment with the  β receptor 
antagonist, metoprolol, prevents cardiomyocyte apoptosis in streptozotocin-induced diabetic 
mice.  [229] 
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9.14 Effect of exercise on myocardial function  
 
The effect of exercise on myocardial function was determined by stratifying subjects 
into three groups based on their exercise history in terms of metabolic equivalent per week. 
All analyses were performed by Repeated Measures Analysis of Variance (Linear Mixed 
Model) with subject treated as a Random effect and Dose/Diabetic Group as fixed effects.  
Dose level is the repeated element. 
There was no significant interaction between diagnostic group and changes in 
myocardial displacement and early diastolic velocity during stress echocardiography, related 
to the previous exercise history of the subjects. (p=0.12 and p=0.56 respectively) There was a 
weak interaction between diagnostic group and the responses of myocardial systolic velocity, 
according to exercise history (p=0.039). 
9.15 Discussion on the effect of exercise  
 
The effect of exercise of myocardial function is well-recognized. Most studies on 
myocardial function in diabetes mellitus failed to include exercise history which is a potential 
confounder in assessing longitudinal myocardial function.  
In my study, detailed exercise history was taken and the effects of exercise on 
myocardial function in type 1 diabetes mellitus during dobutamine stress were further 
analysed. The findings imply that those changes in longitudinal myocardial function observed 
in my study are unlikely to be due to physical inactivity of the subjects with diabetes mellitus, 
or conversely due to increased responses because of greater physical fitness in the controls.  
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CHAPTER 10- RESULTS - Correlates of myocardial function 
 
10.1 Correlates of myocardial function (stress group)  
 
Correlates of diastolic function in all the subjects who had stress echocardiography 
are shown in Table 10.1 
 
Table 10.1: Pearson correlations between anthropometric measures/biochemical results 
and myocardial function (n=40)  
 
 E A E/A Lateral 
e’ 
Medial  
e’ 
E/e’ 
 r 
p 
r 
p 
r 
p 
r 
p 
r 
p 
r 
p 
Age 
 
-0.14 
0.39 
-0.23 
0.15 
-0.23 
0.16 
-0.06 
0.70 
0.09 
0.58 
0.30 
0.86 
BMI 
 
0.13 
0.42 
0.1 
0.53 
-0.23 
0.14 
-0.03 
0.86 
0.08 
0.61 
0.40 
0.01* 
Waist 
circumference 
-0.04 
0.83 
-0.05 
0.78 
-0.24 
0.14 
-0.27 
0.09 
0.04 
0.79 
0.35 
0.03* 
Waist hip 
ratio 
-0.19 
0.24 
-0.07 
0.65 
-0.12 
0.48 
-0.41 
0.009** 
-0.07 
0.67 
0.14 
0.41 
Total 
cholesterol 
-0.17 
0.31 
0.24 
0.14 
0.06 
0.72 
-0.17 
0.31 
-0.17 
0.30 
-0.09 
0.60 
HDL 0.16 
0.32 
-0.004 
0.98 
-0.23 
0.15 
0.42 
0.007* 
0.44 
0.005* 
-0.21 
0.20 
LDL -0.09 
0.56 
0.25 
0.12 
0.19 
0.23 
-0.13 
0.42 
-0.23 
0.15 
-0.11 
0.52 
TG -0.18 
0.26 
-0.12 
0.47 
-0.09 
0.58 
-0.38 
0.02* 
-0.21 
0.20 
0.29 
0.07 
hsCRP 0.13 
0.43 
0.40 
0.01** 
-0.09 
0.58 
-0.09 
0.58 
-0.18 
0.91 
0.23 
0.15 
 
In these subjects, BMI and waist circumference correlated positively with E/e’ ratio, 
waist circumference with E/e’ ratio. Waist-hip ratio correlated inversely with lateral e’. These 
relationships are displayed in figures 10.1, 10.2 and 10.3. 
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Figure 10.1: Correlation between BMI and E/e’ (n=40) 
 
 
Figure 10.2: Correlation between waist circumference and E/e’ (n=40) 
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Figure 10.3: Correlation between waist hip ratio and lateral e’ (n=40) 
  
 
Summary (correlates of myocardial function on stress group analysis)  
 
When myocardial function was analysed as a whole group including both type 1 
diabetes mellitus and controls, E/e’ increases with BMI and waist circumference whereas 
lateral e’ decreases with increasing waist hip ratio, increasing serum triglycerides and 
decreasing HDL.  
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10.2 Correlates of Myocardial function in type 1 diabetes mellitus  
 
Correlates of diastolic myocardial function in 19 subjects with type 1 diabetes 
mellitus are shown in table 10.3. 
Table 10.2: Pearson correlations between anthropometric measures/biochemical results 
and myocardial function in subjects with type 1 diabetes mellitus (n=19) 
 
 E 
(r,p) 
A 
(r,p) 
E/A 
(r,p) 
Lateral 
e’ 
(r,p) 
Medial e’ 
(r,p) 
E/e’ 
(r,p) 
BMI 0.23 
0.35 
0.24 
0.32 
-0.38 
0.11 
0.21 
0.38 
0.37 
0.12 
0.57 
0.01** 
Waist 
circumference 
-0.12 
0.64 
0.03 
0.90 
-0.37 
0.11 
-0.16 
0.50 
0.14 
0.57 
0.40 
0.09 
Waist hip 
ratio 
-0.28 
0.25 
0.02 
0.92 
-0.18 
0.35 
-0.45 
0.05* 
-0.15 
0.54 
0.17 
0.49 
Total 
cholesterol 
-0.001 
1.0 
0.34 
0.18 
0.04 
0.88 
-0.13 
0.60 
-0.13 
0.59 
-0.02 
0.93 
HDL 0.19 
0.44 
0.24 
0.32 
-0.31 
0.19 
0.33 
0.17 
0.36 
0.13 
-0.13 
0.59 
LDL 0.07 
0.78 
0.33 
0.17 
0.22 
0.37 
-0.05 
0.85 
-0.23 
0.35 
-0.1 
0.68 
TG -0.19 
0.44 
-0.29 
0.22 
-0.14 
0.56 
-0.35 
0.14 
-0.07 
0.79 
0.33 
0.017 
hsCRP 0.12 
0.62 
0.55 
0.02* 
-0.16 
0.53 
-0.14 
0.58 
0.002 
0.99 
0.38 
0.11 
Fasting 
glucose 
0.03 
0.91 
0.13 
0.60 
0.03 
0.92 
-0.47 
0.051 
-0.18 
0.48 
0.03 
0.89 
HbA1c -0.25 
0.31 
-0.04 
0.89 
0.04 
0.88 
-0.31 
0.22 
-0.19 
0.46 
0.06 
0.82 
 
Lateral e’ correlates negatively with waist hip ratio, and E/e’ correlates positively 
with BMI. Lateral mitral inflow diastolic velocity (A) positively correlates with hsCRP.  No 
correlations were observed between diastolic velocities and HbA1c in type 1 diabetes 
mellitus. In the diabetic subjects, the indices of diastolic function at rest were not 
significantly related to HbA1c; correlations (Pearson) with HbA1c were -0.25 (p=0.31) for E, 
-0.04 (p =0.89) for the E/A ratio, and -0.27 (p = 0.28) for the mean early diastolic velocity of 
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mitral annular motion. However, there is a trend for negative correlation between lateral e’ 
and fasting glucose level (p=0.051) 
Figure 10.4: Correlations between BMI and E/e’ ratio in subjects with type 1 diabetes 
mellitus (n = 19)  
 
Figure 10.5: Correlation between waist hip ratio and lateral e’ in subjects with type 1 
diabetes mellitus (n=19) 
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Multiple regression analysis  
 
On multi-linear regression analysis, in a model which consists of BMI, waist hip ratio, 
total cholesterol, fasting glucose and HbA1c as predictors was used. BMI and total 
cholesterol were independent predictors for mean e’ (β coefficient = 0.79, p=0.01; and β 
coefficient = -0.68, p=0.02, respectively) and for medial e’ (β coefficient = 0.84, p=0.02; and 
β coefficient= -0.65, p=0.04, respectively) in type 1 diabetes mellitus  
 Similarly, in the same model for type 1 diabetes mellitus, waist-hip ratio and total 
cholesterol were independent predictors for lateral mitral annular tissue velocity. (β 
coefficient = -0.51, p=0.02; and β coefficient = - 0.56, p=0.04, respectively). Mitral inflow 
early diastolic velocity (E) was independently predicted by BMI (β coefficient = 0.74, p = 
0.05) in type 1 diabetes mellitus. Fasting blood glucose and HbA1c  were not selected by the 
model and therefore did not predict any of the indices of myocardial function (lateral, medial 
and mean mitral annular velocities and mitral inflow early diastolic velocity (E).)  
Correlates of myocardial velocities in T1DM are shown in table 10.3. 
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Table 10.3: Pearson’s correlation of myocardial velocities and displacement, with age, 
HbA1c and vascular parameters, in type 1 diabetes mellitus (n=19)  
 
 Age 
 
WHR 
 
HbA1c 
 
cIMT 
 
AIx 
 
 r 
p 
r 
p 
r 
p 
r 
p 
r 
p 
Displacement -0.14 
0.55 
-0.21 
0.39 
-0.14 
0.5 
-0.27 
0.27 
-0.52 
0.02* 
PSV -0.23 
0.34 
-0.2 
0.42 
-0.50 
0.04 
-0.36 
0.13 
-0.37 
0.12 
E 
(tissue) 
-0.29 
0.23 
0.29 
0.24 
-0.36 
0.14 
-0.24 
0.33 
-0.58 
0.01* 
A 
(tissue)  
0.53 
0.02* 
0.47 
0.05* 
-0.19 
0.45 
0.47 
0.04* 
0.22 
0.37 
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Figure 10.6: Correlation between augmentation index and displacement  
 
 
Displacement negatively correlates with augmentation index in type 1 diabetes 
mellitus.  (r= -0.52, p=0.02) (figure 10.6) 
Figure 10.7: Correlation between augmentation index and early diastolic velocity E 
(tissue velocity)  
 
 
 
 Early diastolic velocity E also negatively correlates with augmentation index in 
type 1 diabetes mellitus. (r= -0.58, p=0.01) (figure 10.7) 
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Figure 10.8: Correlation between augmentation index and medial mitral annular tissue 
velocity (medial e’) in type 1 diabetes mellitus (n=19)  
 
 
 
 
Augmentation index correlates inversely with medial e’ in subjects with type 1 diabetes 
mellitus. (r=-0.52, p=0.02)  (Figure 10.8)  
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Figure 10.9: Correlation between age and late diastolic tissue velocity A 
 
 
Figure 10.10: Correlation between waist hip ratio and late diastolic tissue velocity (A)  
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Figure 10.11: Correlation between mean cIMT and late diastolic tissue velocity 
 
 
 
 
Late diastolic tissue velocity A positively correlates with age (r=0.53, p=0.02), waist 
hip ratio (r= 0.47, 0.05) and cIMT  (r=0.47, p=0.04) in subjects with type 1 diabetes mellitus. 
(figures 10.9,10.10, and 10.11)  
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Figure 10.12: Correlation between mean peak systolic velocity and HbA1c  
 
A negative correlation between peak systolic velocity and HbA1c was noted in type 1 
diabetes mellitus. (r= -0.5, p=0.04)  (figure 10.13) 
Multiple regression analysis  
On multiple regression analysis, in a model consisting age, waist hip ratio, SBP, 
serum triglycerides, stiffness index β, cIMT, and HbA1c, WHR predicted displacement (β 
coefficient = -0.5, p=0.04) in the control group.  
In a model consisting age, waist-hip ratio, SBP, serum triglycerides, stiffness index β, 
cIMT, HbA1c and total cholesterol, WHR predicts mean E in controls (β coefficient = -0.73, 
p=0.009) and in type 1 diabetes mellitus (β coefficient = -0.66, p=0.05). In the same model, 
stiffness index β also predicts mean E. (β coefficient =0.67, p=0.03) 
In a model consisting of age, waist hip ratio, serum triglycerides, stiffness index β, 
cIMT, HDL, HbA1c and augmentation index, peak systolic velocity is predicted by HbA1c 
(β coefficient = -0.72, p=0.02) and cIMT ( β coefficient = -0.88, p=0.05).   
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Summary (Correlates of myocardial function in type 1 diabetes mellitus)  
 
Early tissue diastolic velocity E and mean displacement decrease with increasing AIx 
whereas late tissue diastolic velocity A increases with increasing age, waist hip ratio, and 
cIMT. Peak systolic velocity (PSV) decreases with high HbA1c.  Left ventricular filling 
pressure increases with raised BMI. Lateral e’ decreases with increasing waist hip ratio.  
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10.3 Correlates of myocardial function in control group 
 
Pearson correlations of diastolic myocardial function for control group is shown table 
10.5.  
Table 10.4: Pearson correlations between anthropometric measures and biochemical 
results, with myocardial function in control subjects (n=21) 
 
 
 E 
(r,p) 
A 
(r,p) 
E/A 
(r,p) 
lateral e’ 
(r,p) 
medial e’ 
(r,p) 
E/e’ 
(r,p)  
BMI 0.01 
0.96 
-0.51 
0.02* 
0.44 
0.04* 
-0.16 
0.48 
-0.13 
0.59 
0.09 
0.72 
Waist 
circumference 
0.07 
0.77 
-0.17 
0.45 
0.18 
0.45 
-0.42 
0.06 
-0.11 
0.65 
0.31 
0.17 
Waist hip 
ratio 
-0.09 
0.70 
-0.16 
0.48 
0.09 
0.71 
-0.42 
0.06 
0.02 
0.95 
0.1 
0.67 
total 
cholesterol 
-0.46 
0.03* 
-0.28 
0.22 
0.001 
0.99 
-0.24 
0.30 
-0.01 
0.96 
0.09 
0.70 
HDL 0.09 
0.71 
-0.12 
0.60 
0.32 
0.16 
0.37 
0.10 
0.35 
0.12 
-0.39 
0.08 
LDL -0.42 
0.06 
-0.19 
0.42 
-0.11 
0.65 
-0.09 
0.69 
0.03 
0.91 
-0.13 
0.58 
TG -0.12 
0.59 
-0.09 
0.71 
-0.05 
0.82 
-0.27 
0.25 
-0.24 
0.29 
0.25 
0.28 
hsCRP 0.17 
0.46 
0.11 
0.63 
0.03 
0.91 
0.05 
0.83 
0.11 
0.65 
0.01 
0.96 
 
BMI negatively correlates with late diastolic velocity (A) and positively correlates 
with E/A ratio in control subjects. (figure 10.13 and 10.14) 
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Figure 10.13: Correlations between BMI and late diastolic (mitral inflow) velocity (A) in 
control subjects (n=21)  
 
 
 
Figure 10.14: Correlations between BMI and E/A ratio in control subjects (n=21)  
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Figure 10.15: Correlation between total cholesterol and early diastolic velocity (mitral 
inflow) (E) in control subjects (n=21)  
 
 
 
 Early diastolic velocity (E) decreases with increasing level of total cholesterol in 
control subjects. (figure 10.15)  
Summary (correlates of myocardial function in control group) 
 
Early diastolic E and late diastolic A velocities decrease with increasing BMI and 
cholesterol, respectively whereas E/A ratio increases with increasing BMI.  
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10.4 Discussion on correlates  of myocardial function in type 1 diabetes 
mellitus  
 
When data were analysed from the subjects with type 1 diabetes mellitus and the 
controls together, estimated mean left ventricular filling pressure, using E/e’ ratio, increased 
with BMI and waist circumference, and lateral mitral annular early diastolic velocity 
decreased with increasing waist-hip ratio. These results imply that irrespective of diabetic 
status, left ventricular diastolic function is adversely affected by increasing obesity and in 
particular central obesity. 
On subgroup analysis, in type 1 diabetes mellitus, the early diastolic tissue velocity 
and the mean displacement of the basal myocardial segments decreased with increasing 
central systolic blood pressure (estimated from the augmentation index). The late diastolic 
tissue velocity A increased with increasing age, waist-hip ratio, and cIMT. Peak systolic 
velocity (PSV) decreased with high HbA1c.  Left ventricular filling pressure increased with 
raised BMI. Lateral e’ decreased with increasing waist hip ratio. These results suggest that 
myocardial function may be adversely affected by conduit artery stiffness, and early 
atherosclerosis, as well as obesity.  
A modest correlation between PSV and HbA1c was observed, but no other 
correlations were found between HbA1c and myocardial function in this study. Most 
significant correlations were between myocardial function and features of adiposity. It may 
imply that the influence of glycaemia on myocardial function in type 1 diabetes mellitus may 
not be as strong as that of adiposity. In fact, the link between HbA1c and cardiovascular 
disease in type 1 diabetes mellitus is not consistent.  
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The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) showed that 
elevated glycosylated haemoglobin level was associated with both all cause and 
cardiovascular mortality in T1DM. [230] However, some major epidemiological studies such 
as the Pittsburgh Epidemiology of Diabetes Complications (EDC) study and the EURODIAB 
study did not demonstrate a link between hyperglycaemia and cardiovascular disease or 
mortality in T1DM. [231] [232] Kilpatrick et al , after analysing  data from the DCCT trial, 
argued that it is mean blood glucose rather than HbA1c that has better predictive value for 
cardiovascular disease in type 1 diabetes mellitus. [233] A meta-analysis based on three 
prospective studies of glycosylated haemoglobin and coronary heart disease in T1DM 
concluded that there is a moderate increase in risk of cardiovascular disease with increasing 
levels of glycosylated haemoglobin. [234] 
In an observational study , 20, 985 patients with type 1 diabetes mellitus with mean 
age of 38.6 years  were followed up for nine years. [235] The hazard ratio for development of 
heart failure was 3.98 (95% CI 2.23 –7.14) in those patients whose HbA1c was more than 
10.5 % in comparison with a control group of patients who had lower HbA1c levels (mean 
6.5%)  Similar changes were noted in a study of 48,858 patients, of whom the majority had 
type 2 diabetes mellitus. It was observed that for every 1% increase in HbA1c there was an 
8% increase in the risk of heart failure or death related to heart failure. [236] Even in those 
patients who were not previously diagnosed with diabetes mellitus or those who were not on 
any treatment for diabetes mellitus, HbA1c seem to be a strong predictor of mortality in a 
group of older patients with impaired left ventricular systolic function. [237] Good et al 
studied a group of patients with a median age of 72 years and they found that mortality in 
those patients with left ventricular systolic dysfunction increased sharply when HbA1c was 
higher than 6.7%.  
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The relationship between HbA1c and cardiovascular mortality may not be 
straightforward or linear. The strategy of bringing HbA1c closer to normal did not work in 
type 2 diabetes mellitus patients in the ACCORD study. [238]  In fact, in an observational 
study of ambulatory patients with established heart failure, the relationship between HbA1c 
and overall mortality was found to be  U- shaped. 
There is evidence to suggest that poor glycaemic control or higher HbA1c is 
associated with development of heart failure in type 1 diabetes mellitus.  
Nevertheless, the link between HbA1c or glycaemic control and more subtle, 
subclinical myocardial dysfunction in type 1 diabetes mellitus in particular is not consistently 
observed. In a study of 25 patients with type 1 diabetes mellitus and 26 healthy controls, 
HbA1c was found to be correlated with indexes of increased left ventricular filling pressure 
such E/e’ and E/Vp ( mitral inflow velocity). [81] Similarly, HbA1c was negatively 
correlated with features of diastolic dysfunction such as E/A ratio, Em and Em/Am in study 
of 50 type 2 diabetes mellitus and 50 controls. [121]  A similar negative correlation between 
HbA1c and diastolic E/A ratio was reported even in children and adolescents with type 1 
diabetes mellitus. [187] No correlation between HbA1c and echocardiographic data was 
found in a study of 40 type 1 diabetes mellitus subjects and 40 controls. [98]  
In my study, only one association between myocardial function and HbA1c was 
observed – the peak systolic velocity of long-axis shortening of the left ventricle (PSV) was 
inversely related to HbA1c. However, it was observed that estimated mean left ventricular 
filling pressure (E/e’) correlated positively with BMI and waist circumference, and lateral 
mitral annular early diastolic velocity e’ correlated negatively with waist-hip ratio. Moreover, 
lateral and medial mitral annular velocities were positively correlated with serum HDL, and 
lateral mitral annular velocity was negatively correlated with serum triglycerides, and waist-
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hip ratio, when data were analysed as a whole group. Further subgroup analysis showed that 
in the control group, BMI correlated negatively with late diastolic velocity (A) and positively 
with E/A ratio, whereas in the diabetic group, BMI, waist-hip ratio and hsCRP correlated 
positively with E/e’ ratio, lateral e’ and late diastolic velocity (A).  
These findings suggest that even in young subjects and irrespective of their diabetic 
status, myocardial function seems to be more related to features of metabolic syndrome and 
obesity rather than actual blood glucose level. In the Pittsburgh Epidemiology of Diabetes 
Complications (EDC) study, after 10 years of follow up of 603 patients with type 1 diabetes 
mellitus, it was concluded that factors such as insulin resistance, HDL cholesterol, and non-
HDL cholesterol, rather than glycaemia, predict cardiovascular disease in type 1 diabetes 
mellitus. [231] In the same study, coronary artery calcification was reported to be related to 
features of adiposity such as visceral adipose tissue, subcutaneous adipose tissue, BMI and 
waist circumference, again in type 1 diabetes mellitus. [239]  
With changes in life style, the prevalence of obesity is increasing in young subjects 
with T1DM. Insulin sensitivity has been found to be reduced in T1DM children and 
adolescents. The Finn Diane Study proved that the prevalence of metabolic syndrome was as 
high as 35-40% in T1DM. Insulin sensitivity was lower in pubertal and post pubertal 
adolescents and in those with high BMI, and waist circumference. [240]  
Elevated insulin resistance is a known risk factor for macrovascular complications in 
type 2 diabetes mellitus. Insulin resistance and metabolic syndrome are also associated with 
both micro and macrovascular complications in T1DM. [241] In the DCCT study, the 
intensive therapy group gained more weight than the conventional treatment group, and had 
changes similar to those seen in the metabolic syndrome such as high blood pressure, high 
triglycerides, and  high total and LDL cholesterol.[242] Many epidemiological studies 
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showed that high total cholesterol,[200] high LDL, high triglycerides, and low HDL[199]  
[107] are associated with cardiovascular disease in type 1 diabetes mellitus. 
Moreover, myocardial steatosis or higher myocardial triglycerides contents on 
1
H-
magnetic resonance spectroscopy have been reported in type 2 diabetes mellitus. [243]  Ng et 
al demonstrated that myocardial triglycerides contents correlated with global LV longitudinal 
strain, global LV longitudinal systolic strain rate and diastolic strain rate. [244] Rijzewijk et 
al also demonstrated the link between diastolic dysfunction and myocardial triglyceride 
contents in type 2 diabetes mellitus. [245] 
However, the presence of triglycerides in the myocardium in itself is not thought to be 
pathological currently. It may be a mere reflection of increased exposure of the myocardium 
to high lipid environment.[246] 
In patients with diabetes mellitus, the myocardium uses free fatty acids as its main 
energy source because of reduced glucose transport into the cells secondary to impaired 
transcription of glucose transport such as GLUT-4 and increased availability of free fatty 
acids because of hypertriglyceridemia. [247] Increased fatty acid utilization by cardiac 
muscle has been described in both type 1 and type 2 diabetes mellitus. [248] This increase in 
free fatty acid oxidation, and altered substrate metabolism, increases oxygen consumption in 
the myocardium. Transgenic mouse models showed that exposure to free fatty acids even in 
the absence of hyperglycaemia could cause lipotoxicity in cardiac muscles.[249] [250] 
Obesity is a known independent risk factor for heart failure. [251] Increase in waist 
circumference and waist-hip ratio has been shown to link with the risk of heart failure. [252] 
In this study, I have described an association between features of adiposity such as 
high waist-hip ratio, dyslipidaemia and adverse diastolic function in a group of young 
subjects irrespective of their diabetic status; the mean age was 21.1 ± 3.6 years in T1DM and 
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24.2 ± 2.9 years in controls, and the mean BMI  25.1 ± 3.1 in type 1 diabetes mellitus and 
24.2 ± 2.7 in controls. Only a modest correlation was found between glycaemia and peak 
longitudinal systolic function. In order to delay or prevent the development of overt heart 
failure or cardiovascular disease in young subjects with type 1 diabetes mellitus, it may be 
prudent that other risk factors such as lipid profiles are controlled in the early stages of 
diabetes mellitus as well as glycaemic control.  
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CHAPTER 11- RESULTS - Vascular structure and function 
 
11.1 Reproducibility of vascular measurements  
 
Five volunteers were recruited and high-resolution ultrasound scans were performed 
on both sides of the neck, for cIMT measurement, and stiffness parameters β and ε. Images of 
the carotid artery were acquired 1 cm below the carotid bulb. Images were analysed off-line 
using Vascular Image Laboratory Software, and cIMT was measured on the far wall within 
1cm of carotid bulb. A mean value from the two sides was taken. Stiffness parameters β and ε 
were acquired at the same time and average values were taken. The same procedures, both 
scanning and analysis, were repeated in the same subjects after 2 weeks. Reproducibility was 
calculated as shown in Figure 11.1 and Table 11.1.  
 
 
Figure 11.1: Coefficient of variation (CV) of vascular measurements  
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Table 11.1: Intra-observer reproducibility of vascular measurements (Bland-Altman 
Analysis) 
 
 Bias SD of Bias 95% limit of agreement  
From  To  
cIMT -0.006 0.029 -0.062 0.05 
Stiffness 
parameter β 
-0.59 0.98 -2.52 1.34 
Stiffness 
parameter ε 
-6.3 17.95 -41.48 28.88 
 
11.2 Discussion on vascular reproducibility  
 
Intra-observer variability of cIMT was reported to be range from 2.4% to 10.6%. 
[253] [254] Reproducibility of near wall and far wall cIMT are similar. However, ultrasonic 
far wall measurements more accurately  reflect the true thickness. [255]  The intra-observer 
coefficient of variation of 2.6% found in my study is therefore comparable with other studies.  
In a study of 10 healthy subjects, Niki et al reported that coefficient of variation for β 
is less than 15%. [256] Intra-observer coefficient of variation (CV) was reported to range 
from 15.5% to 18.6% for ε and from 15.9 % to 19.2% for stiffness index β by Swampillai in 
her thesis. [257] Therefore, the CVs for stiffness index β and ε in my study compare 
favourably to previous reports. The numbers of paired analyses were small, however. 
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11.3 Vascular stiffness and cIMT  
 
Table 11.2 shows the results of tests of vascular structure and function in the subjects 
with type 1 diabetes mellitus and the controls. 
 
Table 11.2: Markers of vascular stiffness and cIMT (T1DM vs. controls)  
 
 
Type 1 Diabetes 
Mellitus 
(n=19) 
Controls 
(n=34) 
P value 
Augmentation index (AIx) 
%  
2.34 ± 11.22 3.39 ± 12.61 0.77 
cIMT (mm)  0.50 ± 0.60 0.48 ± 0.50 0.39 
Beta index β 4.44 ± 0.84 4.90 ± 1.07 0.11 
Epsilon  52.29 ± 12.23 59.47 ± 14.55 0.07 
 
There was no significant difference between controls (n = 18) and T1DM ( n=13) in 
carotid-femoral pulse wave velocity but there was a trend for it to be higher in the diabetic 
subjects (5.53 ± 0.74 m/s in controls vs. 5.73 ± 1.13 m/s in the diabetics, p = 0.06). Pulse 
wave velocity was added to the protocol after the study started, and so it was assessed only in 
31 subjects (13 T1DM and 18 controls).  
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11.4 Univariate Analysis of Variance of vascular function  
 
Vascular measurements such as AIx had a wide range, and may be influenced by 
many factors.. Therefore, differences between groups in cIMT, augmentation index, β and ε 
were analysed further after being corrected for age, sex, BMI, waist-hip ratio and blood 
pressure.  
11.4.1 Relationship between age and diabetes/controls for cIMT  
 
The following figure shows the relationship between age and mean cIMT in type 1 
diabetes mellitus and control group. 
Figure 11.2: Relationship between age (years) and mean cIMT (mm) 
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There is strong interaction between age and diagnostic group for this variable. In this 
small sample, age did not appear to influence mean cIMT in the control group, whereas there 
was a clear relationship in the diabetic group – with cIMT increasing with age   in type 1 
diabetes mellitus (R
2 
= 0.56, p= 002).  
11.4.2 Relationship between age and stiffness parameter β 
 
The following figure shows the relationship between mean β and age in both type 1 
diabetes mellitus and control group.  
Figure 11.3: Relationship between age (years) and mean β 
 
 
  Mean β correlates with age stronger in control group (R2=0.14, 
p=0.04). 
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11.4.3 Relationship between age and stiffness parameter ε  
 
Figure 11.4 Relationship between age and stiffness parameter ε 
 
 
In the control group, mean ε correlated with age. (R2=0.11, p=0.01) 
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11.4.4 Relationship between age and augmentation index  
 
Augmentation index increased both in subjects with type 1 diabetes mellitus and in 
controls. (figure 11.5) 
 
Figure 11.5: Relationship between age and augmentation index  
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11.4.5 Relationship between age and pulse wave velocity  
  
 
The following diagram shows the relationship between mean PWV and age.  
 
 
Figure 11.6: relationship between mean pulse wave velocity (PWV) (m/s) and age 
(years)  
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11.5 Wave Intensity Results 
 
Data were analysed by wave intensity methods. Net wave intensity was separated into 
forward and backward compression waves by applying water-hammer equation to pressure-
volume loop, using an automated software. Timing, duration, amplitude and net energy of 
individual waves were measured. All wave intensity data set were assessed statistically for 
quality, using published methods, and those with noisy data and abnormal quality indices 
were excluded. Results are therefore presented for the remaining 50 subjects (19 type 1 
diabetes mellitus and 31 controls). Table 11.3.  
 
Table 11.3: Wave intensity analyses 
 
  
Type 1 diabetes 
mellitus 
(n =19) 
Controls 
(n=31) 
P-value 
Local wave speed (cm/s) 2.53  ± 2.21 2.71 ± 0.95 0.70 
Mean arterial BP (mmHg) 85.63 ± 5.68 84.97 ±  6.2 0.71 
Stiffness index β 4.49 ± 1.25 4.81 ± 1.26 0.39 
Pressure-strain elastic 
modulus ε (kPa) 
 
54.47 ± 15.78 57.29 ± 16.29 0.55 
AIx (%) 3.37 ± 15.56 2.87 ± 19.67 0.93 
AIx 4
th
 derivative -1.75 ± 6.37 -1.13 ± 10.99 0.82 
 
  
 
 
 
 
 
170 
Those data with skewed distribution were log transformed and analysed. (Table 11.4) 
Table 11.4: Log transformed wave intensity results (all data were log transformed)  
 
 
 Type 1 diabetes 
mellitus 
Controls P value 
FCW peak 1.13 ± 0.15 1.06 ± 0.19 0.23 
FCW integral 2.76 ± 0.16 2.74 ± 0.20 0.71 
Duration FCW 2.00 ± 0.06 2.04 ± 0.04 0.005* 
BCW peak 0.73 ± 0.38 0.63 ± 0.28 0.28 
BCW integral 2.44 ± 0.34 2.37 ± 0.26 0.39 
Duration BCW 2.08 ± 0.06 2.10 ± 0.07 0.44 
FEW peak 0.41 ± 0.20 0.38 ± 0.23 0.67 
FEW integral 1.91 ± 0.21 2.85 ± 0.23 0.35 
Duration FEW 2.87 ± 0.18 1.81 ± 0.12 0.17 
FCWP peak 1.75 ± 0.30 1.77 ± 0.11 0.79 
FCWP integral 3.54 ± 0.13 3.54 ± 0.11 0.93 
BCWP peak 1.58 ± 0.16 1.52 ± 0.13 0.16 
BCWP integral 3.4 ± 0.14 3.38 ± 0.12 0.44 
BCWP/FCWP peak 1.83 ± 0.39 1.76 ± 0.10 0.31 
BCWP/FCWP integral 1.85 ± 0.04 1.84 ± 0.05 0.41 
 
FCW = forward compression wave, BCW= backward compression wave, FEW= forward 
expansion wave, FCWP= forward compression wave pressure, BCWP= backward 
compression wave pressure. 
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11.6 Discussion on vascular structure and function  
 
There were no significant differences between the diabetic group and the controls, in 
augmentation index (AIx), pulse wave velocity, carotid intima-media thickness, and the 
indices of conduit arterial stiffness β and ε. Also, no differences were noted after adjustments 
for age, sex, waist-hip ratio and blood pressure.  
The finding that AIx is not different between T1DM and control is contrary to many 
other studies. Heilman et al studied 30 children (ages 4.7 to 18.6 years) with type 1 diabetes 
mellitus, with a mean duration of diabetes mellitus of 5.4 ± 3.4 years and mean HbA1c of 
9.8%, and 30 healthy controls, and they demonstrated that children with T1DM had increased 
AIx @75 (augmentation index adjusted for heart rate at 75/minute) and increased cIMT. 
[258] Similarly, Haller et al demonstrated increased AIx @ 75 in 43 children who were 10 -
18 years old. However, in these studies,  the wide age range could potentially be a 
confounding factor, if the results are influenced by growth and rapidly changing arterial 
structure such as diameter. [259] 
 Many studies showed an increased AIx in type 1 diabetes mellitus. Wilkinson et al 
reported increased AIx and PWV in 35 patients with T1DM aged 30 years who had had 
diabetes mellitus for a minimum of 10 years. [171] Lacy et al studied a mixture of type 1 and 
type 2 diabetes mellitus subjects and found that PWV  but not AIx was increased in diabetes 
mellitus. [168] 
In a larger study involving 535 subjects with type 1 diabetes mellitus (age 14.6 ± 3.3 
years) and 241 controls (age 21.4 ± 2.5 years), AIx @ 75 was higher in type 1 diabetes 
mellitus and the presence of diabetes mellitus, male sex and increased mean arterial pressure 
were independent determinants of arterial stiffness. [260] BMI, SBP and DBP were higher in 
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subjects with type 1 diabetes mellitus in this study.  However, Yu et al reported normal 
arterial stiffness in young subjects with type 1 diabetes mellitus. [261] In the SEARCH for 
Diabetes in Youth study, Wadwa et al  [262] studied arterial stiffness, PWV and AIx75 in 
young subjects with type 1 and type 2 diabetes mellitus and demonstrated that subjects with 
type 2 diabetes mellitus had a higher AIx and PWV. They also reported that arterial stiffness 
was associated with waist circumference and blood pressure, irrespective of diabetes type.  
Increased cIMT in type 1 diabetes mellitus has been reported in many studies. [148] 
[263] The differences between the findings in my study and other studies might be explained 
if  I was studying a different cohort of subjects with type 1 diabetes mellitus; in my study, 
subjects with T1DM had a relatively short duration of diabetes mellitus. However, Atabek et 
al studied 45 patients with type 1 diabetes mellitus aged 14.5 ± 2.5 years who had had 
diabetes mellitus for 4.4 ± 2.5 years and they reported that cIMT was thicker in type 1 
diabetes mellitus and that it was positively associated with the duration of diabetes mellitus. 
[148] Vastagh et al demonstrated a thicker cIMT in 42 patients with type 1 diabetes mellitus ( 
aged 34 ± 10 years with an average duration of diabetes mellitus 15 ± 10 years) when 
compared to age-matched controls. [263] 
Brachetta et al reported increased arterial stiffness in a group of type 1 diabetes 
mellitus patients with diabetes mellitus for more than 10 years, related to their duration of 
disease. [264] cIMT changes with time and treatment, and it may regress or progress with 
time or treatment. [153] [154] [155] Assessing cIMT at one particular time-point and 
interpreting it may be difficult.  
Using analysis of variance, no differences between T1DM and controls were observed 
for any of the measurements of vascular function, namely cIMT, augmentation index, pulse 
wave velocity, β and ε. The main consistent finding was the association between age and 
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vascular function. A strong interaction between age and vascular function was observed both 
in type 1 diabetes mellitus and in controls. In TIDM group, age was a significant factor for 
cIMT, AIx and PWV whereas in the control age was a significant factor for β and ε, AIx and 
pwv.  
It is well-recognized that conduit arteries becomes stiffer as age progresses.  
McEniery et al showed that both augmentation index and PWV increases with age. [265]  
Pulse wave velocity (PWV) increases gradually until about 60 years of age. [266] [267] 
Interactions between age and cIMT, AIx and PWV in subjects with T1DM with a narrow age 
range of  21.1 ± 3.6 years, may be a sign that diabetes mellitus is accelerating the vascular 
aging process. No other studies were found concerning β and ε in subjects with type 1 
diabetes mellitus.  
Wave intensity measurement at the carotid artery by echo-tracking technique is not 
widely used in clinical practice. Wave separation could provide further information about 
interactions between the heart and arterial system but acquiring the data is technically 
challenging and the variability of the data is relatively high; hence it is now appreciated that 
its power to show differences is low unless sample sizes are large  
The duration of the forward compression wave (FCW) was shorter in subjects with 
type 1 diabetes mellitus than in the controls. This shorter duration of FCW may merely be a 
reflection of the faster heart rate in type 1 diabetes mellitus. Apart from duration of FCW, no 
other differences between type 1 diabetes mellitus and controls were noted; for example the 
diabetic subjects did not demonstrate increased backwards wave reflections. Therefore, there 
was no evidence in this study of changes in wave intensity or abnormalities of local wave 
travel in the carotid artery, in type 1 diabetes mellitus subjects when compared with controls. 
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11.7Correlates of vascular function  
 
11.7.1 Correlates of vascular function (whole group) 
 
Correlates of vascular function for the whole group are shown in table 11.5. 
 
Table 11.5: Correlates of vascular function (n=53) 
 
  
r 
p 
Age 
r 
p 
Weight 
r 
p 
Waist Hip 
Ratio 
r 
p 
β 
r 
p 
 
0.9 
0.000* 
 
0.28 
0.05* 
 
0.32 
0.02* 
 
0.22 
0.13 
 
r 
p 
-  
0.33 
0.02* 
 
0.41 
0.003* 
 
0.37 
0.008* 
 
 
 
Pressure-strain elastic modulus ε and stiffness parameter β positively correlated with 
age and weight, when data were analysed as one group including the diabetics and controls. 
Carotid ε also correlates positively with waist-hip ratio. Irrespective of the diabetes status, the 
carotid artery stiffens with increasing age and body weight. 
11.7.2 Correlates of vascular structure and function in type 1 diabetes mellitus 
(n=19)  
 
Only cIMT is observed to correlate positively with age (r = 0.75, p = 0.000) (shown in 
Figure 11.7) and waist-hip ratio (r= 0.5, p=0.31) (shown in Figure 11.8) in type 1 diabetes 
mellitus.   
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Figure 11.7: Correlation between cIMT and Age  
  
 
Figure 11.8: Correlation between cIMT and waist hip ratio 
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11.8 Discussion on correlates of vascular function 
 
Stiffness parameter β and pressure-strain elastic modulus ε increases with age. 
Kawasaki et al demonstrated that β increases with advancing age as the vessel diameter 
increases and the percentage of cyclical change in diameter decreases. [268] Mitchell et al 
reported increased arterial stiffness with ageing in healthy men and women. [266] The 
findings in this study are consistent with other studies.  
Stiffness parameter β and pressure-strain modulus ε also increase with features of 
adiposity such as increasing weight and waist-hip ratio. In a prospective study involving 14 
non-obese men who were followed up over 6 to 8 weeks, stiffness index β was found to be 
increased with weight gain and arterial stiffness was associated with total abdominal fat, 
abdominal visceral fat and waist circumference. [269] 
In this study, similar changes were observed for cIMT in subjects with type 1 diabetes 
mellitus. cIMT increased with increasing age and waist-hip ratio, more clearly in type 1 
diabetes mellitus than in controls. 
Age was associated with cIMT in many studies in type 1 diabetes mellitus. [270] 
[263] cIMT was also reported to be associated with markers of obesity such as increased BMI 
in type 1 diabetes mellitus. Therefore, central adiposity may play an important role in 
progression of subclinical atherosclerosis.  
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CHAPTER 12 – SUMMARY AND CONCLUSIONS 
 
12.1 General discussion 
 
Main findings in this thesis are: 
1. Subjects with T1DM have normal global systolic left ventricular function and normal left 
ventricular mass index when compared with age-matched controls, but they have reduced 
medial mitral annular excursion on M-mode echocardiography, indicating a reduction in 
longitudinal function of the left ventricle. (Chapter 6.1 and 6.3) 
2. Subjects with T1DM have a lower mitral E/A ratio, related to a lower early diastolic 
velocity (E) and an increased late diastolic velocity (A), indicating impaired ventricular 
relaxation or diastolic dysfunction. (Chapter 8.1) 
3. Subjects with T1DM have reduced longitudinal displacement on myocardial velocity 
imaging at rest and during dobutamine stress. (Chapter 9.3) 
4. Subjects with T1DM, however, have normal longitudinal systolic velocity at rest and 
during dobutamine stress. (Chapter 9.4) 
5. Subjects with T1DM, have normal radial myocardial systolic function. (Chapter 9.5) 
6. Subjects with T1DM showed incremental increases in peak systolic velocity in response 
to dobutamine, and thus, they have normal myocardial functional reserve. (Chapter 9.7) 
7. Subjects with T1DM showed normal systolic strain, peak early diastolic strain rate and 
peak systolic strain rate at rest and during dobutamine stress. (Chapter 9.10) 
8. Observed differences in longitudinal function are not explained by the effects of 
exercise. (Chapter 9.14) 
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9. Features of adiposity and adverse lipid levels correlate with adverse diastolic function in 
young subjects (including type 1 diabetes mellitus and controls). (Chapter 10.1)  
10. Similarly, increased BMI and waist hip ratio in type 1 diabetes mellitus correlate with 
reduced left ventricular diastolic function. (Chapter 10.2) 
11. In young subjects with type 1 diabetes mellitus, mean displacement and mean early 
diastolic velocity are inversely related to central aortic blood pressure (augmentation 
index) .(Chapter 10.2) 
12. In young subjects with type 1 diabetes mellitus, only mean peak systolic velocity in the 
basal segments is inversely related to HbA1c. (Chapter 10.2) 
13. HbA1c and cIMT are independent predictors for peak systolic velocity (PSV) whereas 
BMI and total cholesterol are independent predictors for diastolic velocities. (Mean e’ 
and medial mitral annular e’). (Chapter 10.2)  
14. Young normotensive subjects with type 1 diabetes mellitus showed no evidence of early 
atherosclerosis and conduit artery stiffness when compared with controls. (Chapter 12.1) 
15. In type 1 diabetes mellitus patients and controls analysed as one group, conduit arterial 
stiffness (beta and epsilon in the common carotid artery) is related to features of 
adiposity such as weight and waist-hip ratio. (Chapter 13.1) 
I have demonstrated that in young subjects with type 1 diabetes mellitus who do not 
have any other complications, there is evidence of reduced longitudinal myocardial function 
of the left ventricle, both systolic and diastolic. This finding is in agreement with other 
studies in type 1 diabetes mellitus. Di Cori et al reported reduction in systolic strain and strain 
rate in 40 subjects with type 1 diabetes mellitus (28 ± 4.2 years). [98] Similarly, Palmieri et al 
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demonstrated lower systolic strain and strain rate in 20 patients with type 1 diabetes mellitus. 
(aged 34 ± 10 years) [104] Apart from an M-mode echocardiography study by Raev et al 
[78], the largest study using tissue Doppler in type 1 diabetes mellitus was carried out by 
Konduracka et al, and they reported normal left ventricular function in 185 subjects with type 
1 diabetes mellitus (age 34.8 ± 7.9 years). [88] However, in Konduracka’s study, systolic 
velocity was not reported. The findings in my study showed that there is reduced longitudinal 
movement of the myocardium (displacement) on myocardial velocity imaging in type 1 
diabetes mellitus and this was supported by the finding of reduced medial mitral annular 
excursion. Nevertheless, PSV remains similar between the two groups, implying that the 
duration of systole must be shorter in the subjects with diabetes mellitus. In fact, in the 
Copenhagen City Heart Study, it was noted that even though longitudinal displacement was 
significantly lower in diabetic subjects, peak systolic velocity was not. [271] It suggests that 
displacement is a more sensitive parameter than PSV in detecting subclinical myocardial 
dysfunction.   
This reduction in myocardial displacement was found throughout the dobutamine 
infusion. However, myocardial functional reserve was normal in my study. This is the first 
study to demonstrate myocardial function reserve in terms of incremental change in peak 
systolic velocity but myocardial functional reserve in response to dobutamine has been 
reported in type 2 diabetes mellitus. Vinereanu et al reported a reduction in myocardial 
functional reserve [85] whereas Fang et al [86]  reported a normal functional reserve. Studies 
in type 2 diabetes mellitus usually involve older patients and subjects invariably tend to have 
confounders such as hypertension.  
In my study, I have demonstrated in young subjects with type 1 diabetes mellitus who 
do not have any other complications and who are normotensive, that myocardial functional 
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reserve is preserved. In my study, peak systolic velocity (PSV) did not show any difference 
between patients and controls at rest or at peak doses of dobutamine, but the response was 
significantly lower at intermediate doses of dobutamine (10 μg/kg/minute and 20 
μg/kg/minute). 
Normal myocardial functional reserve indicates that subjects with type 1 diabetes 
mellitus have preserved metabolic capability to cope with increased work load of the 
myocardium. In other words, small vessel disease is unlikely as one would expect reduction 
in myocardial functional reserve with any form of vascular disease in the event of increased 
oxygen demand. In a magnetic resonance spectroscopy and stress magnetic resonance 
imaging study in type 1 diabetes mellitus, it was shown that myocardial energetics in type 1 
diabetes mellitus was impaired as indicated by reduced phosphocreatinine/γ-ATP ratio and 
that this impairment was independent of coronary microvascular function. Therefore, early 
changes in myocardial dysfunction may be due to metabolic changes. [272] 
A few studies in type 2 diabetes mellitus have shown that there was reduction in 
longitudinal myocardial function with an increase in radial function. [89] [85] It was 
hypothesized that increased radial function may be a “compensatory” response to reduction in 
longitudinal function as longitudinal fibres are more prone to the effects of ischaemia. 
However, Ernande et al reported reduction in radial function in type 2 diabetes mellitus. [90] 
In my study, I did not find any reduction in radial myocardial function. The inconsistencies in 
these findings of increased radial function may be due to the technical difficulty in obtaining 
radial velocities on myocardial velocity imaging as myocardial velocity obtained by TDI  are 
angle dependent and prone to the motion of the heart. Moreover, it may be due to the 
differences in the pathophysiology between type 1 and type 2 diabetes mellitus. Subjects in 
type 2 diabetes mellitus tend to have other associated confounding factors such as 
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hypertension. Lastly, the results may vary depending on the clinical stage in the natural 
history of the disease.  
Contrary to many other studies, I did not find any evidence of vascular disease in the 
study group. The subjects with type 1 diabetes mellitus in the study had had diabetes mellitus 
for a relatively shorter duration of diabetes mellitus and none of the subjects had any other 
complications of diabetes mellitus such as retinopathy and microalbuminuria. However, it is 
noted that conduit artery stiffness correlates with features of adiposity and abnormal lipid 
profile. 
 In fact, no strong correlations between changes in myocardial function and glycaemia 
were observed apart from the association between peak systolic velocity (PSV) and mean 
HbA1c. This finding is consistent with finding by Vinereanu et al. [85]  Nevertheless, 
adverse myocardial function correlates with features of adiposity such as increased waist 
circumference and adverse lipid levels. In the diabetic heart, glucose uptake is reduced and 
there is increased utilization of free fatty acids (FFA). [273]  The use of FFA for energy is 
less energy efficient. This increased utilization of FFA may be due to increased availability of 
FFA in the circulation. Reduced glucose uptake, increased FFA uptake and reduced diastolic 
function were reported in 78 patients with type 2 diabetes mellitus. [274]  Obesity itself is 
known to be associated with myocardial dysfunction or heart failure. [275]  
Similarly, although vascular function in young subjects with type diabetes mellitus 
did not differ statistically from those of controls, factors which correlated with vascular 
structure and function were similar to those of myocardial function in my study. Body 
weight, higher BMI and abnormal lipids seem to be more significant determinants of both 
myocardial and vascular function than are glycaemia or blood glucose level.  
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Patients with diabetes mellitus have a poorer prognosis when they have heart failure. 
[276]  The prevalence of subclinical diastolic dysfunction in type 2 diabetes mellitus was 
reported to be as high as 40%. [82]  [277] The prevalence of clinical heart failure in type 2 
diabetes mellitus has been reported to be about 12%. [278] Early detection of subclinical 
disease may be helpful in preventing heart failure, if it can lead to earlier interventions that 
have been proved to be effective.  
In my study, reduced myocardial function was observed in young subjects with type 1 
diabetes mellitus despite them having comparable vascular function and structure to controls. 
It is possible that metabolic changes in diabetes mellitus affect both myocardium and blood 
vessels at the same time. Later in the evolution of the disease, other risk factors such as 
hypertension and dyslipidaemia might exacerbate conduit arterial stiffness which in turn 
might worsen myocardial dysfunction. Obesity is observed to be independently associated 
with the prevalence of heart failure with preserved ejection fraction in diabetes mellitus.[279] 
Co-existing hypertension worsens left ventricular diastolic function in patients with type 2 
diabetes mellitus. [280]  
In my study, it was also noted that augmentation index negatively correlates with 
displacement and early diastolic tissue velocity E whereas cIMT positively correlates with 
late diastolic velocity A in type 1 diabetes mellitus. There are not many studies which studied 
both myocardial function and vascular function at the same time, particularly in type 1 
diabetes mellitus. Endothelial dysfunction as indicated by flow mediated dilation was 
associated with the number of left ventricular segments with myocardial dysfunction in type 
1 diabetes mellitus. [100] Loimaala et al found that pulse wave velocity negatively correlated 
with mitral annular early diastolic velocity. [116]  The association between vascular function 
and myocardial function is not observed to be strong in my study. This may be due to the fact 
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that subjects have not developed detectable vascular dysfunction yet or may be due to small 
number of subjects in the study.  
12.2 Clinical Implications  
 
Tissue Doppler imaging or myocardial velocity imaging may be useful in detecting 
early myocardial dysfunction in young subjects with type 1 diabetes mellitus. Longitudinal 
displacement may be the most sensitive parameter to detect early subclinical dysfunction in 
type 1 diabetes mellitus. However, in the absence of long-term clinical studies, its use should 
currently be on an individual basis. 
In fact, early changes in the myocardium may be functional or metabolic. If that is the 
case, early treatment of cardiovascular risk factors might halt progression into overt heart 
failure. DCCT/EDIC study has proved that intensive glycaemic control reduced 
cardiovascular disease and mortality in type 1 diabetes mellitus.[109] Intensive treatment was 
associated with weight gain and metabolic syndrome and its consequences. [241] However, 
benefit of intensive treatment still outweighs the risks of metabolic syndrome.  
In my study, it appears that even in young subjects who have normal BMI and normal 
lipid profiles, body weight and lipid level seem to play a significant role in determining 
subclinical myocardial and vascular function. It is possible that the same metabolic 
abnormalities or pathophysiological process affect both myocardial and vascular function 
simultaneously at an early stage in the disease process. It is imperative that a multiple risk 
control approach is used in the management of type 1 diabetes mellitus so that long-term 
cardiovascular complications can be reduced, delayed or prevented. It implies that early 
management in type 1 diabetes mellitus should also concentrate on multiple risk factors 
management even in a younger age group on top of good glycaemic control.   
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12.3 Study limitations 
Sample size is a major limitation in my study. Despite my regular efforts of recruiting 
from diabetic clinics in Cardiff and Vale NHS trust hospitals, only 19 type 1 diabetes mellitus 
patients were recruited. However, I managed to recruit 34 controls. Excellent reproducibility 
in myocardial velocity imaging should limit type 2 error.  
In my study, pseudonormalizaton of mitral inflow velocity pattern was not excluded 
as Valsalva manoeuvre was not performed during echocardiography and pulmonary vein 
flow was not measured. However, it is very unlikely that diastolic dysfunction in young 
subjects with type 1 diabetes mellitus would be that advanced without other complications.  
Another limitation of my study was that autonomic function was not tested as the 
study was mainly designed to detect subclinical myocardial and vascular dysfunction and 
myocardial functional reserve. Again, in the absence of other microvascular complications, it 
is very unlikely that subjects would have significant autonomic neuropathy.  
This study is a cross-sectional study and therefore, it is not possible to define causal 
relationship in any of the associations observed in the study.  
12.4 Conclusions 
  
Subjects with type 1 diabetes mellitus have reduced longitudinal myocardial function 
but normal myocardial functional reserve. Features of adiposity such as increased waist 
circumference, dyslipidaemia and hyperglycaemia associate with adverse myocardial 
function in young subjects with type 1 diabetes mellitus. Controlling lipid levels and 
maintaining body weight may be as important as glycaemic control in type 1 diabetes 
mellitus.  
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12.5 Future directions  
  
 A longitudinal follow-up study with myocardial velocity imaging may increase 
current understanding of the natural history of diabetic cardiomyopathy. 
 An intervention study to observe the effects of lipid and weight control on myocardial 
function in type 1 diabetes mellitus may help to reduce cardiovascular mortality in type 1 
diabetes mellitus.  
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